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Abstract
 The de novo design of three generations of copper-peptides as structural and 
functional models for the type 2 copper center (T2Cu) in copper nitrite reductase 
(CuNiR) is described. Using an α-helical coiled coil scaffold, a tris-histidine site is 
introduced in the TRI peptide, yielding TRIW-H [sequence: Ac-G WKALEEK 
(LKALEEK)2 HKALEEK G-NH2].  
 While the protein scaffold is completely different from that in native CuNiR, 
copper binds with high affinity in both cuprous and cupric forms, with a three-coordinate 
cuprous state [Cu(I)(His)3+] and likely a five-coordinate cupric state [Cu(II)(His)3(OH2)1–
2
2+]. Redox chemistry is demonstrated for the first time in a de novo designed copper-
peptide system. Although the reduction potential of Cu(II)/(I)(TRIW-H)32+/+ is 150–200 
mV higher than that of the native T2Cu in CuNiR, it is still capable of catalyzing nitrite 
reduction in the presence of sodium ascorbate as a reductant with multiple turnovers. The 
first generation model establishes the minimal requirements to confer NiR activity in this 
system.   
 To understand the fundamental structure-function relationship of this Cu(His)3 
center with the ultimate goal of improving the catalytic activity, two more generations of 
models are described, with designs based on the modifications of the charged residues at 
the helical interface (second generation) and the interior (third generation) of the helical 
coiled coils, respectively. The second generation peptides have a key glutamate residue 
replacing the lysine residue at the 22nd position (TRIW-EH sequence: Ac-G WKALEEK 
LKALEEK LKALEEE HKALEEK G-NH2). By systematically modifying the charged 
residues to the C-terminus of the copper site (the 24th and 27th positions), a series of 
peptides with modifications at the helical interface are designed. These changes lead to 
modulated copper-binding affinities, deprotonation equilibria, and reduction potentials. 
While trends in reduction potential and rates correlate with the total charge of the 
! xxviii 
peptides, it is believed that modification of H-bonding to the histidine site causes the 
observed changes. The NiR rate is influenced to a small extent (4–fold at pH 5.8) with 
these modifications.  
 Two strategies are used for the third generation models: mutating the leucine at 
19th position into an alanine and changing the histidine to N-methyl histidine. The interior 
modifications, with a maximum 1300-fold observed rate enhancement, are far more 
effective in tuning the NiR rates than the second generation alterations.   
 This thesis lays the groundwork for the incorporation of metal centers in de novo 
designed peptide scaffolds to carry out redox catalysis.  
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Chapter I . Protein design: toward functional metalloenzymes 
 
 Protein design is a valuable tool for understanding the fundamental factors that 
dictate protein structure and function. The field of protein design has seen significant 
progress over the past 30 years, with a growing range of applications in areas of research 
from fundamental biochemistry to biotechnology and medicine. Protein design is no 
trivial task. It is an ultimate test of our understanding of structure−function relationships 
and requires a combined knowledge of physics, chemistry, and biology. Evolution is 
nature’s method of designing proteins, which has been very effective in producing 
scaffolds with exquisite structural details, breath-taking efficiency, and high selectivity. 
Rapid advancement of computer applications in biotechnology now enables one to model 
the evolution of a particular protein on a human time scale, instead of an evolutionary 
time scale; however, it is still quite a challenge to select an optimal solution from the 
enormous amount of mutations and to understand how these selective factors relate to the 
function of the protein. From the early examples of designing polypeptides or proteins 
that are stable in aqueous environments to today’s novel functional metalloproteins, 
protein design has advanced to a stage where it is possible to create structures never 
before seen in nature, with functions not found in nature and novel sequences not derived 
from nature while exhibiting desired properties. 
 The main goal of this thesis is to design a structural and functional model for 
copper nitrite reductase (CuNiR) using de novo protein design approach. It is important to 
realize that the progress toward designing functional metalloenzyme mimics is built upon 
many previous endeavors of constructing a stable metal-binding site in a peptidic/protein 
scaffold. Here, I will highlight a few representative cases of designed proteins to illustrate 
the strategies for incorporating functional metal-binding sites into designed 
protein/peptide scaffolds based on a recently published review article authored by me and 
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coworkers.1 I will discuss the general considerations of constructing a metal-binding site 
and introduce protein redesign and de novo design in section 1. Section 2 will focus on 
selected designed non-heme iron proteins that are capable of catalyzing 
oxidation/oxygenation reactions. Section 3 will describe the design of functional zinc-
binding proteins that have hydrolytic activities. Section 4 will describe the design of 
copper centers. Section 5 will outline this thesis.  
1. Introduction 
1) General considerations 
 Before delving into specific cases of designed protein systems, I will delineate 
some general considerations as a foundation for both protein redesign and de novo 
design. The fundamental interactions that play important roles in determining protein 
structures are hydrophobic, electrostatic, hydrogen bond (H-bond), and van der Waals 
interactions. Conceptually, creating a stable protein scaffold is a trade-off between the 
unfavorable entropy and favorable enthalpy upon protein folding, in addition to the 
entropic term of the surrounding water molecules,2 all of which eventually lead to the 
notion of positive and negative design that distinguishes the unique, native fold versus 
other folded states.3 Accordingly, in the process of designing a stable protein construct, 
one needs to consider how to utilize hydrophobic interactions as a driving force for 
folding, electrostatic interactions to build salt bridges, H-bonds to create secondary 
structures, and van der Waals interactions for packing. Additionally, when designing 
helix bundles, the helical dipole is an important factor to take into account because it will 
contribute to the alignment of helices. When it comes to incorporating a metal-binding 
site, it is critical to consider whether the site is a pre-organized ligand environment or if 
the metal ions would direct the ligand coordination.4 There are reported examples where 
metal ions are responsible for protein folding, in which case the binding of metal ions is 
the major force for overcoming the unfavorable entropy upon protein folding.5–7 
Moreover, ligand recognition, metal specificity, and substrate specificity (if applicable) 
are the next level of design goals. 
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 Rational protein design has been aided by the development of automated 
algorithms, despite the tremendous complexity associated with protein structures and 
sequences and the degrees of freedom of the calculation. Several strategies have been 
developed to reduce the degrees of freedom and improve search algorithms for energy 
minimization, which are widely used in the construction of suitable metal-binding sites 
(see later sections in this chapter).  One of the earliest programs enlisted for protein 
design is InsightII/Discover (MSI), which was applied to the development of helical 
bundle proteins.8–13 This program uses molecular mechanics to achieve energy 
minimization. The rational design algorithm Dezymer, for example, searches proteins of 
known structure for locations where side chain rotamers can be introduced to form a site 
of known coordination.14,15 This program is particularly useful in the redesign of 
metalloproteins because it can identify a novel metal-binding site based on user-defined 
geometry in a protein of known structure. On the other hand, the numerical computer 
method, Rosetta, developed in the laboratory of David Baker, takes short fragments of 
proteins and assembles them by a Monte Carlo strategy to form a native-like protein 
conformation.16 The prerequisite for Rosetta design is a library of fragments representing 
all of the possible local structures of various native proteins. After the Monte Carlo 
assembly, the folding and stability of the designed sequences are evaluated based on the 
comparison between conformational parameters and known protein structures. Metal 
Search, developed by Clarke and Yuan, is written specifically for designing tetrahedral 
metal-binding sites in proteins.17 
2)  Protein redesign and de novo design 
 The effort of protein design can be categorized into redesign, which is to 
rationally engineer desired functionality into an existing protein scaffold,18–26 and de novo 
design, which is to build a peptidic or protein system that is not directly related to any 
sequence found in nature yet folds into a predicted structure and/or carries out desired 
reactions.1,27–29 Each functional designed metalloprotein system requires both a stable 
protein scaffold or “ligand” and an incorporated metal-binding site. Part of the previous 
literature addressed how protein scaffolds are designed in terms of fundamental physical 
properties such as the energy landscape associated with folding and packing of a protein 
! 4 
from a biophysical perspective, which is the foundation of designing functional 
models.28–35 Knowledge of the critical factors that govern protein stability and other 
properties allows researchers to begin incorporating cofactors to pursue better 
performance or novel functions of designed proteins. Previous reviews on this topic 
elaborated the strategies of certain metal cofactor functionality and characterization of 
designed metalloproteins.1,18,20,27,36–42 
 Metalloproteins are essential biomacromolecules that play important roles ranging 
from structural stabilization to chemical signaling and catalysis in metabolic processes 
necessary to sustain life on the planet. Over millions of years, nature has evolved a set of 
metalloenzymes that function as electron transfer or catalytic centers. Biochemists, 
biophysicists, and chemists are intrigued by the fundamental molecular transformations 
that occur within various metalloenzymes. One approach to studying these functions is to 
design and engineer new metal-binding sites into existing native proteins: protein 
redesign.18,43,44 The ultimate goal of protein redesign is to impart improved or novel 
properties, for example, new activities, inverted stereoselectivity, or new substrate 
specificity, into existing proteins, that is, to teach the old enzyme new “tricks”.44,45 What 
protein design teaches us about the structure−function relationship will eventually allow 
us to harness the richness of native protein structures and the diverse functions of 
metalloproteins to construct new proteins for biomedical and pharmaceutical 
applications. 
 To create novel artificial metalloenzymes, a fundamental understanding of the 
structure−function relationship is necessary to predict and control the active site 
properties of a particular system. More often than previously believed, native proteins 
exhibit intrinsic catalytic promiscuity, using a single active site to catalyze more than one 
chemical transformation.46,47 The microenvironment modification of active sites can allow 
a wider range of chemical transformations to occur within naturally existing scaffolds. 
Moreover, metalloenzymes have been evolved to exhibit optimal catalytic efficiencies in 
the context of their metabolic transformations; however, the activity of a single isolated 
metalloenzyme is not necessarily the “best”. This leaves chemical space for protein 
redesign to achieve modified activity and/or specificity. The advantage of a protein 
redesign strategy is that it can bypass the problem of developing a stable protein fold 
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because many native proteins have remarkable adaptability for changes. Protein redesign 
strategy has proven to be one of the most effective approaches in the design and 
engineering of artificial metalloenzymes. Although biochemical and biophysical studies 
generally focus on features that result in the modification of functions, design allows us 
to incorporate only those features that are believed to be necessary for reactivity. By 
applying a minimal number of changes to convert a known protein to a metalloprotein 
with a specific cofactor and activity, the basic requirements for a certain activity can be 
examined in the absence of complications from the limits of stability and symmetry of the 
scaffold. One can also seek to improve upon the native function of a metalloprotein by 
making systematic changes, favoring greater stability, altering inhibition profiles, or 
affecting reactivity as needed for a particular purpose. 
 Arguably more challenging than protein redesign, de novo or “from scratch” 
design has helped to disentangle structure−function relationships on a fundamental level 
and to create novel properties and functions in peptidic/ protein systems that are not 
necessarily related to native protein sequences. Designing proteins from scratch was 
considered a bold endeavor in its infancy; however, the challenges did not prevent 
researchers from trying. As Richard Feynman expressed, “What I cannot create I do not 
understand.”48 Indeed, de novo design is the ultimate test of our understanding of the 
fundamental factors that dictate protein folding, structure, and function using a 
minimalist approach.29 It involves constructing a peptide sequence that spontaneously 
folds into a unique, predictable three-dimensional structure while retaining sufficient 
complexity and functionality to provide an adequate model for a protein.10,27,29,49,50 What 
distinguishes de novo design from other types of protein design or engineering strategies 
is that it is based on first principles,51 which refer to the postulation that the primary 
amino acid sequence determines the three-dimensional structure of a protein. Richardson 
presented a vivid analogy of the protein folding problem at the Biophysical Society 
National Lecture in 1992: the folded protein can be thought of as an origami canary with 
the amino acid sequence being the creased piece of paper from which it is folded.32 Thus, 
protein redesign amounts to modifying the wings or the tail of the folded origami canary, 
while de novo design starts with a flat piece of paper to figure out the crease patterns 
needed to fold it into a three-dimensional origami canary.  
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 The goal of de novo design is to create stable peptidic/ protein constructs with 
desirable functions and properties comparable to or better than those of native proteins. 
Combined with the knowledge learned from synthetic model complex studies and protein 
redesign work, de novo design should eventually lead to novel applications in 
biocatalysis and pharmaceuticals. Ever since the first reported de novo designed 
peptides,49,52 this approach has been utilized to understand the interplay between protein 
structure and function, heavy metal toxicity, electron transfer, and structural and catalytic 
sites in metalloproteins.  
 Rather than designing each new protein from scratch, previous de novo scaffolds 
can serve as a starting point for the design of metalloproteins (much as natural proteins 
are the starting points in protein redesign). Although there are fewer de novo designed 
scaffolds to choose from as compared to the number of natural proteins, the existing ones 
cover the most important and common structural motifs found in nature. Choosing a 
starting scaffold is a critical first step of de novo metalloprotein design because the 
scaffold provides the protein environment and orients the residue side chains, which have 
a profound impact on metal coordination. There are a few excellent and exhaustive 
reviews discussing the de novo design of turns, β-sheets, and other motifs.53–58 Since most 
of the functional metalloenzyme mimics are associated with α-helical coiled coils, I will 
focus on the design based on α-helical coiled coils. Finally, it is worth mentioning that 
computational protein design has contributed greatly to the establishment and expansion 
of the field. The major goal of computational design is to identify amino acid sequences 
compatible with a stable, folded, three-dimensional structure or to find the lowest free- 
energy structure for a specific amino acid sequence. I will omit a detailed discussion on 
computational design because the effort of this approach in the past few decades has 
already been reviewed extensively.34,40,59–71 
2. Design of catalytic non-heme iron proteins 
 Iron is the most abundant trace metal in the human body and it plays important 
roles in an array of metalloenzymes.72 Some of the earliest and most successful protein 
design efforts are focused on creating an iron-binding site, which warrants a discussion of 
selected designed iron proteins. Since the goal of this thesis is to design a catalytic center, 
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I will omit detailed descriptions of electron transfer iron sites. Interested readers can refer 
to Ref 1.  
 Nonheme iron centers are defined as those in which iron is coordinated by ligands 
other than polydentate tetrapyrroles (e.g., porphyrins). Figure I-1 illustrates the six 
general types of nonheme iron centers including mononuclear, binuclear, and iron−sulfur 
centers. Nonheme iron centers exhibit a broad range of functions, including electron 
transfer, substrate oxidation and reduction, and metal ion transport.73 The redesign of 
nonheme iron proteins aims to explore the factors that govern the redox properties and 
reactivity of the iron center, elucidate the influence of interactions between different key 
amino acid residues, and construct a novel functional nonheme iron site into another 
nonheme iron protein. Besides electron transfer, nonheme iron centers can also serve 
different reaction purposes including oxygenation (protocatechuate 3,4-dioxygenase,74,75 
catechol 2,3-dioxygenase76), peroxidation (rubrerythrin77), oxidation (ribonucleotide 
reductase (RnR),78 1–aminocyclopropane carboxylic acid oxidase79), superoxide 
dismutation [iron superoxide dismutase (SOD)80], hydroxylation (phenylalanine 
hydroxylase,81,82 calavaminate synthase83), and H-abstraction (iron-bound bleomycin84–86). 
Several comprehensive reviews cover the structures, functions, and mechanistic 
perspectives of these native nonheme iron centers, so we will omit a detailed description 
of each enzyme.73,87–89 There are several examples of redesigned nonheme iron proteins 
that use iron as a catalytic center to control the redox properties and reactivity of the 
protein.  
 
Figure I-1. Nonheme iron centers. Reproduced with permission from ref 73. Copyright 
1991 Elsevier.  
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 SOD catalyzes the disproportionation of superoxide into molecular oxygen and 
hydrogen peroxide, an important gating mechanism for controlling cellular oxidative 
stress.90 Three types of SODs have been discovered in a variety of organisms: NiSOD in 
certain fungi and bacteria,91 CuZnSOD in eukaryotic cells,92 and Fe/MnSOD in bacteria, 
some plant chloroplasts, and mitocondria.80,93,94 FeSOD and MnSOD share a high 
sequence homology, including the same amino acid ligand set, and, therefore, are 
considered as one general type. Metal ion substitutions result in a loss of activity,95–97 
likely a reflection of the different midpoint potentials of FeSOD and MnSOD.98,99 In 
FeSOD, iron is bound in a trigonal bipyramidal geometry with two His and One Asp on 
the trigonal plane and one water/hydroxide and one additional His as axial ligands.80,93,100 
This coordination environment was constructed into Trx using the rational protein design 
program, Dezymer.101 The mutations Leu7His, Phs27Asp, Ile60His, and Asp63His 
constructing the FeSOD active site, together with several other mutations for structural 
stability, yielded Trx-SOD. Fe-Trx-SOD exhibits spectroscopic features similar to those 
observed in WT FeSOD and readily catalyzes superoxide dismutation. Although the rate 
of Fe-Trx-SOD is ∼104-fold lower than that of the WT enzyme, it remains an excellent 
model toward elucidating the chemical details in native proteins.  
 Using Dezymer, Benson et al. introduced a mononuclear (His)3 iron-binding site 
and an oxygen-binding pocket into Trx,24 with the goal of creating an empty binding site 
on the iron center for facilitating substrate access. The oxygen-binding center was created 
by examining the locations that could sterically accommodate a molecular oxygen. Six 
locations were selected, including three sites in a groove (G1− G3), two sites in a shallow 
pocket (S1 and S2), and one site in a deep pocket (D1). The reduction potentials of this 
Fe(His)3 center are location-dependent: the relatively buried G3 and D1 sites have 
significantly lower reduction potentials (+28 ± 2 and +10 ± 2 mV, respectively), whereas 
the more exposed S1 site has a higher potential (+440 ± 2mV). Fenton, SOD, and 
Udenfriend reactions were tested for these mutants, demonstrating that the stabilization of 
surface electrostatics, transition states, and the elimination of nonspecific electron 
transfer processes all contribute to the specificity of the catalytic reaction.  
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Figure I-2. The active site of Fe(II)-FeBMb. Fe(II)B is represented by a green sphere. The 
Fe(II)-bound water is represented by a red sphere. PDB code: 3K9Z. Bond lengths in the 
figure are in angstroms.  
 In nitric oxide reductase (NOR), a nonheme iron center, FeB, is coupled to a heme 
center, which promotes the two-electron reduction of NO, producing N2O and water.102,103 
On the basis of a previously reported CuBMb construct, where a (His)3 site was 
introduced close to the heme center in Mb for copper binding,104 Yeung et al. successfully 
designed a NOR mimic by coupling a nonheme iron center [Fe(His)3] to the heme center 
in Mb.105 Specifically, the Val68Glu mutation was chosen in addition to the two 
preexisting mutations in CuBMb (Leu29His and Phe43His). The resulting FeBMb protein 
contains a nonheme iron coordinated to three His residues (His29, His43, and His64) and 
Glu68 revealed by its crystal structure (Figure I-2). The presence of the FeB site 
dramatically increases the reduction potential of the heme center, from −158 to −46 mV 
(vs NHE), which, along with EPR data, supports the coupling of two iron centers. Fe(II)-
FeBMb is also a functional model of NOR to catalyze NO reduction into N2O.  
 To design a model closer to native NOR, Lin et al. introduced a second Glu 
residue in close proximity to the FeB-heme site.106 Previous reports indicated that a few 
Glu residues are critical for retaining NOR activity;107,108 however, because of the 
complexity of the native protein, the precise functional role of each Glu remains 
unknown. An Ile residue on the second coordination sphere of FeB was mutated to Glu in 
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the simplified model, FeBMb, to elucidate its function. The crystal structure of Fe(II)-
I107E-FeBMb was solved, showing that Fe(II) is coordinated to three His residues, 
Glu68, and a water molecule situated between Fe(II) and Glu107. Glu107 was proposed 
to facilitate proton uptake. Under single turnover conditions, after ∼20 h, the yield of N2O 
catalyzed by Fe(II)-I107E-FeBMb is 24%, more than twice that catalyzed by Fe(II)-
FeBMb (∼10%), reflecting the important functional role of Glu107. Moreover, the 
introduction of Glu107 does not alter the reduction potential of the heme center, showing 
that the effect of the conserved Glu residues is not additive, but rather depends on the 
location of the Glu residue. Metal ion substitutions were carried out to confirm the role of 
the nonheme metal center. Structural differences such as altered H-bonding networks and 
coordination geometries are observed in the crystal structures when Fe(II) was substituted 
with Cu(II) and Zn(II), showing that FeB site is involved in the structural fine-tuning.  
 Several proteins contain di-iron oxo active sites that carry out various reactions. 
For example, both hemerythrin and methane monooxyganse contain a di-iron oxo site, 
which functions as an O2 carrier center in hemerythrin109 and a methane hydroxylation 
site in methane monooxygenase (MMO).110 One of the major goals of protein redesign is 
to investigate whether it is possible to swap similar active sites from proteins that exhibit 
dissimilar functions, which may lead to a more in-depth understanding of how structure 
relates to activities in metalloprotein active sites. DeMaré et al. redesigned the di-iron site 
in rubrerythrin (Rr) to mimic that of RnR R2.111 Although the physiological function of 
Rr is yet to be determined, this study contributes to improving the understanding of the 
functional aspect of the di-iron center. Specifically, the authors created Rr mutants 
aiming to probe the possibility of forming a tyrosyl radical near the active site 
(Leu60Tyr) and to determine the role of a coordinating Glu residue (Glu97Ala). The X-
ray crystal structures for both Leu60Tyr and Glu97Ala mutants show minimal structural 
perturbation as compared to WT-Rr. Leu60Tyr is located in a position similar to the 
stable tyrosyl radical-forming position in native RnR R2; however, EPR and UV−vis 
spectroscopies do not show any tyrosyl radical feature in Leu60Tyr-Rr. Ferroxidase 
reactions were carried out with the mutants. Only the Glu97Ala mutant, in which the 
directly coordinating Glu ligand is removed, shows decreased activity, while the distal 
mutation in L60Y-Rr does not result in variation of the activity. These results suggest that 
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the physiological reaction of Rr involves ferroxidase-like activity. In L60Y-Rr, Tyr does 
not form an H-bond with an iron-coordinating carboxylate, as would have been required 
to form the tyrosyl radical during the ferroxidase reaction.  
 Moreover, a di-iron center with activity resembling that of MMO was introduced 
into RnR R2 through a series of mutations.112 The crystal structures of RnR R2 from 
different species show similar di-iron sites as well as the conserved residues Phe208, 
Phe212, and Ile234, which form a hydrophobic patch. Tyr122 forms a radical to initiate 
the catalytic cycle for ribonucleotide reduction.113,114 To investigate the role of Phe208 
and how it may influence Tyr122 radical formation, Örmo et al. mutated Phe208 to Tyr, 
yielding an RnR R2 mutant that does not have a tyrosyl radical, based on the absence of a 
characteristic 410 nm feature in the absorption spectrum. The Raman spectrum shows the 
presence of a ferric bidentate catecholate species, likely derived from the protein rather 
than an exogenous ligand. The authors postulated that the Tyr108 could be the precursor 
of the dihydroxyphenylalanine ligand, the formation of which is proposed. Scheme I-1 
(Reproduced from ref 112 with permission. Copyright 2012 American Society for 
Biochemistry and Molecular Biology) shows the self-hydroxylation activity of this di-
iron center, which involves the formation of a ferric-peroxide that transforms to a high-
valent Fe(IV)−oxo species.  
 
 
Scheme I-1 
 Di-iron center has also been incorporated into de novo designed scaffolds. 
DeGrado and co-workers have used retrostructural analysis of the active sites of several 
carboxylate-bridged di-iron proteins to design a family of artificial metalloproteins as 
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models for enzymes such as RnR and bacterioferritin.115–120 Despite a low sequence 
identity (<5%) and overall complex protein folds, the active sites of these proteins are all 
found within a simple antiparallel D2-symmetric four-helix bundle.117 The Due Ferri (two-
iron, DF) proteins, designed to understand how solvent accessibility, polarity, and 
electrostatic environment influence the properties, are comprised of a binuclear metal site 
with two chelating Glu residues, two His residues, and two bridging Glu residues. These 
primary ligands are buried in the interior of the scaffold with metal geometries stabilized 
by a network of hydrogen bonds to second-shell ligands. The parent model, DF1, is an 
antiparallel dimer of noncovalently associated HLH motifs, each 48 residues in length.117 
The design was approached by first carefully defining the above-described dimetal 
coordinating site and second shell residues and then incorporating mainly hydrophobic 
core residues for packing and hydrophilic interfacial residues to define the topology. The 
design was first structurally characterized as a di-Zn(II) complex (but also binds Fe(II) 
and Co(II) in solution), confirming the presence of the dimetal cofactor near the center of 
the dimer.117 The subsequent apo-DF1 NMR structure demonstrated that the metal site is 
largely preorganized.121 Each metal is five-coordinate with a sixth vacant site lying on 
adjoining faces of the two metal ions to provide a potential binding site for small 
molecules. Complete characterization of DF1 was not possible due to low solubility and 
extreme stabilization (the scaffold had to be unfolded and refolded to bind metal). 
Further, Leu residues 13 and 13′ were found to block dimetal site access. 
!
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 DF2 was subsequently designed to increase solubility (more surface hydrophilic 
residues were incorporated, and, in a similar model DF2t, a longer interhelix loop was 
introduced for stabilization and minimization of aggregation) and to allow for access of 
small molecules to the metal site (by replacing Leu residues with Ala and Gly).118,120,121,129–
131 The crystal structures of di-Mn(II)-L13A-DF1976 and di-Mn(II)-L13G-DF1981 
confirm the presence of the designed cavity (which increases in size going from the larger 
Ala to Gly) filled with ordered water molecules. Notably, the asymmetric unit of di-
Mn(II)-L13G- DF1 has four independent dimers, three of which have bridging water 
molecules and intermetal distances of 3.6 Å and one with two terminal water molecules 
and an intermetal distance of 4.2 Å.130 Superimposition of the structures revealed that two 
copies of the N-terminal helices have shifted in opposite directions, leading to the 
increased metal−metal bond length. Dubbed the sliding-helix mechanism, it is postulated 
that this mechanism could occur in native systems for signal transduction, but it would be 
difficult to observe this effect experimentally.  
 Having developed a construct with improved properties and a larger active site 
cavity, a combinatorial approach was undertaken to search for a functional assembly. To 
this end, DFtet, a noncovalent assembly of four separate helices that could easily be 
varied, was designed.132 One of the resulting heterotetramers, DFtet A2B2,132 with all Gly 
residues replacing the Leu and Ala residues in the active site cavity (G4-DFtet), could 
perform the rapid two-electron oxidation of 4-aminophenol to benzoquinone monoamine 
with a kcat/KM of 25.7 M−1s−1 and a rate enhancement of ∼1000-fold relative to the 
background reaction (and no detectable intermediates).128 Further, this de novo design 
approach also demonstrates that the activity is sensitive to changes of the size of a methyl 
group in the active site cavity (substituting Gly for Ala decreased the rate up to 5-fold). 
The diferrous form of another resulting heterotetramer, DFtet AA’B2, reacts with oxygen 
to form a peroxo-bridged diferric species similar to an important reactive intermediate 
found in many native proteins.133 Given difficulties involving complex stoichiometry and 
unwanted ligand-exchange reactions with G4-DFtet, DF3 was designed on the basis of 
the original DF1 sequence with all Gly residues around the active site to accommodate 
the substrate and with modified loop residues to stabilize the resulting fold.127 Like DFtet, 
DF3 is a phenol oxidase for the substrates 4–aminophenol (kcat/KM of 23 M−1s−1), 3,5-di-
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tert-butyl-catechol (3,5-DTBC, kcat/KM of 100 M−1s−1), and p-phenylenediamine (kcat/KM of 
14 M-1s-1) (Table I-1). No phenol oxidase activity was observed for o-phenylenediamine. 
These results are consistent with crystallographic analysis of the size of the cavity. The 
active site cleft created by the Gly mutations, at its narrowest, matched the width of the 
phenyl ring and, in wider sections, substitutions at the 3 and 5 positions could be 
accommodated.  
 A single chain DF protein, DFsc (with Ala residues around the active site), was 
also designed, and the NMR structure of di-Zn(II)-DFsc was obtained.134,135 While rapid 
oxidation of the diferrous center was observed, it was due to an off-pathway iron-
tyrosinate complex and not the important diferric intermediate observed for the other 
diferrous DF proteins.136,137 Substitution of the four Ala residues to Gly (G4-DFsc) led to 
the minimization of this complex and a scaffold, which could also catalyze 4-
aminophenol oxidation on the same order of magnitude as DFsc was obtained.138 Most 
recently, the DeGrado group has shown that a single mutation (from Ile) provides an 
additional coordinating His residue at the dimetal center of G4-DFsc and results in a 
protein that can now catalyze the N-hydroxylation of arylamines such as p-anisidine, an 
activity not detected for G4-DFsc.138 Only three additional mutations outside of the 
coordination sphere were made to counterbalance the steric clashes and unfavorable 
electrostatic interactions introduced by the His residue. The design does not fold well in 
the absence of metal, but does adopt a fold similar to those of the other DF proteins in the 
presence of divalent metals. It is particularly striking that addition of a single metal-
coordinating residue can result in complete loss of one activity, phenol oxidation, and 
generate another, N-hydroxylation. This work is an excellent example of how de novo 
design can be utilized to directly correlate structure with function by removing much of 
the complexity of native proteins. 
3. Design of hydrolytic zinc proteins 
 Following iron, zinc is the second most abundant trace metal in the human body. 
The major roles of zinc in proteins are catalytic (including cocatalytic) and structural. The 
major difference between structural zinc sites, as in zinc fingers (ZFs), and catalytic sites, 
as in carbonic anhydrase (CA), is that structural sites have saturated coordination spheres, 
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with amino acid ligands His and/or Cys bound to the zinc ion, whereas catalytic centers 
have at least one vacant site allowing for solvent (water) or substrate coordination.139 
Bound water is a feature of catalytic zinc centers, as it can be activated for ionization, 
polarization, or displaced by another ligand, such as an alcohol substrate.140 I will discuss 
herein the redesign of a structural ZF site into a catalytic site, and the design of a zinc site 
for phosphate hydrolysis. Then I will introduce a few de novo designed zinc-binding 
peptides that have carbonic anhydrase activities. One of the de novo designed zinc-
peptide, in particular, is an important foundation to this thesis work.  
3)  Redesign of zinc fingers for catalysis 
 ZFs are ubiquitous, small protein domains that bind to DNA to regulate gene 
expression. ZFs are now classified into at least 14 different classes, based on the metal-
coordinating ligand as well as the protein fold, if known.141 ZFs utilize four Cys and/or 
His residues for tetrahedral metal binding, forming a Zn(Cys)x(His)4−x coordination site. 
Three commonly studied ZF proteins are those with Cys4, Cys2HisCys, and Cys2His2 
sites.142 Cys4 ZFs constitute one class, which are usually found in nuclear receptors and 
play important roles in developmental biology.143–161 Another class of ZFs is the nucleic 
acid binding proteins that have Cys2HisCys binding site.162–174 The third, best-known, and 
most common ZF motif in eukaryotes is the His2Cys2 metal-binding site.141,168,175–180 The 
secondary structure of ZF proteins consists of an α-helix packed against a two-stranded 
antiparallel β-sheet. The opposite side of the α-helix with respect to β-sheet packing 
associates to DNA for gene regulation, whereas the β-hairpin region does not interact 
with DNA but instead is a structural component of the domain.181–183 For all three types of 
ZF domains, Zn(II) is almost always necessary for protein folding yet is not directly 
involved in the DNA-binding activity.177,184 
 Based on a wild-type (WT) ZF protein ZF(CCHH), Nomura et al. incorporated an 
unsaturated Zn(II) binding site by mutating the coordinating His and Cys residues into an 
Ala or a Gly.185 CD spectroscopy shows that Zn(II) still induces α-helix formation for 
some of the mutants. Because of the unsaturation of the coordination at the Zn(II) ion, all 
of the mutants exhibit pNPA hydrolysis activity. Furthermore, increasing the number of 
ligating His residues leads to higher catalytic activity, due to the increased Lewis acidity 
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of Zn(II). Inhibition studies were carried out to confirm the catalytic role of the Zn(II)-
bound protein complex. Interestingly, the Zn(II)-bound complex of ZF(HHHH) exhibits 
enantioselective esterase activity toward Boc-glutamine 4-nitrophenyl ester (Gln-ONp), 
indicating that the Zn(II) active site in this protein is situated in an asymmetric 
environment.  
 Follow-up studies using the ZF protein derivative ZF(HHHH) (Zn·1) and a 
previously reported three-tandem ZF protein186 derivative Zn·2 (where two Cys residues 
were mutated to two His) showed that these Zn−protein complexes could hydrolytically 
cleave DNA.187 A supercoiled plasmid DNA, pUC19GC, was used as a substrate to 
examine the nuclease activity. Because of preferred binding of Zn·2 to the GC box of the 
DNA duplex, selective hydrolytic cleavage of DNA could be achieved with moderate 
activity. To improve the DNA cleavage activity, Negi et al. combined ZF structural sites 
with a nuclease site into one design, yielding ZWH4.188 ZWH4 contains four Zn(II)-
binding sites, three of which are Cys2His2 ZF sites and the fourth a His4 hydrolytic site. 
Zinc-bound ZWH4 catalyzes DNA cleavage with a clear production of different forms of 
products depending on the protein concentration. Specifically, at 25, 50 equiv. of ZWH4/ 
DNA, the cleavage reaction produced form II (a nicked circular form), a mixture of form 
II and form III (a linear form) products, respectively. This report shows how further 
control of the specificity of artificial nucleases can be achieved. 
 Many designed ZF nucleases have been developed to obtain alternative methods 
to gene therapy. Porteus and Baltimore analyzed gene targeting with homodimers 
consisted of an artificial ZF binding domain, QQR, to create a DNA double-stranded 
break in a genomic target.189 Nakatsukasa et al. also placed a ZF protein on either side of 
a functional DNA cleavage linker.190 Ideally, these new systems will be capable of unique 
and specific DNA cleavage and could ultimately be used to manipulate genetic 
information to precisely alter or replace damaged or disease-correlated DNA sequences. 
However, off-target site cleavage induced by ZF nucleases could result in cytotoxicity 
that must be mitigated for these systems to be useful as routine medicinal nucleases.  
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4) Designed zinc enzymes for phosphate hydrolysis 
 The Baker group has developed a computational method for redesigning 
metalloenzymes to catalyze noncognate reactions, and computationally redesigned a 
Zn(II)-containing mouse adenosine deaminase for organophosphate hydrolysis.122 The 
approach harnesses de novo enzyme computational design methods.191–193 Scaffolds are 
selected that contain backbones that can support active sites for the target reaction, and 
then the binding pocket sequence is optimized for the transition state. Applying this 
approach to existing metalloenzymes will address only the geometric compatibility of the 
site with the transition state and not the reactivity of WT functional groups. This is a 
valuable consideration as most enzymatic redesign involves altering substrate specificity 
or stereoselectivity, enhancing a preexisting promiscuous activity,194 or relies on having 
structural homologues that already have the desired activity (in the case of introducing 
mechanistically related activities) as a starting point.195 One example involved the 
redesign of the Zn(II)-containing glyoxalase II enzyme into a β-lactamase through 
extensive modifications made through insertion, deletion, and substitution of several 
active site loops and subsequent point mutations.196 This redesign alters both the metal-
binding geometry and the substrate-binding pocket, yet both glyoxalase II and metallo β-
lactamase enzymes contain binuclear metal ions essential to the hydrolysis reaction. 
 In this study, organophosphate hydrolysis was chosen as a target reaction and 
Zn(II) metalloenzymes as templates for supporting this activity, given that Zn(II) ions 
serve as powerful catalysts in many hydrolase enzymes with diverse mechanisms. Several 
mononuclear Zn(II) enzymes were examined for their geometric compatibility with the 
transition state of the target reaction (using methyl paraoxon and diethyl 7-
hydroxycoumarinyl, or DECP, as substrates). Residues were introduced for both H-
bonding interactions and shape complementarity leading to a set of 12 possible designed 
proteins for experimental characterization. One of these hydrolyzed DECP with a modest 
efficiency of ∼4 M−1s−1. The template enzyme for this model was adenosine deaminase, 
which, although also a hydrolytic enzyme, is distinct in terms of its transition state 
geometry, leaving group character, and inherent reactivity at the substrate electrophilic 
center. Eight mutations relative to the parent WT complex were made in the 
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computational design model, seven for shape complementary interactions and one for an 
H-bond interaction to the nucleophile in the model. The Zn(II)-coordinating residues, 
Asp and three His residues (in a trigonal bipyramidal geometry with one open 
coordination site), and the catalytic residues, Glu217 and His238, were all retained from 
the WT enzyme (Figure I-3A). The WT enzyme showed no acceleration for DECP 
hydrolysis over buffer at <20 mM enzyme. Using the initial velocity, the substrate 
concentration at which it was measured, and 20 μM enzyme concentration, a kcat/KM ≈ 
10−3 M−1s−1 was estimated. Mutation of Glu217, a residue involved in proton shuttling in 
the WT enzyme, to Gln results in complete loss of activity, indicating that this residue is 
crucial for organophosphate hydrolysis.  
 
Figure I-3. (A) Spatial clustering of WT and activity-enhancing residues in a Zn(II)-
containing mouse adenosine deaminase. Residues in which computationally designed 
simultaneous substitutions were essential for the emergence of organophosphate 
hydrolysis activity are highlighted in blue. Deaminase residues retained in the most active 
variant of PT3 (purple), and positions in which activity-enhancing mutations occur during 
directed evolution (green) form two separate spatial clusters. Residue side chain identities 
are from the deaminase crystal structure (PDB code: 1A4L), and the transition state 
model is shown in gray sticks. (B) Superposition of the PT3.1 design model (gold) and 
the crystal structure (green, PDB code: 3T1G) shows that, although the overall backbone 
similarity is high (backbone rms deviation = 0.65 Å), there are small shifts in two active 
site-proximal loops. Reproduced with permission from ref 122. Copyright 2012 Nature 
Publishing Group. 
 Directed evolution, a method used in protein engineering for evolving proteins 
through an iterative process of preparing mutants and selecting those with the desired 
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properties,197 was undertaken to gain a better understanding of the missing elements in 
this computational design method. Three rounds were performed, the first in which a set 
of selected residues around the active site was considered and three new mutations were 
incorporated, leading to a 40-fold increase in efficiency. Two subsequent rounds were 
carried out, the second by introducing random mutations, and the third considering a 
single residue identified to be in a suboptimal position by crystallography. These led to 
four more mutations, and another 10-fold increase in efficiency for each round, resulting 
in a total 2500-fold improvement over the initial computational design model. The 
biggest contributor to the increase came from the first round of directed evolution, and 
involved mutation of Val to the bulkier Phe, resulting in increased hydrophobicity around 
the catalytic residue Glu217 (Figure I-3). The authors propose that, although Zn(II) in the 
WT enzyme activates the hydroxyl nucleophile, Zn(II) in the design model is more likely 
to polarize the P−O bond, along with the side chain of His238, and Glu217 is the general 
base that activates the nucleophile (although a crystal structure with a bound substrate or 
transition state analogue is required to prove this). These results indicate that the 
redesigned protein may operate with a mechanism different from that of the WT enzyme. 
 Analysis of the computational design protocol revealed some of its shortcomings. 
Most of the mutations that result in an improved efficiency are due to an increase in kcat. 
The biggest increase came from the Val218Phe mutation in the first round of directed 
evolution. This residue does not directly contact the transition state, but it does increase 
the bulk around the catalytically critical side chain of Glu217, probably modulating its 
pKa and reactivity. Analysis of the apo-PT3.1 (from the first round of directed evolution) 
crystal structure reveals that, although much of the backbone and other elements of the 
structure match the design model, some conformational shifts in the loop backbone 
structure proximal to the active site were observed (Figure I-3). These acted to 
accommodate the bulkier side chain that came from the Val218Phe mutation. Notably, 
the design was carried out on a fixed WT backbone so this mutation would have caused 
clashes in the design model. The authors’ future efforts will be in developing 
computational enzyme design methodology to allow more backbone flexibility and 
incorporate pKa effects with more accurate electrostatic interaction models. Although the 
primary coordination environment around the metal has not been changed in this enzyme 
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redesign, this study demonstrates an effective approach to harnessing the inherent 
catalytic power of metal ions and introducing new reactivity into an existing 
metalloenzyme in a way that does not rely on preexisting activity. This study 
demonstrates the importance that the surrounding protein structure can have on the 
activity of the “same” metal site, given that both the substrate and the reaction 
mechanism are different. As a result, this approach can be one way of generating 
powerful metalloenzymes to catalyze novel reactions for a variety of biocatalyst 
applications. The catalytic efficiency of this enzyme is compared to other designed 
system in Table I-1. More recently, the Baker group has expanded the realm of 
computational protein design by incorporating an unnatural amino acid (2,2’-bipyridine-
5yl)alanine (2,2’-bpy-Ala) into native proteins.198 RosettaMatch and RosettaDesign were 
used to search for the backbone location for the bpy-Ala residue and introduce additional 
interactions to stabilize the protein, respectively. The resulting protein scaffolds bind to 
divalent metal ions with a relatively high affinity, laying a solid foundation for the future 
design of unnatural amino acid-containing hydrolases. 
 Many native nucleases contain metal ions such as Mg(II), Ca(II), Cu(II), and 
Zn(II),199–204 which enhance catalytic activity by acting as Lewis acid catalysts or 
activators for either the nucleophilic attack or the leaving group departure.199–202,205–214 
Early attempts to incorporate a Zn(II) binding moiety in a peptidic scaffold to carry out 
hydrolytic phosphate cleavage reactions were performed by the Scrimin group.215,216 They 
installed 2 equiv of an azacrown functionalized amino acid, (S)-2-amino-3-[1-(1,4,7-
triazacyclononane)]propanoic acid (ATANP), into a water-soluble heptapeptide chain 
that adopts a 310-helix structure. This peptide binds up to 2 equiv of Zn(II) at the 
azacrown sites, which cooperatively catalyze the cleavage of an RNA model substrate 2-
hydroxypropyl-p-nitrophenol phosphate (HPNP) (Scheme I-2, Figure I-4). This 
represents the first example of a short, water-soluble 310-helix peptide with catalytic 
activity. Further studies involved binding other divalent metal ions such as Cu(II) and 
Ni(II) to the azacrown site of the same scaffold with minor adjustments to the amino acid 
side chains and examination of their reactivity toward HPNP cleavage. Although all three 
metal-bound peptides exhibit catalytic activity, the Zn(II)-peptide has the highest activity, 
more than 3-fold faster than the Ni(II)- and Cu(II)-peptides. It was shown that the 
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dinuclear metallopeptide complex with a 310-helix structure has higher activity than the 
smaller dipeptide without any secondary structure due to the proper positioning of the 
substrate. Only upon binding two metal ions 6.3 Å apart, as is the case occurring in a 
310-helix peptide, could an HPNP molecule be properly activated and subsequently 
cleaved.216 With the incorporation of an interchelating moiety (an acridine ring) at the N-
terminus for DNA binding, the dinuclear Zn(II)-peptide was able to perform hydrolytic 
cleavage of plasmid DNA pBR322.217  
 
Scheme I-2 
 
! 24 
Figure I-4. Proposed cleavage mechanism of HPNP. Reproduced with permission from 
ref 215. Copyright 1999 American Chemical Society. 
 On the basis of the same principle, Scarso et al. designed a peptide template 
T(P1)3 that is capable of binding 4 equiv of Zn(II).218 This peptide template consists of 
three copies of P1a, which is a designed 310-helix heptapeptide chain that has one 
azacrown Zn(II) binding moiety (Figure I-5A), and a tris(2-aminoethyl)amine (Tren) 
moiety as a platform onto which three peptide strands were attached. Because Tren can 
bind 1 equiv of Zn(II) itself, the fully Zn(II)-bound complex contains 3 equiv of Zn(II) 
bound to the peptide and 1 equiv of Zn(II) at the Tren center (Figure I-5B). This complex 
was able to carry out the transphosphorylation of HPNP (Scheme I-2) with the highest 
rates when 4 equiv of Zn(II) were bound. In addition, allosteric control of Zn(II) binding 
to Tren was observed for T(P1)3, which led to the cooperative interactions between the 
Zn(II)-azacrown moieties, previously demonstrated to be critical to the rates of the 
cleavage reaction.215,216 Oligomeric RNA cleavage was also attempted with Zn(II)4(T-
(P1)3), but proved to be less efficient than the more flexible apo-(T(P1)3).  
! 25 
 
Figure I-5. Molecular models of (A) P1a-Zn(II) complex top view and side view; and (B) 
Zn(II)4(T(P1)3) complex top view and side view. Reproduced with permission from ref 
218. Copyright 2002 National Academy of Sciences. 
 The same Zn(II)(1,4,7-triazacyclononane) moiety was also integrated into a de 
novo designed helix−loop−helix (HLH) motif.219 The 42-residue peptides PR I−III were 
designed on the basis of the sequence of SA-42 and KO-42 that Baltzer and co-workers 
previously reported.220–222 PRI has two ATANP on each helical strand at the i/(i+4) 
positions, assuming the peptide adopts an α-helical conformation, yielding four Zn(II) 
binding sites. PRII has two ATANP on one helical strand at the i/(i+4) positions, and 
PRIIII has one ATANP on each strand. All three peptides adopt predicted HLH 
conformations at a neutral pH range. The apparent second-order rate constant of Zn(II)4-
PRI toward HPNP cleavage was improved by 3-fold as compared to the first Zn(II)-
peptide with the aridine ring (k2 = 0.16 M−1s−1 for Zn(II)4-PRI and 0.05 M−1s−1 for Zn(II)2- 
310).215,216 Zn(II)2-PRII and Zn(II)2-PRIII show comparable second-order rate constants 
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(k2 = 0.094 and 0.084 M−1s−1, respectively), both smaller than that of Zn(II)4-PRI. Rossi et 
al. also showed cooperativity between at least two Zn(II) ions in the metal-loaded 
peptides. They proposed two possible pathways for the hydrolysis reaction to proceed 
coorperatively, both of which involve two Zn(II) ions acting together to interact with the 
substrate hydroxyl or Zn(II)-bound water molecules.219 Overall, the efforts on designing 
zinc phosphate hydrolase demonstrate the utilization of the Lewis acidity of Zn(II), which 
is also an important feature entailed in the next section.  
5) Design of carbonic anhydrase mimics 
 CA is a Zn(II)-containing enzyme that is found in almost all plants, algae, and 
mammals, whose function is fundamental to many eukaryotic biological processes such 
as respiration, ion transport, and acid−base balance.223–225 The physiological reaction 
catalyzed by CA is the interconversion between CO2 and HCO3−; however, the catalytic 
promiscuity of CA allows for the rational design of the active site to exhibit increased 
activity toward ester hydrolysis.  
 
Figure I-6. CA H-bonding network based on the crystal structure of CA (PDB code: 
3KS3226).  Reproduced from Ref 1. Copyright American Chemical Society 2014.  
 High-resolution crystal structures of CA reveal that Zn(II) is coordinated to three 
His residues (His94, 96, 119) and a water molecule/hydroxide ion, that is H-bonded to 
the hydroxyl side chain of a nearby residue, Thr199, which, in turn, forms an H-bond 
with Glu106 (Figure I-6).227–230 The active site is contained in a twisted beta-sheet. The 
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redesign of the active site of CA involves modification of the first or outer coordination 
spheres. Fierke, Christianson, and co-workers pioneered studies mutating both 
coordinating and noncoordinating residues around the Zn(II) center in CA.231–237 
Specifically, one or more of the Zn(II)-coordinating His residues (His94, 96, 119) were 
substituted with a neutral, nonpolar, noncoordinating amino acid residue (Ala), 
carboxylate-containing residues (Asp, Glu), a thiolate-containing residue (Cys), and 
carboxyamide-containing residues (Gln, Asn), and observed varied Zn(II)-binding 
affinities and catalytic rates and efficiencies.232–234,238 The substitution of any coordinating 
His residue decreased the Zn(II)-binding affinity by ∼104−105-fold. The pKa of Zn(II)-
bound water, representing conversion to the active Zn(II)-hydroxide species, increased by 
at least one pH unit when His residues were replaced with other residues (pKa(WT–CAII) = 
6.8 ± 0.1,239 pKa(mutants) ≥ 8.4). In addition to catalyzing physiological CO2 hydration, CAII 
can also catalyze ester hydrolysis, which is another important hallmark of its activity. The 
catalytic efficiency of both pNPA hydrolysis and CO2 hydration decreased significantly 
with the substitutions described above. Although these studies were reviewed in an 
earlier contribution,231 it is important to revisit them briefly here because they have 
provided important insight into the role of coordinating His residues, outer-sphere 
residues, and the mechanistic aspects of CO2 hydration, which are relevant for the de 
novo designed CA models.  
 The studies on native CA illustrate that the coordinating His residues are essential 
in maintaining the Zn(II)-binding affinity, the pKa of Zn(II)-bound water, the stability of 
Zn(II)-bound hydroxide, and the negatively charged transition state for CO2 hydration. 
Moreover, these His residues might also play a role in forcing the tetrahedral 
coordination geometry, found in native CAII, over trigonal bipyramidal geometry.231 
 The modification of the second coordination sphere of the Zn(II) site in CA 
focuses on the alteration of hydrogen bonding (H-bonding) interactions, particularly by 
substituting Thr199, Thr200, and Gln92 residues that were shown to be important in 
maintaining the H-bonding network around the active site.235–237,240,241 In WT-CAII, 
Thr199 accepts an H-bond from Zn(II)-bound hydroxide and donates an H-bond to 
Glu106, building a proton transfer chain to facilitate CO2 hydration.230 The crystal 
structure of Co(II)-substituted Thr199Cys-CAII reveals that the substitution of Thr199 
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with a Cys residue leads to the displacement of the Zn(II)-bound water by the thiolate 
ligand.240,242 The additional coordinating ligand, Cys, results in a Zn(II) affinity increase 
in of 4-fold; however, the catalytic efficiency of CO2 hydration is compromised 
substantially. Similarly, Thr199 is replaced with Glu, Asp, or His residues.237 Both 
mutants with residues containing carboxylate groups (Thr199Glu and Thr199Asp) show 
displacement of Zn(II)-bound water by the carboxylate ligand in their crystal structures, 
although the O(carboxylate)− Zn(II) distances are different. For the Thr199Asp mutant, 
the two oxygens from the carboxylate of Asp bind Zn(II) in a bidentate fashion with a 
Zn(II)−O distance of 2.5 Å, whereas the carboxylate in the Thr199Glu mutant displaces a 
water molecule and adopts a unidentate binding mode with a Zn(II)−O distance of 2.2 Å. 
Only Thr199Glu exhibits a significant increase in the Zn(II)-binding affinity (200-fold), 
demonstrating the influence of metal−ligand separation and side chain torsion angles on 
protein−metal affinity. In contrast to Thr199Asp and Thr199Glu, Thr199His does not 
coordinate Zn(II). The Zn(II) affinity of the Thr199His mutant decreased by as much as 
20-fold as compared to that of the WTCAII [Kd = 7.7(±1.3) × 10−11 M for Thr199His, Kd 
= 4(±1) × 10−12 M for WTCAII]. In addition to Thr199, residues at the 200 position are 
also polar residues (Thr, Asn, or His) that influence the catalytic efficiency of CO2 
hydration for different CA isozymes.243 Krebs et al. substituted Thr200 with a Ser residue 
in CAII, with little to no change in the catalytic efficiency for CO2 hydration, but a 4-fold 
increase in the catalytic efficiency for pNPA hydrolysis was observed.241 The crystal 
structure of the Thr200Ser mutant shows that this substitution results in relocation of 
His64, which was thought to change the solvent structure around the active site and to 
modify the proton transfer chain. Moreover, two additional important second-sphere 
residues, Gln92 and Glu117, H-bonded to the imidazoles of His94 and His119, 
respectively, were mutated to examine alteration of the H-bond length (Gln92Asn, 
Glu117Asp) or charge (Gln92Glu) of the H-bond acceptor.235,237 These studies illustrate 
the importance of these H-bonding residues for maintaining proper Zn(II) affinity, but 
also suggest that changing the length or charge of donor residues does not alter the 
affinity significantly (≤3-fold decrease in Zn(II) affinity). More importantly, these 
second-sphere residues indirectly influence the stability of the pentacoordinate transition 
state during CO2 hydration, altering the catalytic efficiency.  
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 The substitution of residues on the secondary coordination sphere, Thr200Cys/His 
and Asn67His, results in increased catalytic efficiency for pNPA hydrolysis.241,244 
Additionally, the substitution of Thr200 by His, Leu, Ile, Lys, Arg, Ser, etc., led to a 
variation of substrate specificity, which might be explained by the dissimilar van der 
Waals volume of the side chains and their interactions with different substrates. 
Furthermore, a directed evolution method was used to produce an esterase toward a less 
active, bulkier substrate 2-naphthyl acetate (2NA).245 The most successful variant with 
Thr200Ala and Ala65Val mutations, where the Ala to Val substitution was thought to 
increase the “affinity” of the hydrophobic substrate, raised the catalytic efficiency toward 
large aromatic substrates. Later, variants of human carbonic anhydrase II (hCAII) were 
designed by Höst et al. with the goal of modulating the size and increasing the shape of 
the hydrophobic pocket for ester binding.194,195 The hydrophobic pocket close to the Zn(II) 
site in hCAII is defined by four amino acids: Val121, Val143, Leu198, and Trp209.239 In 
this work, increasing the size of the pocket was achieved by Val121Ala/Val143Ala 
mutations, which showed a significant increase in the catalytic efficiency toward larger 
substrates with longer acyl chains.194 Moreover, a Thr200Ala mutation was introduced in 
addition to the two Val mutations, creating a hCAII derivative with a catalytic efficiency 
5 orders of magnitude better than that of the WT-hCAII toward pNPA hydrolysis.195 
These efforts provide the foundation for elucidating the structure−function relationship of 
the active site of CA, shedding light on the de novo design of Zn(II) hydrolytic sites (vide 
infra). 
 Designed zinc metalloprotein systems have shown modest activity until recently. 
Notably, a few successful examples of hydrolytic zinc centers have been reported based 
on redesigns of native proteins. There has been no precedent of incorporating an efficient 
zinc hydrolytic center in a novel peptide sequence until Dr. Melissa Zastrow from our 
group reported her CA mimic based on the TRI family peptides.125 It is important to 
introduce the basis of this construct and the design of CA mimic here because my copper-
peptides share the same scaffold and similar sequences.  
 A well-defined coiled coil scaffold based on the heptad repeat approach is used as 
a basic construct for this thesis. Using the program InsightII/Discover,246 DeGrado 
applied negative design principles3,27,33 to prepare the 29 amino acid peptide CoilSer 
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(CS)8,9 (Table I-2), which was acetylated at the N-terminus and amidated at the C-
terminus, with the intention of generating an antiparallel four-stranded coiled coil 
(4SCC). However, X-ray analysis demonstrates that the resulting aggregate is an 
antiparallel (two “up” C-termini and one “up” N-terminus) three-stranded coiled coil 
(3SCC).9 The basis of this approach is to exploit the heptad repeat, known to induce α-
helix formation. Simply, the concept is that a peptide assembly will form through 
“hydrophobic collapse”247–250 based on the exclusion of hydrophobic residues from the 
aqueous phase. Control of strand number is achieved by matching the packing of the 
hydrophobes into the desired aggregates (2SCC, 3SCC, or 4SCC). Orientational control 
(parallel vs antiparallel) and solubility are conferred by hydrophilic, charged residues 
placed at the interhelical interface. These charged residues form salt bridges at 
appropriate pH conditions.  
 A heptad is composed of seven amino acid residues, denoted as abcdefg, where a 
and d positions are usually hydrophobic residues, and e and g positions are salt-bridging 
residues.251,252 The connectivities between helices and overlapping hydrophobes are often 
represented as helical wheel diagrams (Figure I-7). For heptads containing Leu, the 
addition of each 7 amino acid repeat confers ∼9 kcal/mol of stability to the system.253,254 It 
should be noted that the intrinsic nature of the heptad places the a residue of the first 
heptad slightly (∼20°) out of phase with the a residue of the following heptad. To 
optimize packing of the hydrophobes, the resultant α-helices twist or supercoil around 
one another. This is where the name “coiled coil” comes from as α-helices (coils) 
supercoil around each other to form the stable aggregate. 
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Figure I-7. Helical wheel diagram of (A) 2SCC, (B) 3SCC, and (C) 4SCC. Reproduced 
with permission from ref 251. Copyright 2004 American Chemical Society. 
 Because of the high symmetry of these systems, one must determine whether a 
single protein fold exists in a “native-like fold”, or has multiple similar energy 
conformations, which is then termed a “molten globule”.255–257 Usually, increasing the 
number of heptads or increasing the asymmetry in the sequence will lead to native-like 
folds. DeGrado demonstrated that a parallel 3SCC can be achieved by preparing Coil-
VaLd.11 This sequence alternates Val and Leu residues at the a and d positions, 
respectively, assuring that all helices are aligned by commensurate matching of the amino 
acid side chains in each layer. 
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 On the basis of these early studies, DeGrado and Pecoraro designed the 
amphipathic peptide scaffold known as the TRI family of peptides, so named because a 
parallel 3SCC scaffold was desired. This scaffold utilizes the generic heptad repeat, 
LKALEEK, and is capped by Gly residues at either end.10,12,13 The peptides in this group 
are BABY, TRI, and GRAND, which have three, four, and five heptad repeats, 
respectively (Table I-2). The N-termini are acetylated and C-termini amidated to align the 
helical dipole, facilitating the assembly of the coiled coils.10,12,252  
 The TRI-family peptides self-assemble upon dissolving in water into 2SCCs at 
low pH (< 5) and 3SCCs at higher pH (> 5.5).10,12 The Leu residues in the interior of the 
helix bundle can be substituted for heavy or transition metal-binding residues such as Cys 
or His. The locations of the mutations included in this chapter are described in Table I-2. 
At physiological pH, these peptides adopt a 3-fold symmetry, which is an excellent 
framework to generate trigonal, tetrahedral, or trigonal pyramidal metal coordination 
environments.39  
 Despite the prevalence of multisite metalloproteins in nature, there are few reports 
of designed two-site metalloproteins in which two different metals exist in separate 
binding sites.7,124,125,258 Of these, only one has reported catalytic activity (Table I-1).124,125 
This de novo designed 3SCC contains two metal sites, one for structural stabilization 
(HgS3) and the second for hydrolytic activity (ZnN3O) within just a few hundred-fold of 
the native CA. To design a 3SCC, which discriminates two different metals in two 
different sites, the peptide TRIL9CL23H was used together with a metal ion with high 
affinity for thiolate ligands but low affinity for His (Hg(II)). Previous work demonstrated 
that Hg(II) can be used to induce folding in unfolded peptides and increase 
thermodynamic stability in prefolded peptides (as demonstrated by CD denaturation 
studies).13,124,125 Additionally, Hg(II) provides a well-studied spectroscopic tag for the 
formation of a 3SCC (UV−vis and 199Hg NMR differentiate between linear HgS2 found in 
a 2SCC and trigonal HgS3).259 In the presence of this highly stable Hg(II)pep3 complex, 
Zn(II) then binds solely to the His3 site.  
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Figure I-8. Ribbon diagrams of the [Hg(II)]S[Zn(II)(H2O/OH−)]N(CSL9PenL23H)3n+ 
parallel 3SCC (one of two different 3-helix bundles present in the asymmetric unit) at pH 
8.5. Shown are the main chain atoms represented as helical ribbons (cyan) and the Pen 
and His side chains in stick form (sulfur = yellow, nitrogen = blue, oxygen = red). (A) 
One of two trimers found in the asymmetric unit of the crystal structure; (B) a top down 
view of the structural trigonal thiolate site, Hg(II)S3, confirming the proposed structure of 
Hg(II) in Cys-containing TRI peptides.10 This metal site should mimic well the structural 
site in the metalloregulatory protein MerR.260 (C) A side view of the tetrahedral catalytic 
site, Zn(II)N3O, which closely mimics CA and matrix metalloproteinase active sites.261 
All figures are shown with 2Fo − Fc electron density contoured at 1.5σ overlaid. 
Reproduced with permission from Ref 1. Copyright 2014 American Chemical Society.  
 One motivation behind the development of a Zn(II)N3 site was to model the active 
site of CA, which catalyzes the reversible hydration of carbon dioxide and is one of the 
fastest known and most well-studied zinc metalloenzymes, making it an excellent system 
for de novo design mimicry studies. X-ray crystallographic studies on the Hg(II)Zn(II) 
complex of the related peptide sequence CSL9PenL23H (the CS sequence has properties 
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similar to those of TRI in solution) confirmed the presence of Hg(II) in the sulfur site 
(fully trigonal in one of the 3SCCs in the asymmetric unit and T-shaped in the second) 
and a Zn(II)N3X site in both 3SCCs in the asymmetric unit, analogous to that found in 
CA (Figure I-8).125  
 This X-ray structure was significant for two reasons. First, it demonstrated that 
the proposed trigonal Hg(II) center for Hg(II)(TRIL16C)3− existed as was predicted (vide 
supra) and provided the first structural model for the Hg(II) binding site in the 
metalloregulatory protein MerR.260,262–264 Second, this work demonstrated that the native 
protein fold of CA was not necessary to achieve a closely similar structural model for the 
first coordination sphere of the Zn(II)(His)3(H2O) center. One can conclude that for the 
first coordination sphere, this type of center can be accommodated in protein structures as 
varied as a twisted β-sheet with a long water channel as found in the native enzyme or in 
the hydrophobic interior of an α-helical coiled coil as shown for 
[Hg(II)]S[Zn(II)(OH2/OH−)]N(TRIL9CL23H)3n+.  
 Finding that the structural similarity of the Zn(II) site to that in CA is limited to 
the first coordination sphere (Figure I-9) allowed, for the first time, to begin to address 
what is the minimal unit required for catalytic activity in this type of system. To do this, 
Pecoraro and co-workers initially looked at whether the construct could catalyze the 
hydrolysis of pNPA, the non-physiological substrate of CA often used for analysis of its 
reactivity as compared to mutants and small molecule model complexes. Analysis of 
these reactivity studies demonstrates that hydrolysis of pNPA by 
[Hg(II)]S[Zn(II)(OH2/OH−)]N(TRI-L9CL23H)3n+ follows enzyme-like saturation kinetics 
with a maximal kcat/KM of 31 ± 4 M−1s−1, about 550-fold more efficient than comparable 
small molecule model complexes.124,125,265–267 Further, it is within ∼100-fold of the 
maximum efficiency of CAII and has a similar pH-dependent profile (increasing with 
increasing pH), yet the pKa is shifted ∼2 units higher (9.0 ± 0.1 versus 6.8 for CAII).268,269 
Importantly, the model compares even more favorably with CA mutants such as 
Thr199Ala in which the Thr residue that forms a hydrogen bond to the Zn(II)-bound 
solvent is replaced by Ala and as a result loses ∼100-fold of its catalytic efficiency along 
with an increase in pKa of about 2 units.231,270,271 Therefore, it is reasonable to assume that 
the design of further secondary interactions similar to those found in CA is needed to 
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bridge the differences between this design and the native enzyme (assuming it is possible 
in this alternate scaffold). One other designed Zn(II)N3 site (vide infra) catalyzes pNPA 
with a kcat/KM ∼20-fold faster than [Hg(II)]S[Zn(II)(OH2/OH−)]N(TRIL9CL23H)3n+ and has 
a pKa of 8.2 ± 0.1.123 CA’s physiologically relevant reaction, CO2 hydration, was also 
examined, which yields an efficiency of ∼1.8 × 105 M−1s−1 (pH 9.5) that is within ∼500-
fold of that of CA and faster than any reported small molecule complex.125,272–279 There are 
no reports of CO2 hydration by other designed protein systems.  
 
Figure I-9. Overlay of the Zn(II)N3O site in [Hg(II)]S[Zn(II)(H2O/OH−)]N(CSL9PenL23-
H)3n+ with the active site of human CAII. [Hg(II)]S[Zn(II)(H2O/OH−)]N(CSL9PenL23H)3n+ 
is shown in cyan (PDB code: 3PBJ) and CAII in tan (PDB code: 2CBA). (A) Top-down 
view of the overlay with CAII. The solvent molecule associated with [Hg(II)]S[Zn(II)-
(H2O/OH−)]N(CSL9PenL23H)3n+ is shown in red, and that associated with CAII lies 
underneath. (B) Side-on view of the overlay with CAII. The model displays an excellent 
structural overlay for the first coordination sphere atoms with CAII; however, the 
orientation of the imidazoles differs between the two proteins. Another subtle difference 
is that the present structure has three ε amino nitrogens bound to the Zn(II) ion, whereas 
CAII has a mixed two ε and one δ coordination sphere. Overlay was performed manually 
in PyMol. Reproduced with permission from Ref 1. Copyright 2014 American Chemical 
Society.  
 Having demonstrated that a significant amount of hydrolytic activity can be 
achieved simply by removing an active site from its native scaffold and placing it into a 
3SCC, the next major aim was to incorporate secondary interactions to modulate the 
properties of this site (activity, pKa, binding affinity). As mentioned above, the design of 
H-bonding channels so often found in native proteins is likely necessary. However, this 
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advanced design will likely require changes to the location of the active site within the 
3SCC to retain stability and potentially allow for improved substrate access. To this end, 
Pecoraro and co-workers recently reported the systematic variation of the Zn(II) active 
site along the TRI sequence.124 It is important to note that, although the properties of the 
Zn(II) site remain roughly the same in the absence of the Hg(II)S3 site, they chose to 
retain the structural site when moving the active site along the linear sequence to take 
advantage of the Hg(II)S3 chromophore’s utility as a spectroscopic tag to ensure that the 
oligomeric state (trimer) remained. The first variation in sequence involved switching the 
locations of the two different metal sites to generate 
[Zn(II)(OH2/OH−)]N[Hg(II)]S(TRIL9H-L23C)3n+. Assuming that the general orientation of 
the Zn(II) site remains constant (with the Zn(II)-bound solvent molecule oriented toward 
the N-terminus), it was expected and found that the substrate access was improved. This 
was further confirmed through inhibition studies using one of the products, acetate, and 
fitting the pNPA kinetic data for competitive inhibition. The KI’s for the Zn(II) sites in 
(TRIW-H)3 and [Hg(II)]S(TRIL9CL23H)3− are similar (0.34 ± 0.01 and 0.32 ± 0.01 M, 
respectively), while that for [Hg(II)]S(TRIL9HL23C)3− is 0.20 ± 0.01 M.124 Despite the 
improved substrate access, however, the catalytic rate is decreased relative to the original 
model. Overall, the maximal catalytic efficiency is about the same as the original model 
with and without the structural site (24 ± 3 M−1s−1).  
 The second variation in sequence involves moving the His3 site from the 23rd 
position closer to the N-terminus of the coiled coil and into a d site to yield 
TRIL9CL19H. It is worth considering why a and d sites might be different. If one 
considers the sequence LKALEEKLKALEEK, one realizes that going from an a position 
to a d position requires a spacer of two amino acids LKAL, whereas proceeding from d 
to a requires three amino acids, LEEKL. This sequence difference requires that layers be 
separated asymmetrically within the helical core. Second, because of the rotation of the 
peptide backbone around the helix, it is expected that the side chain of an a position 
hydrophobe or metal ligand will be oriented slightly differently from that of a d position 
side chain. Thus, either steric effects based on the layer above a metal or the positioning 
of a metal ligand will be different depending on the choice between an a or a d position 
for the metal-binding site. Analysis of the hydrolysis of pNPA by the metal-bound 
! 38 
complex of this peptide showed that while maximal catalytic efficiency is approximately 
the same as for those previously described, the substrate access is slightly worse, while 
the maximal catalytic rate is improved. The most drastic difference with this sequence, 
however, is that the kinetic pKa shifted up to 9.6 (all of the others are approximately the 
same within error, ∼9−9.2). It is unclear whether this is due to the altered orientation of 
the His ligands (from a site to d site) or simply the change in location. The KI of acetate 
inhibition for L19H is approximately the same as for the L23H peptides, 0.36 ± 0.01 M. 
The apparent dissociation constants of Zn(II) to the His3 site for all of the above-
described complexes vary from ∼0.2 μM (L23H sites) to 0.4 μM (L19H) to 0.8 μM 
(L9H) at pH 9, demonstrating some location-dependence. Generally, these binding 
affinities indicate that the designs bind Zn(II) well and are in the same range as for 
similar designs with three binding ligands; however, they remain weak as compared to 
native Zn(II) enzymes (Kd ∼ nanomolar to picomolar).6,36,231,280–288  
 In summary, despite drastic variation in the location of the active site along this 
3SCC, significant catalytic efficiency for hydrolysis is retained, suggesting that this may 
represent the “baseline” activity in this type of model. Further, Pecoraro and co-workers 
have shown that location can be used to control binding affinity, pKa, catalytic rate, and 
substrate and solvent access (and selectivity). Although there are very few studies 
examining the effects of the protein matrix on the active site in this way,24 such a 
systematic approach is very important to future design endeavors, especially when 
deciding on the placement of the active site. As a whole, these studies demonstrated that 
replicating the exact protein fold of the native system was unnecessary to achieve a 
structural and functional model; however, maximal catalysis may still be critically 
dependent on the native protein structure as the incorporation of water channels, H-bonds 
for activation or stabilization of the substrate or intermediates, and H-bonds to metal 
coordinated amino acids may be best facilitated by β-sheet structure rather than α-
helices.  
 Although most designed enzymes rely on monomeric structures with metal sites 
inserted into their cores, Der and co-workers serendipitously discovered that a designed 
Zn(II) site at the interface of a homodimer (MID1-Zn) could effectively catalyze pNPA 
and p-nitrophenyl phosphate (pNPP) hydrolysis (Table I-1).123,289 The motivation behind 
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the design was to use metal-binding sites at a designed protein interface to improve 
computational design protocols for protein−protein interactions. Given that metals form 
stronger interactions with the side chains of residues such as His, Cys, Asp, and Glu than 
do protein−protein hydrogen bonds or van der Waals contacts, it is reasonable to 
postulate that metal-binding interactions should overcome suboptimal hydrogen-bonding 
patterns or packing at the interface in a design.  
 The design was based on a two-residue Zn(II) binding site on a monomeric 
protein (derived from the Rab4-binding domain of rabenosyn), which was then dimerized 
and computationally optimized to form what was intended to be two ZnHis4 binding sites 
at the interface of a homodimer.289 The design model, which also included interactions 
between Met38, Tyr41, and Phe42 on both chains for forming a hydrophobic core at the 
interface, was named MID1 (metal interface design 1). As intended, MID1 forms a dimer 
at high micromolar concentrations both with and without Zn(II) present, but the 
dissociation constant in the presence of Zn(II) is more than 100-fold stronger than it is in 
its absence (Kd < 30 nM). X-ray crystallography demonstrates that MID1-Zn closely 
resembles the model, although with some key differences (Figure I-10). One difference is 
that only three His residues coordinate each Zn(II) ion at the interfaces. The coordination 
sphere is completed either by carboxylate groups from the C-terminal Asp or by a 
symmetry-related molecule or tartrate from the crystallization buffer. A small deviation 
in the binding orientation and in the protein−protein interface contacts was also observed. 
Despite these differences, a high affinity metal-mediated homodimer site was prepared 
using only computational design without any optimization by directed evolution.  
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Figure I-10. X-ray crystal structure of MID1-zinc, a designed protein with a metal-
mediated protein interface. The red mesh represents the active site cleft above the open 
coordination site of the ZnHis3 metal site. Reproduced with permission from Ref 1. 
Copyright 2012 American Chemical Society. 
 Although the original intention was to obtain a ZnHis4 site, Der et al. observed 
that the presence of tartrate in the ZnHis3 represented a small binding pocket (∼6 Å wide 
and 4 Å deep), suggesting that the interface metal site may display esterase activity 
toward substrates like pNPA and pNPP. Indeed, MID1-Zn effectively catalyzes pNPA 
hydrolysis with more than 50 turnovers and a rate of 0.22 s−1 and KM = 0.47 mM at pH 
8.5.123 The reaction is pH-dependent (increasing efficiency with increasing pH) and has a 
kinetic pKa of 8.2 ± 0.1 and a maximal efficiency of 630 ± 90 M−1s−1. Control 
experiments using the apo version of the homodimer, a mutated version with no His 
binding residues, the WT monomer on which the design was based mutated with His 
residues, and free zinc all demonstrated no significant activity above the background, 
confirming that the interface pocket and Zn(II)-binding site are both required for 
catalysis. Further, mutation of some of the surrounding His residues to Glu demonstrated 
a loss of activity because the open coordination site was closed (His12Glu and 
His35Glu). Despite the original design intention of two Zn(II) sites, only one active site is 
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observed in the crystal structure (only one tartrate is bound to one Zn(II) site), and the 
dimer is fully formed with 1 equiv of Zn(II) for 2 equiv of monomer (no additional 
activity is observed with more Zn(II) present). Although pNPP is intrinsically less 
reactive, MID1-Zn still effectively catalyzes its hydrolysis with an efficiency of 14 M−1s−1 
at pH 8.5. The KM for this reaction, 12 μM, is 40 times lower than that for pNPA because 
of favorable electrostatic interactions between the negative phosphate group and positive 
Zn(II) active site.  
 The authors discuss the importance of the binding cleft in achieving these 
efficiencies. However, while enhancing efficiencies, it is expected that such an open 
catalytic site is likely to exhibit significant product inhibition, which has been a bane to 
small molecule model compounds. Synthetic models are relatively ineffective given that 
they have no binding cleft, although this can be improved somewhat in apolar solvents, 
which can simulate the apolarity of an active site cleft.290 Further discussions and 
comparisons will be made in a later section where the de novo design of a ZnHis3O site in 
a 3SCC is described. Regardless, this study of a minimalist engineered enzyme 
demonstrates that cleft formation at protein interfaces provides another effective strategy 
for the rational engineering of new catalytic activities.  
4. Design of copper proteins 
 Copper proteins play an important role in maintaining the redox poise and 
catalyzing oxidoreductase chemistry. The two major functions of copper centers are 
electron transfer and catalysis, both of which have been the target for protein redesign 
and de novo design efforts. Over the past two decades, the redesign of copper centers has 
seen considerable successful examples that involve the modulation of copper electron 
transfer capacity, tuning the catalytic activity, and the incorporation of copper centers 
with novel reactivity into foreign proteins. These studies address important issues such as 
the function of each copper-coordinating ligand, the role of protein secondary or tertiary 
structure, possible electron transfer pathways, etc. De novo designed copper centers, 
however, were still scarce at the time that this thesis began. Although there were a few 
reports of copper-binding peptides that share spectroscopic features of either a 
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cupredoxin site or a type 2 copper (T2Cu) center, no reactivity was demonstrated. Since 
the focus of this thesis is to design a functional model for a copper enzyme nitrite 
reductase (NiR), I will only summarize the effort of designing an electron transfer center. 
I will then discuss a few examples of designed type 2 centers. For a more detailed 
discussion on designing copper electron transfer proteins, readers can refer to Ref 1.  
 
The design of copper electron transfer centers 
 Copper electron transfer centers encompass cupredoxin (type 1 copper, T1Cu), 
CuA, and some T2Cu centers. They function in electron transfer chains or in chemical 
reactions by relaying electrons to the catalytic centers.291–295 Both cupredoxin and CuA 
centers are found in an overall Greek β-barrel fold, with the metal-binding ligands in a 
pocket between loops, protected from solvent access. T1Cu centers are mononuclear 
copper centers coordinated to two imidazole N atoms from His residues and the thiolate 
from a Cys residue in a trigonal plane (CysHis2).296,297 In addition, one or two weak axial 
ligands can be bound to the copper center, resulting in a distorted tetrahedral geometry 
that is not preferred by either Cu(II) or Cu(I) metal ions.298 This unique structural feature 
provides cupredoxins with unusual spectroscopic and redox properties. The contribution 
of the copper electronic structure to its function and spectroscopic properties has been 
thoroughly studied.296–312 CuA is a binuclear copper center with a diamond shaped [2Cu-
2S(Cys)] core structure and NHis, SMet, and Obackbone ligands bound to the copper ions 
(Figure I-11). CuA centers have a unique structural feature, the Cu−Cu bond, which is not 
commonly observed in biological systems for first row transition metals.313,314 The 
electronic and spectroscopic characteristics of CuA centers have been previously reported 
and reviewed.291,297,301–303,308,309,315–318 
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Figure I-11. CuA center in N2OR from Pseudomonas nautica. The purple spheres are 
copper ions. PDB code: 1QNI.319 
 Azurin (Az), a native T1Cu protein, has been widely used in studies intended for 
modulating the redox and electron transfer properties of the copper center. Az is a small 
protein with a T1Cu center that shuttles electrons in certain types of denitrifying 
bacteria.320–322 At its T1Cu site, copper is coordinated to two His (His47, 117) and a Cys 
(Cys112) in a trigonal plane, while weakly interacting with two axial ligands, Met121 
and a carbonyl oxygen from Gly45.323 The electron transfer function of Az was proposed 
to be related to cellular redox stress.324 Extensive studies have been carried out to probe 
the roles of each ligand to the spectroscopic features, redox properties, and the impact of 
certain substitutions on the driving force and the reorganization energy of the electron 
transfer process.325–339 In particular, Lu and co-workers carried out a series of studies 
aiming to address the roles of the Cys ligand,340,341 the axial Met ligand,342–344 and 
secondary coordination sphere interactions.345 In these studies, a semisynthetic method 
that allows the fusion of a recombinantly expressed protein with a synthetic peptide 
containing the desired substitutions was used to incorporate unnatural amino acids into 
Az.346 The impact of these residues on the spectroscopic and redox properties of T1Cu in 
Az highlights the power in using protein redesign to deepen our understanding of the 
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factors that influence redox properties. Furthermore, these designs show varied 
intraprotein electron transfer capability, which is indicative of variation of the 
reorganization energy with rational design.347  
 A CuA center was first introduced into the CyoA subunit of E. coli cytochrome o 
quinol oxidase complex, a scaffold that is devoid of a copper binding site.348,349 
Mutagenesis studies on the CuA-CyoA hybrid protein demonstrate that at least five 
residues, two His, two Cys, and one Met, are essential to construct a CuA site.349 A CuA 
center was then incorporated into an Az, taking the place of the T1Cu center.350–359 The 
roles of each coordinating ligand were examined.351,352,356,358,359 Electron transfer activities 
were also demonstrated for the CuA−Az hybrid protein.353 Moreover, several groups have 
incorporated a CuA center into another T1Cu protein, amicyanin, a cupredoxin found in 
methylotrophic bacteria,360,361 and showed the electron transfer capability in these 
designed systems.360,361 
 The examples introduced above all have the copper electron transfer center in the 
loop region of a Greek β-barrel fold. By creating a copper electron transfer center in α-
helical bundles, people can start to address the question of whether β-sheets are necessary 
to facilitate electron transfer. In addition, the de novo design of copper electron transfer 
centers provides critical insight into how the geometric constraints influence the 
spectroscopy.  
 Schnepf et al. were the first to report a T1Cu center embedded in an antiparallel 
four-helix bundle using a template-assembled synthetic protein (TASP) approach.362,363 
TASP is a de novo design approach that entails a combinatorial assembly of peptides that 
are linked to a preorganized template.364–368 As a result, this strategy bypassed the 
entropically unfavorable nucleation step in the assembly of secondary structures, 
producing the desired peptidic scaffold for further functionalization.366–368 Topological 
templates on the surface were used to covalently attach peptide strands to a 
predetermined packing arrangement. By designing and synthesizing a library of proteins, 
the modification on the first and second coordination sphere was demonstrated by 
changing the coordinating ligands, altering the sterics, polarity, and flexibility of amino 
acid side chains.  
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 Also taking a de novo design approach, Tanaka and co-workers incorporated a 
His2Cys core motif in a four-stranded α-helical coiled coil scaffold to adopt a T1Cu 
site.369,370 Likewise, the amino acid sequence was based on a heptad approach, containing 
Lys and Glu residues to form electrostatic interactions and nonpolar residues such as Ala 
and Leu to establish a hydrophobic interior. The His2Cys residues replace Leu residues in 
three of the four helices, forming a preorganized trigonal planar binding site.369 A few 
exogenous axial ligands were introduced, which gives the copper center a gradual change 
of colors from blue to green, indicative of the change of copper coordination from 
trigonal planar to tetrahedral. Using the same protein scaffold, they modified certain 
residues to accommodate a CuA center.371 Similar to their T1Cu construct, the 
coordinating ligands in the new protein include four His residues and two Cys residues as 
equatorial and bridging ligands, respectively, but are devoid of axial (SMet and Oxx) 
ligands. XAS studies support a CuA coordination environment in this scaffold with typical 
ligand–metal and metal–metal distances similar to those of the native CuA centers.372   
Copper catalytic centers by protein redesign 
Design of a CuB site  
 Heme-copper oxidases (HCOs) are a class of important terminal oxidases that 
catalyze the reduction of molecular oxygen to water, coupled to proton translocations, 
which drive the synthesis of ATP in eukaryotic mitochondria and bacteria.373–378 HCOs 
contain a bimetallic iron−copper center with a CuB site located above the heme porphyrin 
plane, and coordinated by three His residues and a hydroxide ion in a tetrahedral 
geometry.379 Because native HCOs are large membrane proteins that contain other metal-
binding sites, it is challenging to isolate the CuB-heme site for biochemical studies.  
 Lu and co-workers introduced a CuB center into myoglobin (Mb), a small globular 
oxygen-binding protein that does not contain a copper site in its native state.104,380,381 With 
the guidance of molecular modeling of sperm whale myoglobin (swMb), two mutations 
were introduced, Leu29His and Phe43His, which, combined with the distal His64 
residue, form a (His)3 copper binding site.104 The double-mutation does not perturb the 
structure of the protein or the integrity of the heme center. The difference spectrum 
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before and after Cu(II) addition indicates a single Cu(II)-binding site. An important 
method to characterize the CuB-heme site in HCOs is to examine the binding of a small 
bridging ligand. Cyanide was titrated into a solution of CuBMb, leading to changes in the 
UV−vis spectra from a high- to low-spin heme. In the presence of copper, the change 
required less cyanide. These results indicate that cyanide interacts with both CuB and 
heme iron, which is further supported by EPR studies. Moreover, the disappearance of 
the Fe(III)-heme EPR signal upon addition of copper to CuBMb indicates a spin coupling 
between the iron and the copper center, another important feature of HCOs.  
 The kinetics of oxygen binding and its reduction at the CuBMb site was 
investigated by Sigman et al.380 In the absence of copper, the oxygen-binding ability of 
CuBMb decreases in comparison to WTMb. However, once a redox-inactive metal was 
added (e.g., Ag(I)), the oxygen affinity was enhanced. Kinetic studies of oxygen 
reduction suggest that the copper ion facilitates the reduction of oxygen, which then 
converts heme to verdoheme. Protons are necessary for maintaining the integrity of the 
heme center by inhibiting the conversion from heme to verdoheme.380 The redox 
properties of CuBMb were examined using UV−vis spectroelectrochemistry, showing that 
the reduction potential of the heme iron center is strongly dependent on the surrounding 
environment and electrostatics at the distal site.381 Specifically, the reduction potentials 
were determined for CuBMb in the presence and the absence of the bridging ligand 
cyanide, Cu(II), and a redox-inactive Zn(II). The cyanide free complexes generally have 
higher reduction potentials than the cyanide-bound complexes. Most importantly, in the 
absence of cyanide, the reduction potential of the heme center remains the same (+77 to 
+80 mV, vs NHE) whether or not a divalent cation is present. However, in the presence 
of CN−, the reduction potential of Cu(II)−CuBMb is 16 mV higher than that of CuBMb; 
the reduction potential of the Zn(II)−CuBMb was even higher, an effect attributed to the 
addition of positive charge close to the heme center. These studies provide important 
insight into the role of CuB and proton coupled redox processes in native HCOs.  
 X-ray crystallography and relevant biophysical studies reveal a cross-link 
between the copper-coordinating His24 and a Tyr244 residue, an important feature of 
native HCOs. A covalent bond is formed between the carbon C6 of the Tyr residue and 
nitrogen Nε of the His residue. This covalent link is responsible for the decreased pKa 
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values of both the phenol and the imidazole groups.382–385 The importance of the Tyr 
residue at the active site was also demonstrated for the engineered HCO system CuBMb. 
Miner et al. introduced a Tyr residue at two different positions close to the copper-
coordinating His of the CuB site, aiming to examine whether this functionality would lead 
to higher efficiency in reducing oxygen to water.386 A Phe four residues away from the 
copper-coordinating His29 was substituted with a Tyr to mimic the native HCO, leading 
to F33Y-CuBMb. The second design was based on the crystal structure of a cbb3 HCO,387 
and resulted in the G65Y-CuBMb mutant. This second mutant exhibited higher product 
selectivity than F33Y-CuBMb and could cleanly reduce oxygen to produce water with a 
higher TON that was attributed to the better positioning of the Tyr residue.  
 
Scheme I-3 
 Having demonstrated the importance of the Tyr residue in close proximity to the 
copper-coordinating His, to further investigate the role of this cross-linked Tyr-His 
functionality, Liu et al. introduced an unnatural amino acid imiTyr (Scheme I-3) into the 
engineered CuBMb protein, yielding imiTyrCuBMb.388 Cu(II) binds to imiTyrCuBMb with 
a Kd of 1.6 μM, with a perturbation of the Soret band of heme. The rate of oxygen 
reduction was measured in the presence of a reductant and a redox mediator; and catalase 
and SOD were introduced to distinguish between the formation of water and reactive 
oxygen species. The oxygen reduction assay shows that imiTyrCuBMb carries out an 
efficient and selective oxygen reduction to produce water only when Cu(II) is bound to 
the protein. More importantly, the turnover number of Cu(II)-imiTyrCuBMb is almost 3 
times that of Cu(II)-F33YCuBMb (a mutant lacking the Tyr-His cross-link). These studies 
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demonstrated the functional significance of the Tyr-His cross-link in maintaining 
sufficient catalytic activity. 
 Diels-Alder catalysts 
 A series of Cu(II) centers in protein matrices that are capable of catalyzing 
enantioselective Diels−Alder reactions have been reported. Aqueous solutions of Cu(II) 
complexes with amino acids,389,390 Cu(II) DNA intercalating agents,391–393 and 
Cu(II)−phthalocyanine anchored noncovalently to serum albumins394 were shown to carry 
out stereoselective Diels−Alder reactions using (aza)chalchones and cyclopentadiene as 
the reactants (Scheme I-4). Here, I introduce examples of redesigned proteins as catalysts 
for the benchmark reaction described in Scheme I-4.  
 
Scheme I-4 
 The imidazole glycerol phosphate synthase (tHisF) from Thermotoga maritime is 
a thermostable enzyme essential in the biosynthesis of His residue,395 which has a typical 
TIM barrel structure with a narrow bottom and a wide top. This scaffold has been used to 
engineer a His2Asp Cu(II) binding site in proximity to the wide top rim.396 The selective 
mutation of two noncoordinating residues close to Asp at position 11 yielded the mutant 
tHisFL50H/I52H, where the copper binding site is accessible by relatively large 
substrates (Figure I-12). Furthermore, to avoid nonspecific Cu(II) binding, surface Cys 
and His residues were mutated to Ala. An extensive EPR characterization reveals that 
Cu(II) is coordinated to Asp11/His50/His52 residues, matching the proposed model. 
When the reaction reported in Scheme I-4 was carried out, the conversion was 73%, with 
46% ee and an endo/exo ratio of 13:1. The mutation of either the Asp or the His into an 
Ala of the His2Asp site results in lower conversion values and almost negligible 
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enantiomeric excess values, demonstrating the necessity of a stable Cu(II)N2O center to 
catalyze this enantioselective reaction. As reported in the literature, to obtain a significant 
stereoselectivity in Diels−Alder reactions, the substrate must bind to Cu(II) through a 
carbonyl oxygen and a pyridine nitrogen to activate this reaction.394,397 This type of 
activation is required also for the Cu(II)-tHisF protein. The chalcones (an aromatic 
ketone and an enone that form the central core for a variety of important biological 
compounds) lacking the pyridine nitrogen in the ortho position with respect to the 
carbonyl did not react with significant conversion values.396 
 
Figure I-12. Putative Cu(II) binding site in tHisF mutant. (A) top view. (B) side view. 
Models are made based on the crystal structure of tHisF (PDB code: 1THF).398 
 The bovine pancreatic polypeptide (bPP) is a 36 amino acid peptide that contains 
a poly-Pro type II helix (residues 1−8), a turn (9−12), and a helix (13−31).399–401 The poly-
Pro helix is backfolded on the α-helix, and the construct dimerizes in solution. A 31-
amino acid truncated sequence (1−31) of bPP was designed, where Tyr7 was mutated 
into a His, a L-3-pyridylalanine, or a L-4-pyridylalanine residue, while an Asp or Glu 
residue in the loop (position 10) provided additional donor atoms.402 Upon dimerization, a 
His2 or pyridyl2 copper-binding site forms within the intrahelical space of the dimer. 
Further mutations were introduced at the interface between the dimers with an attempt to 
make the interior less sterically crowded. Unfortunately, these mutants were found to 
exist predominantly in their monomeric Cu(II)-peptide form. The best results for the 
reaction shown in Scheme I-4 (complete conversion of the substrate and up to 83% ee) 
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were obtained with the L-3-pyridylalanine mutant (bPPc). As observed for tHisF, the 
coordination of the substrate to the Cu(II)-bound protein is a prerequisite for having the 
highest activity.402 Moreover, Cu(II) or WT bPP 1−31 alone does not show significant 
catalytic activities, neither does the His-containing mutant of bPP. Overall, these results 
demonstrate that the nature of the coordinating groups (pyridyl vs imidazolyl, and their 
diastereoisomers) has a profound impact on regulating the stereoselectivity and the 
activity of these reengineered protein catalysts. Moreover, it has been previously shown 
that the presence of a cavity in the construct is not a strict requirement to achieve control 
of the stereoselectivity. These bPP mutants were also examined as catalysts for the 
Michael addition reaction, exhibiting significant stereoselectivity.402 
 An effective strategy for incorporating a metal cofactor into a protein is to 
incorporate a metal complex to the protein scaffold by a covalent linking approach, 
instead of binding a metal ion directly to the protein amino acid side chains as its ligands. 
Lactococcal multidrug resistance Regulator (LmrR) protein, a dimeric protein of ~13.5 
kDa per subunit, was engineered to catalyze the Diels−Alder reaction shown in Scheme 
I-4.403 LmrR consists of a typical β-winged helix-turn-helix domain with an additional C-
terminal helix.404,405 The large flat hydrophobic core in this dimer was functionalized with 
two phenanthroline- or bpy-based chelating moieties per dimer (one per monomer) 
(Figure I-13).403 Cys residues, which are not present in the WT protein, were incorporated 
into the protein monomers as anchor points for these copper-binding moieties. By 
reacting bromoacetamide-substituted 1,10-phenanthroline (1,10-Phen) or 2,2′-bpy with 
the Cys residues, mutants were generated with the copper-chelating moieties in the 
hydrophobic core. 
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Figure I-13. (A) Schematic representation of the proposed artificial metalloenzyme in 
which a Cu(II) complex is grafted on the dimer interface of a protein scaffold. (B) 
Ligands used for grafting on the dimer interface. (C) Pymol representations of dimeric 
LmrR in a ribbon and a space-filling model (PDB code: 3F8B). Either position 89 (red) 
or position 19 (yellow) was used for the covalent attachment of the copper-chelating 
ligands. Reproduced with permission from ref 403. Copyright 2012 Wiley.  
 The final constructs can bind two Cu(II) ions and still retain their dimeric form. 
The catalytic activity of the Cu(II)(1,10-Phen)-LmrR-M89C for the reaction described in 
Scheme I-4 (monitored after 3 days of reaction) is remarkable: the reaction yields 98% 
conversion of the substrate and 95% ee of the (+)-endo isomer at room temperature. 
Interestingly, an even higher enantiomeric excess (97%) was achieved when the reaction 
was carried out at 4 °C, albeit with a lower conversion (93%). Conversely, the 
Cu(II)(2,2′-bpy)-LmrR-M89C mutant yielded 66% ee of the opposite (−)-endo isomer of 
the Diels−Alder product. This demonstrates that these constructs can be tuned for a 
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desired stereoselectivity through a proper choice of the position and the nature of the 
Cu(II) sites. The design of these constructs was prompted by the observation that in 
DNAzymes, copper(II) sites close to a chiral environment have the ability to catalyze 
Diels−Alder or Michael reactions with a high degree of selectivity.391–393 The chiral 
scaffold, even quite distant from the copper site, could therefore provide efficient 
secondary sphere interactions to induce significant stereoselectivity. 
 De novo designed type 2 copper centers  
 One of the challenges to obtain a stable catalytic copper center is to design a 
peptide with a coordination environment suitable to stabilize copper on both oxidation 
levels. The coordination geometry of Cu(I) is usually linear, trigonal (T-shaped), or 
tetrahedral, while for Cu(II), distorted square planar, tetrahedral, pyramidal, and 
octahedral geometries are commonly observed.406 However, in copper proteins, 
coordination numbers of four or higher (involving weak interactions between the copper 
ion and distal ligands) are prevalent.407 At the same time, the two principal oxidation 
states (+1 and +2) of copper have different hard−soft behaviors: while Cu(I) is a soft 
metal, Cu(II) has a more intermediate-to-hard character. The general strategy to design a 
defined copper binding site is to mutate the hydrophobic residues into coordinating 
residues such as His, Met, Cys, Asp, or Glu in the interior of the two- to four- stranded 
coiled coils. T2Cu centers, in particular Cu(His)3 centers, play multiple roles in native 
proteins. Their functions span from electron transfer to cofactor-assisted oxygen 
activation to nitrite reduction.408–416 For example, in peptidylglycine α-hydroxylating 
monooxygenase (PHM), the CuH center [Cu(His)3] is involved in shuttling electrons to a 
CuM copper center 12.5 Å away where oxygen activation occurs.411,417,418 
 The first case of de novo designed 3SCCs with a T2Cu center CuHis3 was 
reported in 1993.258 The construct consists of a 19-amino acid peptide based on the 
heptad repeat approach. It contains a 4,4′-bpy moiety at the N-terminus, a His residue for 
Cu(II) binding at the C-terminus, and a Tyr residue adjacent to His as a spectroscopic 
probe (sequence: 4,4′-bpy-GELAQKLEQALQKLAAAHYNH2).258 When reacted with 
Ru5Cl122–, three helices assemble into a homotrimeric α-helix bundle from the template 
created by the fac-[Ru(bpyPep)3]2− unit at the N-terminus (Figure I-14).419,420 The 
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presence of this stable Ru(II)(bpyPep)3 unit assists the formation of an α-helix apo-
(peptide)3 construct, which contains a preorganized (His)3 site at the C-terminus available 
for copper binding. Indeed, the addition of Cu(II) to the Ru(II)(peptide)3 leads to 
Cu(II)Ru(II)(peptide)3 with a dissociation constant of ~3 × 10−7 M determined by the 
change of Tyr emission. Ru(II)(peptide)3 possesses a high degree of helical content; the 
addition of Cu(II) to the Ru(II)(peptide)3 does not change the CD spectrum even when 
Cu(II) is 20-fold in excess compared to Ru(II)(peptide)3. Spectroscopic studies reveal that 
the Cu(II)Ru(II)(peptide)3 complex has a ligand-field band centered at 495 nm (ε = 300 
M−1cm−1) and an AII value of 173 G, fully consistent with the presence of a tetrahedral or 
square planar T2Cu site in a (His)3 environment.258 This work represents the first example 
of a stable T2Cu center in a de novo designed α-helical coiled coil scaffold, laying a solid 
foundation for the development of catalytic T2Cu centers. 
 
Figure I-14. A model of Cu(II)Ru(II)-peptide complex. Reproduced with permission from 
ref 258.  
 Tanaka et al. reported the design of a parallel 3SCC (in the presence of metal 
ions) Ile-zipper peptide (IZ) (sequence YGG-(IEKKIEA)4).421 Similar to the TRI peptide 
introduced earlier, the design of this peptide is also based on a heptad repeat approach.8 
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Ile residues are constructed in the interior of the helical coiled coils and Glu and Lys 
residues are on the helical interface. Substitution of the Ile residue on the third heptad 
with a His yields IZ-3aH and with two His substitutions, IZ-3adH.422 In the presence of 
Cu(II), Zn(II), Co(II), or Ni(II), the peptides are converted from random coils to 3SCCs. 
Interestingly, Cu(II) only induces α-helical formation at a concentration below 100 μM; 
excess Cu(II) destabilizes the helices. Cu(II) binds to IZ-3adH with a dissociation 
constant of 17(1) μM. EPR studies show that Cu(II)(IZ-3adH) likely has a T2Cu with 
N3O coordination in a tetragonal geometry.6 An elongated version of IZ-3adH with 
additional His residues was then designed to impart more stability with an additional 
heptad repeat and to incorporate two metal ions in the same peptide scaffold.7 IZ(5)-
2a3adH has three His residues placed along the helix at 2a, 3a, and 3d positions, out of 
which, 2a and 3a are at i and i + 3 positions while 3a and 3d are at i and i + 4 positions. 
Spectroscopic studies indicate that Cu(II) binds at the 2a position to three His residues 
and a solvent water molecule and Ni(II) binds at the 3a and 3d positions.  
 These examples of incorporating copper centers into de novo designed systems 
have laid a solid foundation for imparting catalysis. Nonetheless, in most cases, no redox 
chemistry has been shown, nor are the copper centers very well characterized. Before the 
beginning of this thesis, there was no report of functional copper centers embedded in de 
novo designed proteins. However, such efforts are necessary to evaluate whether a 
simplified protein construct can incorporate copper into a desired coordination 
environment and impart catalytic activity as seen in native copper centers. When I started 
working on this project, Dr. Melissa Zastrow demonstrated hydrolytic activity with zinc-
bound TRI family peptides. Based on the similarity between the zinc center in CA and 
the T2Cu center in CuNiR,423 one asks the question of whether the same construct is 
capable of carrying out redox-active catalytic activities as seen in many T2Cu centers in 
native proteins.   
5. Thesis outline 
 This thesis is focused on designing a structural and functional model for the T2Cu 
in CuNiR. As shown above, the design of metalloenzyme mimics has seen a significant 
progress, however, the de novo design of a catalytic copper center was essentially non-
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existent before this thesis was begun, which emphasizes the novelty of the work 
described in this thesis.  
 In Chapter II, I describe the design and characterization of the first generation 
model Cu(II)/(I)(TRIW-H)32+/+, the sequence of which contains a Trp at the 2nd position as 
a spectroscopic tag and a His at the 23rd position for copper binding. Detailed 
spectroscopic studies are carried out the probe the coordination environment for both 
oxidation states. Cu(I) and Cu(II) affinities to (TRIW-H)3 are determined using 
competitive chelation assays and Trp fluorescence spectroscopy, respectively. Reduction 
potentials of Cu(II)/(I)(TRIW-H)32+/+ are calculated based on the affinities using the 
Nernst equation. This system has a reduction potential that is ~100 to 150 mV higher than 
that of the T2Cu in native CuNiR, possibly due to the stabilization of a trigonal Cu(I). 
Small molecule binding studies are carried out to evaluate the possibility of forming 
substrate-enzyme and product-enzyme complexes. The rates of nitrite reduction catalyzed 
by Cu(II)/(I)(TRIW-H)32+/+ with sodium ascorbate as a sacrificial reductant are reported. I 
then discuss the possibility of going through a different reaction mechanism with this 
model from the native enzyme. This peptide, as a starting point of my thesis work, has 
pronounced advantages over some of the synthetic small molecule models, however, the 
rates are not ideal, which gave me an incentive to design a better model.  
 
Figure I-15. Helical wheel diagram showing the helical interface region (blue) and the 
interior of the coiled coils (yellow).  
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 In Chapter III of this thesis, I present the modulation of reduction potentials and 
NiR rates by modifying the charged residues at the helical interface (Figure I-15), 
yielding a series of peptides (the TRIW-EH series). The intention of this design is to add 
negative charge close to the copper-binding site to stabilize Cu(II), thus lowering the 
reduction potentials. I show that the reduction potentials are lowered by this design 
strategy not from the stabilization of Cu(II) but the destabilization of Cu(I). pH 
conditions also influence the affinities, more so for Cu(II) than for Cu(I). Detailed 
analysis of how charged residues influence both oxidation states is presented. These 
modifications do not abolish the reactivity of the peptides. The peptides of the TRIW-EH 
series all have NiR activity with varied rates. The increase in rate is directly correlated 
with the decrease in reduction potential within the series, which, however, does not mean 
that the electron transfer step is the rate-limiting step in the catalytic cycle. This chapter 
describes the first systematic study on how charged residues influence the copper binding 
affinities, reduction potentials, protonation equilibria, and NiR rates for a T2Cu center, 
showcasing the strength of de novo design in deepening our understanding of the 
structure-function relationship with a highly modular scaffold.  
 In Chapter IV, I describe the modification of the interior of the helical coiled coils 
(Figure I-15) to improve the NiR rates. The TRIW-EH series described in Chapter III 
only varies the rates by as much as four-fold at pH 5.8. In this chapter, I describe the 
design and characterization of a few peptides with rates up to three orders of magnitude 
higher than the initial design. Two strategies are employed in these designs: 1) 
substituting the Leu residue one hydrophobic layer above the copper-binding His residues 
to increase the solvent/substrate access; 2) replacing the natural His with an N-methyl-
His to change the electronics of the imidazole ring and the sterics around the binding site, 
hoping to force Cu(I) into a tetrahedral coordination to lower the reorganization energy 
upon oxidation. I show the design and characterization of a series of peptides that contain 
these features combined with certain charged residue modifications. Michaelis-Menten 
kinetic studies are carried out for selected peptides in this series. Mechanistic insight 
based on the spectroscopic and kinetics data is presented.  
 X-ray absorption spectroscopy (XAS) is a powerful tool for understanding the 
coordination environment of non-crystallographically characterized metal sites in 
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metalloproteins. It is used in all of my previous data chapters to probe the Cu(I) 
coordination environment. In Chapter V, I introduce XAS in more details and describe 
the protocol that I have been using to fit EXAFS data. In addition, I present two short 
stories on a Cu(I)-thiol/thiolate site and a Zn(II)(His)3(OH2/OH–) center to demonstrate 
the application of XAS in characterizing spectroscopically silent systems.  
 In the last chapter, I conclude the major achievements in this thesis and propose 
future directions for this project.   
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Chapter II . Cu(II)/(I)(TRIW-H)32+/+, a structural and 
functional model for copper nitrite reductase
Introduction 
 Many of the recent efforts in de novo protein design to achieve models of 
metalloenzymes have been reviewed in the previous chapter. It is important to realize that 
the design of redox-active centers is still a challenging topic and was particularly true in 
2010 when this thesis research was begun. The difficulty arises because one needs to 
consider the structure and stability of the metal-peptide complexes in both oxidation 
levels involved in the redox process. The importance of metal ion cofactors in redox 
catalysis is underscored by the fact that many of the most employed transition metal ions 
in biological systems are redox active (e.g., iron and copper). The fine-tuning of the first 
and second coordination spheres of copper centers provides a broad range of redox 
potentials for many important biological processes, such as electron transfer, activation 
and transport of dioxygen and oxidative conversion of other small molecules (Figure 
II-1).1–11 The fields seeking to understand copper proteins include biochemistry, 
molecular biology, and medicine; meanwhile, synthesis and spectroscopic 
characterization of low-molecular-weight copper complexes are undertaken. Designing 
copper-peptides de novo stands at a unique position where it allows the incorporation of 
native amino acid ligands with well-controlled metal nucleation states in aqueous 
conditions.  
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Figure II-1. The “biocopper dial” delineating the essential metabolic functions of copper 
proteins. Figure reproduced from Ref.12 with permission.   
 Of particular interest to us is a type 2 copper (T2Cu) center where copper is 
bound to three histidines. This mononuclear Cu(His)3 center serves various functions in 
native proteins. For example, peptidylglycine α-hydroxylating monooxygenase (PHM), 
which catalyzes the hydroxylation of glycine-extended peptide hormones, contains two 
types of copper centers (Figure II-2A), a CuH center where copper is coordinated to three 
histidines and a CuM center where copper is bound to two histidines and a methionine.13 
The role of the CuH center, in this case, is to shuttle an electron to the catalytic CuM site, 
which is involved in oxygen activation.14–16 Copper nitrite reductase (CuNiR), which 
carries out the dissimilatory reduction of nitrite to nitric oxide, contains both a T1Cu and 
a T2Cu center (Figure II-2B). The T2Cu center Cu(His)3(OH2) is the catalytic site while 
the type 1 copper center is the electron transfer site.2,17–21 In addition, a Cu(His)3 site is a 
dioxygen activation center in copper amine oxidase (CuAO) and quercetin 2, 3-
dioxygenase (2, 3-QD) along with other cofactors.6,22–29 (Figure II-2C and D)  
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Figure II-2. Crystal structures of copper enzymes. (A) PHM (PDB code: 1PHM); (B) 
CuNiR (PDB code: 2DY2); (C) CuAO (PDB code: 2OOV); (D) 2, 3-QD (PDB code: 
1JUH).  
 One of the fundamental questions in these systems is how the protein environment 
differentially selects one function over another, which relates to the importance of 
understanding the protein structure-function relationship. One approach to understanding 
this specific T2Cu center is to isolate it into a peptidic environment and investigate its 
properties. The first de novo designed three-stranded coiled coils with a T2Cu center 
Cu(His)3 was reported in 1993 (see Chapter I).30 This work represents the first example of 
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a stable T2Cu center in a de novo designed α-helical coiled coil scaffold, laying a solid 
foundation for the development of catalytic T2Cu centers. Tanaka and coworkers 
reported a series of IZ-derived α-helical coiled coil peptides that bind to copper, forming 
a Cu(II)(His)3(OH2) center (see Chapter I).31,32 These systems, however, are not fully 
characterized in either oxidation level nor have electron transfer or catalysis been 
explored.  
 We reported an X-ray crystal structure of Zn(II) bound to three-histidines in a 
related peptide HgSZnN(CSL9PenL23H)3+ (Figure II-3).33 Based on the similarities 
between Cu(I) and Zn(II), I thought that the TRIW-H system (Table II-1) was a good 
starting scaffold for copper binding. In this chapter, I will describe 1) the characterization 
of this system, including the Cu(II)/(I) coordination environment, binding stoichiometry, 
affinities, and protonation equilibria; 2) studies on small molecule binding by various 
spectroscopic techniques; 3) nitrite reductase activity studies of Cu(II)/(I)(TRIW-H)32+/+. 
The majority of the work described in this chapter has been published in reference 34.  
 
Figure II-3 (A) A model of Cu(TRIW-H)3+/2+ based on the crystal structure of 
Hg(II)SZn(II)N(CSL9PenL23H)3+ (PDB code: 3PBJ33); Overlay of the Zn(II)(His)3(OH2) 
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site in Hg(II)SZn(II)N(CSL9PenL23H)3+ (protein ligands: dark blue; zinc: dark blue 
sphere; zinc-bound water: red) and the T2Cu center in copper NiR from R. sphaeroides 
(PDB code: 2DY221, protein ligands: light green and teal; copper: cyan sphere; copper-
bound water: light pink). (B) Top view; (C) Side view. Figure adapted from Ref 34. 
Table II-1. Peptide sequences used in Chapter II 
Peptidea  a b c d e f g a b c d e f g a b c d e f g a b c d e f g  
TRI Ac-G LKALEEK LKALEEK LKALEEK LKALEEK G-NH2 
TRIL2W Ac-G WKALEEK LKALEEK LKALEEK LKALEEK G-NH2 
TRIW-H Ac-G WKALEEK LKALEEK LKALEEK HKALEEK G-NH2 
TRI-H Ac-G LKALEEK LKALEEK LKALEEK HKALEEK G-NH2 
CSL9PenL23H Ac-E WEALEKK PnbAALESK LQALEKK HEALEHG -NH2 
a. N- and C-termini are acetylated and amidated, respectively 
b. Pn = Pen, penicillamine 
 
Materials and Methods 
General procedures 
 All samples containing Cu(I) were handled in an inert atmosphere box using 
oxygen-free buffer solution or water. A stock solution of [Cu(CH3CN)4]BF4 was prepared 
in degassed acetonitrile (ca. 0.13 M). [Cu(CH3CN)4]BF4 was purchased by Sigma Aldrich 
and dissolved in degassed acetonitrile to obtain a stock solution (the concentration of 
which was determined by spectrophotometric titrations using 2,9-dimethyl-1,10-
phenantroline).35 A CuCl2/(NO3)2 solution was prepared by dissolving the corresponding 
Cu(II) salt in water (degassed water for activity studies) and the concentration was 
determined by inductively coupled plasma (ICP) optical emission spectroscopy located in 
room 2314 in the chemistry building. 
 Unless otherwise stated, all Cu(I)(TRIW-H)3+ and Cu(II)(TRIW-H)32+ solutions 
were prepared by reacting apo-(TRIW-H)3 in aqueous solution with stoichiometric 
amounts of [Cu(CH3CN)4]BF4 acetonitrile solution or CuCl2 aqueous solution. The pH 
values were registered using Hamilton glass microelectrodes. IR spectra were collected 
on a Perkin Elmer Spectrum BX FTIR spectrometer, using a NaCl window gas IR cell. 
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UV-visible spectra were collected on a Varian Cary 100 UV-Vis spectrophotometer with 
a thermostat, using matched quartz cells of 1 and 0.1 cm path length. EPR spectra were 
recorded on a Bruker EMX X-band EPR spectrometer with a liquid nitrogen cryostat. 
Fluorescence spectra were collected on a Fluoromax-2 fluorimeter. 
Peptide Synthesis and Purification.  
 All peptides in this study (Table II-1) were synthesized on an Applied Biosystems 
433A peptide synthesizer using standard protocols36 and purified by reverse-phase HPLC 
on a C18 column at a flow rate of 10 mL/min or 20 mL/min using a linear gradient 
varying from 0.1% trifluoroacetic acid (TFA) in water to 0.1% TFA in 9:1 CH3CN: H2O 
as previously reported.37 Peptides were collected over 27-29 min. Pure peptides were 
characterized by electrospray mass spectrometry located in room 3411. Concentrations of 
TRIW-H and TRIL2W were determined based on the tryptophan absorbance at 280 nm 
(ε = 5500 M-1cm-1).38 
Circular Dichroism (CD) Spectroscopy.  
 CD spectra were collected on an AVIV 62DS spectrometer at 25 oC using 1 cm 
quartz cuvettes. Guanidine hydrochloride (GuaHCl) titrations were carried out using an 
automated titrator with a Microlab 500 series syringe pump based on previously reported 
procedures.39  
NMR spectroscopy.  
 1H NMR spectra were collected on a Varian MR400 spectrometer using gastight 
tubes where appropriate. Samples of apo-(TRI-H)3 and Cu(I)(TRI-H)3+ (2.4-5.7 mM) 
were prepared in deoxygenated 50 mM buffered D2O (MES or HEPES at pH 6.0 or 7.4, 
respectively). The 1H-NMR titration of Cu(I)(TRI-H)3+ (1.6 mM in 25 mM MES buffer in 
D2O) was performed in the pH range 7.3-2.3. A 0.1 M NaOD solution in D2O was used as 
the titrant. The pH values in D2O were corrected using the formula reported in the 
literature.40 
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X-ray absorption spectroscopy.  
 A 1.0 mM Cu(I)(TRIW-H)3+ solution was made in the glovebox with 50 mM 
degassed MES buffer. 1 mM excess apo-3SCC was added to ensure the free Cu(I) 
concentration was minimum (< 0.01 %). The samples were mixed with 50 % glycerol as 
a glassing agent and loaded into a sample cell and frozen in liquid nitrogen. 
 Measurements were carried out at Stanford Synchrotron Radiation Lightsource 
(SSRL) beamline 7-3 with a Si(220) double-crystal monochromator and a flat Rh-coated 
harmonic rejection mirror. Samples were maintained below 10K with an Oxford 
Instruments liquid helium cryostat. Data were measured as fluorescence excitation 
spectra using a 30-element Ge detector array normalized to incident intensity measured 
with a N2 filled ion chamber. Data were measured with steps of 0.25 eV in the XANES 
region (1 sec. integration time) and 0.05 Å-1 in the EXAFS region to k = 13.5 Å-1 (1-20 
sec. integration, k3 weighted). Energies were calibrated by assigning the lowest energy 
inflection point of a copper metal foil as 8980.3 eV. An initial E0 value of 9000 eV was 
used to convert data to k-space, and the background was removed using a 3-region cubic 
spline. EXAFS data analyzed using EXAFSPAK41 and FEFF 9.0.42 A more detailed 
description of the application of XAS on metalloproteins is in Chapter V.  
EXAFS data fitting procedure.  
 Single- and multiple scattering fitting of EXAFS data were performed using 
EXAFSPAK41 with ab initio amplitude and phase parameters calculated using FEFF 
9.0.42 XANES data were normalized using EXAFSPAK. An initial model of Cu(I)-
imidazole coordination was built based on the averaged bond distances reported for the 
crystal structures of synthetic molecules containing Cu(I)-imidazole constituent.  
Cu(II)(TRIW-H)32+ deprotonation equilibria.  
 The visible spectra of Cu(II)(TRIW-H)32+ (0.26 mM) at different pH conditions 
were collected with an un-buffered aqueous solution by adjusting the pH using small 
aliquots of concentrated KOH.  
 Specifically, an n-proton protonation equilibrium can be written as: 
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€ 
Kan =
[H +]n[E n−]
[EHn ] ,  
 which leads to the ratio of concentration 
€ 
[EHn ]
[E n−] =10
n(pKa1 − pH )
.  
 The total absorbance at a particular wavelength can be written as 
€ 
Atotal = ε total • ([E n−]+ [EHn ]) = εE n− • [E n−]+εEHn • [EHn ] 
so 
€ 
ε total =
εE n− • [E n−]+εEHn • [EHn ]
[E n−]+ [EHn ]
=
εE n− +εEHn •10n(pKa1 − pH )
1+10n(pKa1 − pH )      
Equation II-1 
 where 
€ 
εE n−  and 
€ 
εEHn  stand for the extinction coefficients of the individual species 
in different protonation states.  
Binding constants determination.  
 The affinity of the (His)3 site in the 3SCC for Cu(I) was determined using a 
competitive chelation assay. We chose the well-defined Cu(I) chelator bathocuproine 
disulfonate (BCS2-), which binds Cu(I) into a colored species [Cu(BCS)2]3- (λmax = 483 
nm; ε483 nm = 13300 M-1 cm-1; log β2 = 19.8).43 The concentration of peptide stock solution 
was determined from Trp absorbance at 280 nm.44 A solution of 40 μM Cu(I) and 80 μM 
(TRIW-H)3 was prepared in an inert atmosphere box in an aqueous 50 mM buffer 
solution (MES pH 5.9, HEPES pH 7.4) and titrated with a 5.00 mM bathocuproine 
disulfonate solution. The formation of [Cu(BCS)2]3- was monitored by the increase of 
absorbance at 483 nm with UV-visible spectroscopy. All titrant additions were carried 
out in the glovebox. Specfit32 was used to fit the spectrophotometric data taking into 
account the protonation equilibrium of BCS2- at pH 5.9.45 
 A 500 – 800 nM solution of (TRIW-H)3 in 50 mM buffer (MES pH 5.9, HEPES 
pH 7.4) was titrated with a 486 μM CuCl2 solution, which was diluted from a 0.0486 M 
CuCl2 solution. The concentration of the CuCl2 stock solution was determined by ICP. 
EHn nH
+ + En%
Kan
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Upon each addition, the solution was stirred for 10 min to reach equilibrium and 
fluorescence spectra were recorded. The apo-(TRIW-H)3 was titrated with CuCl2 
solution. The dissociation constants were obtained by treating the fluorescence spectra 
with Specfit32,45 taking into account the formation of the Cu(II)/HEPES 1:1 complex (log 
β = 3.22).46  
Reduction potentials.  
 While reduction potentials for metalloproteins and small molecules are often 
determined by direct electrochemical methods, one may extract the same information by 
determining the binding affinities of the metals in both oxidation states to the proteins 
and applying the Nernst Equation. This approach has the added benefit that it allows one 
to track directly the behavior of interest (e.g., reaction rates) not only against the 
reduction potential, but also to see if correlations exist associated with a specific 
oxidation level. The reduction potentials of Cu(II)/(I)(TRIW-H)32+/+ were calculated using 
the methodology shown in Scheme II-1 and Equation II-2, where Eo(Cu, aq) = 0.159 V vs. 
NHE was utilized.34,47 
 
Scheme II-1 
€ 
E o(Cu(pep )3 ) = E o(Cu,aq ) −
2.303RT
nF log
Kd (Cu(I )( pep )3 )
Kd (Cu(II )( pep )3 )  
Equation II-2 
Cu(II) Cu(II)(pep)3
Cu(I) Cu(I)(pep)3E
o(Cu(pep)3)Eo(Cu) e+(pep)3Kd(Cu(I))
Kd(Cu(II))
e+
(pep)3
! 83 
EPR spectroscopy.  
 Three sets of EPR spectra were collected to investigate 1) the Cu(II) coordination 
environment at various pH conditions; 2) how nitrite binding affects the Cu(II) center; 3) 
how azide binding affects the Cu(II) center. All EPR samples contain 1 mM 
Cu(II)(TRIW-H)32+ and 1mM apo-(TRIW-H)3 to ensure that  99% Cu(II) is coordinated 
to the peptide. 30-50% glycerol was added to the aqueous solution as a glassing agent. 
The EPR spectra were collected at 77 K. For experiment 1), the pH condition was 
adjusted by adding small aliquots of concentrated KOH. For experiment 2), small 
aliquots of 0.1 M NaNO2 was added to a buffered solution of 1mM Cu(II)(TRIW-H)32+ 
and 0.5 mM apo-(TRIW-H)3 at pH 5.8 (50 mM MES). The EPR spectra were recorded 
and the binding of NO2- to Cu(II) was tracked by the change of AII. A similar titration was 
carried out for azide.  
Preparation of Cu(I)(CO)(TRIW-H)3+ IR sample.  
 A solution of 1 mM Cu(I), 1.5 mM (TRIW-H)3 in 50 mM buffer (HEPES or 
MES) was made in an inert atmosphere box in 100% D2O. Carbon monoxide (>99%) was 
bubbled through the solution for 20 min. Caution: CO is highly poisonous. Make sure 
that a functional CO detector is installed close to the hood in which the CO purging is 
carried out. The solution was then moved to the glovebox and transferred into an IR cell.  
NiR activity.  
 Reduction of Cu(II)(TRI-H)32+ by ascorbate. The in situ reduction of Cu(II)(TRI-
H)32+ into Cu(I)(TRI-H)3+ was monitored by addition of sodium ascorbate (0.565 μmol, 1 
eq.) to a 0.34 mM Cu(II)(TRI-H)32+ solution in deoxygenated 200 mM MES buffer (pH 
6.0) obtained in 3 mL in a rubber sealed quartz cuvette. The spectra were collected prior 
and after ascorbate addition. 
 NO production. NaNO2 stock solutions (~0.5 mM) were prepared in 200 mM 
aqueous MES pH 6.0, and added to the copper/peptide solution using a gas tight syringe. 
A 0.01 M [Fe(EDTA)]2- solution was prepared from FeSO4·7H2O and H2EDTA in 
deoxygenated 1 M citrate aqueous buffer at pH 5.0. The latter solution (3 mL) was put in 
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a rubber sealed quartz cuvette, the spectrum registered, and then the cuvette connected to 
the reaction vial through a steel canula and kept in an ice bath at 0 °C throughout the 
entire experiment. The reaction in the first solution was initiated by the addition of 1.13 × 
10-3 mmol of NaNO2 (1 eq.) to the copper/peptide solution, using a gas tight syringe. The 
NO produced was quantified from the difference spectrum (ε432 nm = 780 M-1 cm-1 for 
[Fe(NO)(EDTA)]2-) 48 
 The control reaction was performed using an aqueous solution of 
[Cu(CH3CN)4]BF4 under the same conditions described above. The production of NO 
starting from Cu(II)(TRI-H)32+ reduced in situ with ascorbate was performed using the 
same condition described above (200 mM MES pH 6.0). CuCl2·2H2O (1.13 mmol, ca. 
0.07 M in water) was added to the peptide, followed by sodium ascorbate (0.565 mmol). 
All solutions were prepared in an inert atmosphere box. 
 Ascorbate oxidation in the  presence of nitrite. The turnover number (expressed as 
equivalents of electrons per equivalent of copper ions) for the oxidation reaction of 
ascorbate by nitrite in presence of Cu(II)(TRI-H)32+ as the catalyst was determined by UV 
spectroscopy. In this assay, the oxidation of ascorbate as sacrificial reductant was 
monitored spectrophotometrically by observing the decrease of its absorption band at 251 
nm (ε = 8250 M cm-1).49 Since we carried out experiments at different pH conditions, we 
chose 251 nm, the isosbestic point of protonated and deprotonated forms, to calculate the 
consumption of ascorbate. A 2.4 mL solution containing (TRI-H)3 (0.30 mM) and sodium 
nitrite (31.6 mM) was prepared in the glove box using a degassed 200 mM MES solution 
in water. The pH was corrected to the desired value (5.8 or 5.9) by addition of small 
aliquots of a concentrated KOH solution in degassed water. Aliquots (ca. 380 μL) of this 
solution were mixed with 20 μL CuCl2 solution (ca. 3.8 mM) to obtain samples 
containing Cu(II) (0.180 mM), (TRI-H)3 (0.270 mM) and sodium nitrite (30 mM). The 
reaction of oxidation of ascorbate was triggered in the glove box by injecting 20 μL 
freshly prepared sodium ascorbate solution in degassed water (21 mM) to obtain a final 
ascorbate concentration of ca. 1.15 mM (corresponding to a 6.4 fold excess with respect 
to Cu(II)). The solution was transferred into a sealed 0.1 cm path length cuvette, and the 
UV spectra (240-290 nm) were collected every 5 min for 3-5 h total reaction time. The 
control samples containing apo-peptide (90 μM) in place of the Cu(II)-peptide complex 
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were prepared as reported above. This concentration corresponds to the excess apo-
peptide in the samples containing Cu(II)(TRI-H)32+. The oxidation reaction in the 
presence/absence of copper(II) was monitored in triplicates. The turnover number 
(equivalents of electrons per mole of copper) was calculated as two times the average 
moles of ascorbate consumed in the sample containing Cu(II)(TRI-H)32+ subtracted by the 
moles of ascorbate consumed in the sample containing apo-(TRI-H)3, divided by the 
moles of copper(II). Additional control samples containing sodium nitrite (30 mM) in the 
presence/absence of copper chloride (0.21 μM) were prepared in a similar way as 
described above, and their spectra (240-290 nm) were collected in triplicate every 5 min 
for 60 min. A 0.21 μM concentration of Cu(II) is ca. 1.5 times the calculated amount of 
free Cu(II) at pH 5.9 in a sample containing the fully oxidized form of the peptide and a 
50% excess of apo-peptide, based on the determined stability constants. The control of 
the stability of ascorbate in the absence of nitrite was carried out by preparing samples 
containing Cu(II) (0.180 mM), (TRI-H)3 (0.270 mM) and sodium ascorbate (1.15 mM). 
 The dependence of the reaction rate on the concentration of Cu(II)(TRI-H)32+ was 
examined in the 0.171 – 0.513 mM metallopeptide concentration range. All samples 
contain a 0.5 eq. excess of apo-peptide. Both samples and controls were prepared as 
described above, all containing 30 mM nitrite and ca. 1.15 mM ascorbate. The control 
samples contain 0.085 – 0.257 mM apo-peptide corresponding to the excess apo-peptide 
in the corresponding metallopeptide samples. The spectra in the 240-290 nm range were 
collected every 3 min in triplicates. The pH dependence of the rate of oxidation of 
ascorbate in the presence of Cu(II)(TRI-H)32+ was investigated in from pH 5.3 to 6.5. The 
samples were prepared as described above, containing 0.180 mM CuCl2 and 0.270 mM 
(TRI-H)3 (corresponding to a 0.180 mM Cu(II)(TRI-H)32+ and a 0.090 mM excess apo-
peptide), 30 mM sodium nitrite and ca. 1.15 mM sodium ascorbate. All samples were 
prepared in 200 mM MES buffer solution in water and the pH was checked before the 
addition of the freshly prepared sodium ascorbate solution to initiate the reaction. The 
control samples all contain 0.090 mM apo-peptide, 30 mM nitrite and ca. 1.15 mM 
ascorbate. 
 Detection of N2O. A reaction mixture of 0.33 mM Cu(II)(TRIW-H)3 with 0.17 
mM apo-(TRIW-H)3 and 0.1 M NaNO2 was prepared in the glovebox with 50 mM 
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phosphate buffer at pH 5.8 in a schlenk flask. The reaction was initiated by injecting a 
stock solution of sodium ascorbate, pre-adjusted to pH 5.8. The final concentration of 
sodium ascorbate in the solution was 0.017 M. The control reaction was set up with 0.17 
mM apo-(TRIW-H)3 and all the other conditions were kept the same. The gas IR cell (10 
cm, NaCl window) was evacuated using vacuum before connecting to the reaction flask 
with a setup shown as Figure II-4. The IR spectra were collected on a Perkin-Elmer FT-
IR Spectrum BX instrument. Henry’s Law was used to calculate the distribution of the 
putative production of N2O in aqueous and gaseous phase. Henry’s constant for 
N2O/water at room temperature was calculated based on literature values50. A calibration 
curve was made by diluting a series of N2O saturated 50 mM phosphate buffer solution 
into the same reaction setup with the same headspace volume. The system was 
equilibrated for 1 h before connecting to the gas IR cell and FTIR data were collected. 
The absorption peaks at 2234.8 and 2212.9 cm-1 were integrated to calculate the N2O 
production.  
 
Figure II-4. Experimental setup for N2O detection using FTIR spectroscopy.  
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Results 
Characterization of apo-peptide 
Guanidinium chloride denaturation titrations monitored by Circular Dichroism 
spectroscopy 
 A CD spectrum was collected for a solution containing 20 μM TRIW-H 
monomer, 10 mM potassium phosphate at pH 7.0 (Figure II-5). The double well at 208 
and 222 nm signifies α-helical coiled coils. The molar ellipticity of TRIW-H at 222 nm is 
~-30,000 deg!cm2/dmol. Guanidinium chloride (GuaHCl) denaturation titration was 
carried out to evaluate the influence of chemical denaturant on the α-helical character of 
the peptide. This data cannot be quantitatively fit to a two-state model because the 
titration curve did not level off at zero concentration of denaturant.  
 
Figure II-5 (A) CD spectra of apo-TRIW-H in phosphate buffer (10 mM) at pH 7.0 (solid 
line) and apo-TRIW-H after 6.5 M GuaHCl was added (dashed line). (B) GuaHCl 
denaturation of apo-TRIW-H monitored by the molar ellipticity at 222 nm.  
Monitoring the transition of 2SCC to 3SCC by 1H NMR (completed by Dr. Matteo 
Tegoni) 
 1H NMR was used to monitor the transition of 2SCC to 3SCC for TRI-H. 
Specifically, we tracked the chemical shift of the unexchangeable protons on the 
imidazoles (Figure II-6). As the pH was increased from 3.52 to 9.71, we observed the 
transition of two major resonances from (7.37, 8.74 ppm) to (6.75, 7.48 ppm). The two 
resonances at up and down field correspond to Hδ and Hε, respectively. This transition 
can be visualized better if we plot the pH against the Hδ and Hε resonances (Figure II-7). 
In addition, by integrating the signals representing 2SCC and 3SCC and taking the ratios 
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of the two types of signals, we were able to extract a pKa of 6.0(3), which corresponds to 
a 1.38(5) deprotonation process. This pKa, however, could be a combination of two 
deprotonation processes: the deprotonation of glutamic acid into glutamate (pKa ~ 3.9), 
and the deprotonation of imidazolium into imidazole (pKa ~ 6). Both processes will lead 
to the change of the chemical environment of Hδ and Hε. It is worth noting that when the 
apo-peptide forms 100% 3SCC, there are only two resonances, indicating that the 
imidazoles are three-fold symmetric.  
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Figure II-6. 1H NMR of apo-(TRI-H)3 under different pH conditions.  
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Figure II-7. Transition from 2SCC to 3SCC monitored by the chemical shift of Hε and Hδ. 
Characterization of Cu(I)(TRIW-H)3+ and Cu(I)(TRI-H)3+ 
Coordination environment 
 The coordination of Cu(I) in Cu(I)(TRIW-H)3+ complex was investigated by 
XAS. The X-ray absorption spectroscopy edge region of Cu(I) complexes frequently 
shows a resolved transition at ∼8,984 eV attributed to a 1s→4p transition; this is very 
intense for two- coordinate Cu(I), moderately intense for three-coordinate Cu(I), and 
almost undetectable for four-coordinate Cu(I).51 The X-ray absorption near-edge structure 
(XANES) data for Cu(I)(TRIW-H)3+ (Figure II-8A) show a resolved 1s→4p transition at 
∼8,984 eV, characteristic of three-coordinate complexes.51 The spectra for Cu(I)(TRIW-
H)3+ at pH 5.9 and 7.4 are indistinguishable, demonstrating that the Cu(I) structure is 
independent of the pH condition over this range. The extended X-ray absorption fine 
structure (EXAFS) spectra for Cu(I)(TRIW-H)3+ (Figure II-8B and C) show peaks for 
both nearest-neighbor scattering and outer-shell scattering characteristic of imidazole 
ligation. The nearest-neighbor scattering has an amplitude consistent with three low 
atomic weight ligands, with an apparent Cu-(N/O) distance of 1.93 Å, as expected for a 
three-coordinate Cu(I) site. The nearest neighbor and outer-shell scatterings are well 
modeled by using three imidazoles modeled as rigid groups with only a variable Cu-N 
distance and Debye-Waller factors proportional to those calculated ab initio.52 Inclusion 
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of an additional shell to model a putative water ligand did not improve the fit. This, 
together with the XANES evidence for a three-coordinate Cu(I) and the relatively short 
Cu-N distance, all point to a Cu(I) that is ligated only to the three histidine ligands. The 
fitted Debye-Waller factor for the Cu-N shell is large (∼9 × 10−3 Å2), suggesting that the 
site is distorted, as is often seen for three-coordinate Cu(I) sites. Assuming that the 
dynamic Debye-Waller factor is ∼4 × 10−3 Å2, as seen in model compounds, the observed 
value implies a spread in distances of ∼0.1–0.15 Å (Table II-2). 
 
 
Figure II-8 (A) XANES of Cu(I)(TRIW-H)3+ at pH 5.9 (dashed line) and pH 7.4 (solid 
line). (B) Fourier transform of EXAFS of Cu(I)(TRIW-H)3+ at pH 5.9. Insert: EXAFS 
(solid line) and simulation (dashed line). (C) Fourier transform of EXAFS of 
Cu(I)(TRIW-H)3+ at pH 7.4. Insert: EXAFS (solid line) and simulation (dashed line).  
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Table II-2. EXAFS fitting parameters 
First shell Outer shells 
Shell (X) R(Å) σ2(Å2) Shell (Y) R(Å) σ2(Å2) 
Cu(I)(TRIW-H)3+ 
pH 5.9 
F = 0.408 × 102 E0 = -10.88    
3 imid 1.93 0.009 3Cu-C(1)(imid) 2.92 0.013 
   3Cu-C(2)(imid) 2.95 0.013 
   3Cu-N(2)(imid) 4.06 0.018 
   3Cu-C(3)(imid) 4.07 0.018 
Cu(I)(TRIW-H)3+ 
pH 5.9 
F = 0.408 × 102 E0 = -12.20    
3 imid 1.93 0.009 3Cu-C(1)(imid) 2.91 0.014 
1 water 1.81 0.037 3Cu-C(2)(imid) 2.94 0.014 
   3Cu-N(2)(imid) 4.05 0.019 
   3Cu-C(3)(imid) 4.06 0.019 
Cu(I)(TRIW-H)3+ 
pH 7.4 
F = 0.349 × 102 E0 = -10.62    
3 imid 1.93 0.009 3Cu-C(1)(imid) 2.92 0.014 
   3Cu-C(2)(imid) 2.96 0.014 
   3Cu-N(2)(imid) 4.07 0.019 
   3Cu-C(3)(imid) 4.08 0.019 
 
Cu(I) affinities to (TRIW-H)3 
 The affinity of Cu(I) to (TRIW-H)3 was determined by competitive chelation 
assay using BCS2- as a chelator (Figure II-9). Titrations were carried out in triplicate. 
Cu(I) has a high affinity to (TRIW-H)3 at both pH 5.9 (Kd = 3.1(7) pM) and 7.4 (Kd = 
0.20(6) pM).  
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Figure II-9 (A) Cu(I)(TRIW-H)3+ solution titrated with a 5.00 mM BCS2- solution. The 
increased absorbance indicates the formation of Cu(BCS)23- complex. (B) Observed 
absorbance values at 483 nm (dots) and the calculated titration curve (solid line).  
Carbon monoxide binding  
 Since I aimed to design a model for CuNiR, it is necessary to evaluate whether the 
copper center is capable of small molecule binding. The stretching frequency νCO is 2064 
cm-1 (ω1/2 = 14 cm-1) when CO is bound to Cu(I)(TRIW-H)3+ at pH 7.4 (experiment 
completed by Dr. Matteo Tegoni). While this stretching frequency provides definitive 
information of the presence of a four-coordinate Cu(I)(CO)(His)3 center,  it does not 
necessarily prove that in the absence of CO, Cu(I) is three-coordinate (See Chapter IV).  
 XANES of the Cu(I)(CO)(TRIW-H)3+ corroborated the observation from FTIR. 
The pre-edge feature of Cu(I) decreased, suggesting the formation of a four-coordinate 
Cu(I) species (Figure II-10). Since it is relatively challenging to quantify the percentage 
of Cu(I) that is bound to CO, the red spectrum from Figure II-10 might contain mixed 
species of three-coordinate Cu(I)(TRIW-H)3+ and four-coordinate Cu(I)(CO)(TRIW-H)3+. 
Nonetheless, the decrease of the pre-edge peak indicates the formation of a higher 
coordination number Cu(I) species in the sample, pointing to a CO-bound Cu(I)(His)3 
site.  
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Figure II-10. XANES of Cu(I)(TRIW-H)3+ at pH 7.4 (solid black line) and pH 5.8 
(dashed black line), compared to Cu(I)(CO)(TRIW-H)3+ at pH 7.4 (solid red line).  
Characterization of Cu(II)(TRIW-H)32+ and Cu(II)(TRI-H)32+ 
Binding stoichiometry 
 Cu(II) binding to (TRIW-H)3 was examined by UV-vis spectroscopy. Small 
aliquots of 0.05 M CuCl2 (2 μL/aliquot) were added into a buffered solution of (TRIW-
H)3 (pH 7.4 HEPES) and observed the increase of Cu(II) d-d band absorbance (Figure 
II-11A). The Cu(II)(TRIW-H)32+ complex exhibits a broad band centered at 643 nm. The 
change of slopes below and above 1 eq. of Cu(II) indicates the 1:1 binding of Cu(II) to 
(TRIW-H)3 (Figure II-11B). The molar extinction coefficients of Cu(II)(TRI-H)32+ and 
Cu(II)(TRIW-H)32+ are both 135(3) M-1 cm–1 in the pH range of 5.7–7.5.  
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Figure II-11. (A) Titration spectra of Cu(II) into a solution of (TRIW-H)3 at pH 7.4. (B) 
A titration curve showing the binding stoichiometry of Cu(II) to 3SCC. Red spectra and 
dots represent Cu(II) below 1 eq. (with respect to 3SCC); blue spectra and dots represent 
Cu(II) above 1 eq.  
Coordination environment 
 The d-d band absorption maxima are consistent, for both Cu(II)(TRI-H)32+ and 
Cu(II)(TRIW-H)32+, with a Cu(II)(His)3 site that might contain either one or two 
exogenous water ligands (predicted λmax of 634 ± 11 nm).53 Since a λmax of ∼690 nm is 
expected for a Cu(II)(His)2(OH2)2 site,53 these observations support the existence of a 
Cu(II)(His)3(OH2)1–2 site in pH 5.8–7.4.  
 The EPR spectra of both Cu(II)(TRI-H)32+ and Cu(II)(TRIW-H)32+ have features 
typical of T2Cu centers, and for the latter, the spectra do not change significantly in the 
pH range 5.19–7.80 (Figure II-12, Figure II-13), which is consistent with the invariance 
of the λmax and ε from the visible spectra.  The observed g values (gII = 2.27) and 
hyperfine coupling constants (AII = 186 G and 188 G for the two peptides, respectively) 
are somewhat larger than those observed for NiR in which a Cu(His)3(OH2) site is 
present.54,55 These parameters are more consistent with a five-coordinate structure 
Cu(His)3(OH2)2,56–58 with a distorted square pyramidal geometry containing three quasi-
in-plane imidazoles, as consistent with the observed d–d transition at 643 nm.  
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Figure II-12. EPR spectra of Cu(II)(TRIW-H)32+ at pH 5.19 (green), 5.87 (blue), 6.75 
(red), and 7.80 (black).  
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Figure II-13. The EPR spectrum of Cu(II)(TRIW-H)32+ at pH 5.19. Red spectrum: data; 
green spectrum: simulation.  
Cu(II) affinities to (TRIW-H)3 
 The binding affinity of Cu(II) to (TRIW-H)3 was examined by tracking the Trp 
fluorescence quenching upon Cu(II) binding (Figure II-14). The dissociation constants 
were determined at both pH 5.9 (Kd = 40(8) nM) and pH 7.4 (Kd = 8.7(11) nM). To 
ensure that the quenching of Trp is not due to non-specific binding of Cu(II) to (TRIW-
H)3, I carried out a titration of Cu(II) into a solution of TRIL2W, which does not have the 
His residue for Cu(II) binding. No significant change of Trp emission upon the addition 
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of Cu(II) was observed, indicating that the decrease of Trp fluorescence intensity in the 
case of (TRIW-H)3 is due to Cu(II) binding to the (His)3 site (Figure II-15). Based on the 
affinities of Cu(II) and Cu(I) to (TRIW-H)3, the reduction potentials were calculated 
using the Nernst Equation (Scheme II-1 and Equation II-2). The calculated reduction 
potential at pH 5.9 is 400 (30) mV using Cl- as an anion. At pH 7.4, the potential is 430 
(30) mV. 
 
Figure II-14. Cu(II) titration into (TRIW-H)3 at pH 7.4 (50 mM HEPES). (A) Titration 
spectra showing the decrease of Trp fluorescence emission upon Cu(II) addition; (B) 
Observed I350nm values (dots) and calculated titration curve (solid line) 
 
Figure II-15. Cu(II) titration into (TRIL2W)3 at pH 7.4. (A) Titration spectra; (B) Cu(II) 
equivalents added plotted against the quenching percentage of Trp emission at 350 nm.  
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Nitrite binding to Cu(II)(TRIW-H)32+ 
 Upon the addition of small aliquots of sodium nitrite into a solution of 
Cu(II)(TRIW-H)32+, a decrease of AII was observed (Figure II-16). Based on the amount 
of NO2- added in relation to simulated AII, a NO2- dissociation constant range of 1.5 ~ 2.1 
mM can be extracted.  
 
Figure II-16. NO2– titration into 1 mM Cu(II)(TRIW-H)32+ at pH 5.8 monitored by EPR. 
Blue spectrum: Cu(II)(TRIW-H)32+; red spectrum: Cu(II)(TRIW-H)32+ in the presence of 
50 equiv. NO2– (with respect to Cu(II)). The equivalents of NO2- added from the top 
spectrum to the bottom spectrum: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 7, 10, 15, 20, 
30, 50. 
Azide binding to Cu(II)(TRIW-H)32+ 
 Azide is used as a general probe of the interaction between dioxygen species and 
T2Cu centers. The purpose of doing the following experiments is to evaluate whether a 
triatomic anion can bind to Cu(II) center. The azide-bound form of Cu(II)(TRIW-H)32+ 
will be utilized as a calibration point for the water-counting studies using ESEEM (In 
collaboration with Prof. David Britt). In addition, the copper-azide complex can serve as 
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a model for copper-dioxgyen active species, which lays a foundation for future studies on 
the oxygen-related activities of this system.  
 Titration of a solution of azide into a solution of Cu(II)(TRIW-H)32+ at pH 5.8 
(MES) and pH 7.4 (HEPES) was carried out monitored by UV-vis spectroscopy (Figure 
II-17). Under both pH conditions, a peak at 388 nm grows in as azide is added into 
Cu(II)(TRIW-H)32+, which was assigned as LMCT from azide to Cu(II) based on the 
absorption spectra for copper-azide adducts in the literature.59–61 The dissociation 
constants of azide to Cu(II)(TRIW-H)32+ were extracted using Equation II-3. The 
dissociation constants are 10.2 mM at pH 5.8 and 40 mM at pH 7.4. The binding of azide 
to Cu(II)(TRIW-H)32+ is further confirmed by EPR spectroscopy. The addition of azide 
leads to a compressed hyperfine region (Figure II-18).    
 
 
Figure II-17. Azide titration into a solution of Cu(II)(TRIW-H)32+ monitored by UV-vis 
spectroscopy. (A) pH 5.8 (50 mM MES). Insert: titration curve (dots: data points; solid 
line: fitting). (B) pH 7.4 (50 mM HEPES). Insert: titration curve (dots: data points; solid 
line: fitting).  
Y = Bmax!X/(Kd + X) + NS ! X + Y0            
Equation II-3 
(Bmax: maximum binding as a constant; Kd: dissociation constant; NS: slope of the non-
specific binding; Y0: background. Y: absorbance at 388 nm; X: concentration of N3-) 
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Figure II-18. Azide titration into 1 mM Cu(II)(TRIW-H)32+ at pH 7.4 (50 mM HEPES). 
Royal blue spectrum: Cu(II)(TRIW-H)32+; from the second spectrum to the bottom one, 
titrated in 1, 10, 100, 200, and 500 eq. of sodium azide (with respect to Cu(II)).   
pKa of Cu(II)(TRIW-H)32+ 
 The pH-dependent d-d band spectral transformation of Cu(II)(TRIW-H)32+ was 
examined by adding small aliquots of concentrated KOH in to a un-buffered solution of 
Cu(II)(TRIW-H)32+.  
 The appearance of a broad band with a maximum absorbance at 643 nm is 
observed as the pH of a Cu(II)(TRIW-H)32+ solution increases from 2.92 to 5.52 (Figure 
II-19A). This spectrum corresponds to Cu(II)(His)3(OH2)1−2.34 When the pH is raised 
above 7.6, a new set of spectra containing an isosbestic point at 571 nm is observed 
(Figure II-19B). The absorbance at 643 nm decreases while a new band at 514 nm grows 
in intensity. From a fit of the absorbance at 643 nm to Equation II-1, a pKaw value of 
8.53(2) corresponding to the changes in the absorption spectra described above can be 
extracted; this value corresponds to a one-proton deprotonation process (n = 1.11(8)). 
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Figure II-19. pH titration spectra of Cu(II)(TRIW-H)32+ at (A) lower pH (2.92−7.45) and 
(B) higher pH (7.60−10.80).   
 A set of pH titration monitored by EPR spectroscopy supports the existence of 
this deprotonation equilibrium. EPR spectra of Cu(II)(TRIW-H)32+ were collected from 
pH 7.80 to pH 9.14, and they show decreased AII values and increased gII values (Figure 
II-20, Table II-3). 
  
Figure II-20. EPR spectra of 1 mM Cu(II)(TRIW-H)32+ at different pH conditions. Black 
spectrum: pH 5.87; red spectrum: pH 6.75; blue spectrum: pH 7.80; green spectrum: pH 
9.14.  
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Table II-3. EPR simulation parameters of Cu(II)(TRIW-H)32+.  
pH g⊥ gII A⊥ AII/mT Aiso/mT 
5.87 2.05 2.27 0.64 18.58 6.62 
6.75 2.05 2.27 0.64 18.58 6.62 
7.80 2.05 2.27 0.64 18.58 6.62 
9.14 2.05 2.26 0.64 19.29 6.86 
NiR activity 
Reduction of Cu(II)(TRI-H)32+ and oxidation of Cu(I)(TRI-H)32+ 
 The reduction of Cu(II)(TRI-H)32+ by the addition of a stoichiometric amount of 
ascorbate can be achieved within the mixing time (Figure II-21A). Although samples of 
Cu(II)(TRI-H)32+ reduced with sodium ascorbate did not undergo reoxidation for 24 h 
when stored in a sealed cuvette, the visible band at 640 nm reappeared after the solutions 
were exposed to air.  
 The capability of nitrite to oxidize Cu(I)(TRI-H)32+ generated in situ using 
ascorbate was assessed. The 640 nm absorbance of Cu(II)(TRI-H)32+ increases over time 
in samples containing a 100-fold excess of nitrite (Figure II-21B and C). At pH 5.8, the 
recovery of 77% of the initial absorbance is obtained in 70 min. Although the recovery of 
100% of the initial absorbance was not achieved, successive additions of ascorbate to the 
same sample allowed reduction–reoxidation cycles of the Cu(II)(TRI-H)32+ sample for 
another three additions of reductant, with absorbance recoveries of over 65% of the initial 
absorbance (Figure II-22). 
! 104 
 
Figure II-21. Visible spectra of Cu(II)(TRI-H)32+ under various conditions. (A) Spectrum 
of a 0.34 mM solution of Cu(II)(TRI-H)32+ in presence of 30 mM sodium nitrite in 
deoxygenated H2O before (black line) and after (gray line) the addition of 1 equiv. of 
sodium ascorbate (200 mM buffer MES, pH 5.8). (B) Recovery of Cu(II)(TRI-H)32+ 
absorbance. The spectra were collected every 3 min after ascorbate addition. (C) 
Absorbance values at 640 nm vs. time. 
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Figure II-22. Absorbance values at 640 nm as a function of time for a 0.38 mM solution 
of Cu(II)(TRI-H)32+ in the presence of 30 mM sodium nitrite in deoxygenated 200 mM 
aqueous MES buffer at pH 5.8. 1 eq. of sodium ascorbate was added into the solution. 
The arrows indicate further additions of ascorbate (1 eq. each). Dashed line: absorbance 
of the initial Cu(II)(TRI-H)32+ solution. 
Nitric oxide production 
 The production of NO by reacting Cu(I)(TRI-H)3+ with 1 eq of nitrite at pH 5.8 
was demonstrated by visible spectroscopy by trapping the evolved gas as the colored 
[Fe(NO)(EDTA)]2− complex (Figure II-23).48 More importantly, the production of NO 
was observed at pH 5.8 using both Cu(I)(TRI-H)3+ and ascorbate-reduced Cu(II)(TRI-
H)32+. For these two samples, the amounts of trapped NO are 71% and 48% after 1 h of 
that of a control sample containing [Cu(I)(CH3CN)4]+, respectively. 
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Figure II-23. Spectra of a solution of [Fe(EDTA)]2- in aqueous 1 M citrate buffer at pH 5 
before (thin line) and after (dashed line) being sparged with a nitrogen stream previously 
fluxed into a reaction vessel containing Cu(I)(TRI-H)3+ and sodium nitrite (both 2.26 
mM) in deoxygenated aqueous 200 mM MES buffer at pH 5.8. The thick line is the 
difference between the two spectra described above. 
Detection of nitrous oxide 
 Based on Henry’s Law, the concentrations of a series of standard samples of 
nitrous oxide aqueous solutions (total N2O range: 8.18 × 10-6~6.95 × 10-5 mol) were 
calculated. The concentrations were then correlated with the integration of IR absorbance 
of the doubled peaks at 2234.8 and 2212.9 cm-1 (Figure II-24A and B).62,63 The headspace 
gas collected at different time points (3.5, 23, 28, 30, 41, 45 h) for the reaction mixture of 
nitrite reduction was examined for its N2O percentage (Figure II-24A). The amount of 
N2O produced has a yield lower than 0.09%, which is within the error of this experiment. 
A control experiment was carried out with apo-peptide for which the N2O level was 
below the detection limit. Therefore, nitrite reduction catalyzed by Cu(II)(TRIW-H)32+ 
does not produce N2O.  
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Figure II-24. (A) FTIR spectra of a series of known concentrations of N2O (black, blue, 
purple, red, and cyan spectra) and the gas collected from the headspace of nitrite 
reduction catalyzed by Cu(II)(TRIW-H)32+ at pH 5.8 (rectangular box). (B) Calibration 
curve resulting in y = 2.4 × 106 x (R2 = 0.9928).  
NiR activity under catalytic conditions 
 The NiR activity under catalytic conditions ([Asc-]= 1.15 mM, [NO2-] = 30 mM, 
[Cu(II)(TRIW-H)32+] or  [Cu(II)(TRI-H)32+] = 0.180 mM) were examined. The quantity of 
ascorbate oxidized in 175 min at pH 5.9, correcting for the background reaction, 
corresponds to 1.5(2) times the amount of Cu(II)(TRI-H)32+, which results in a turnover 
number of 3.0 expressed as moles of electrons per mole of Cu(II)(TRI-H)32+. Moreover, 
five turnovers were achieved at pH 5.8 in 220 min (Figure II-25B). The rate of the 
background reaction of ascorbate with nitrite is not influenced by the presence of either 
traces of Cu(II) ion (0.21 μM) or apo-(TRI-H)3 (0.90 mM, Figure II-26A), and ascorbate 
is stable in the absence of nitrite (Figure II-26A). The oxidation rate of the ascorbate also 
linearly depends on the concentration of Cu(II)(TRI-H)32+ (0.171–0.513 mM, Figure 
II-26B and C). These observations suggest that ascorbate acts as a sacrificial reductant for 
Cu(II)(TRI-H)32+, and that the Cu(I)(TRI-H)3+ species is catalytically active in reducing 
nitrite to NO. Both the kinetics of oxidation of Cu(I)(TRI-H)3+ (through the recovery of 
absorbance at 640 nm) and of ascorbate (through the decrease of absorbance at 265 nm) 
were studied as a function of pH. The initial rate of reoxidation of Cu(I)(TRI-H)3+ (vCu,ox) 
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was examined between pH 5.8 and 7.4. The initial rate decreases as pH increases from 
5.8 to 7.4 (Figure II-27A). The pseudo-first order rate constants kfirst,Cu (vCu,ox = 
kfirst,Cu·[Cu(II)(TRI-H)32+]) determined from the initial rates (12 min) as a function of pH 
are reported in Table II-4 and in Figure II-27. The rate of oxidation of ascorbate in the 
presence of Cu(I)(TRI-H)3+ and nitrite (vAsc,ox) was studied in the pH range 5.3–6.5. The 
initial rate of the reaction depicted in Scheme II-2 decreases with increasing pH, as 
shown in Figure II-27C and D (dH-Asc = dehydroascorbate).  
 
Figure II-25. (A) UV spectra of a solution of sodium ascorbate and sodium nitrite (pH 
5.9) collected every 5 min, containing Cu(II)(TRI-H)32+ (0.180 mM) and apo-(TRI-H)3 
(0.090 mM). (B) ■, decrease of [Asc−] vs. time in samples, as in A; ○, samples containing 
only apo-(TRI-H)3 (0.090 mM), pH 5.8.  
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Figure II-26. (A) Values of –(A-A0) at 265 nm vs. time for solutions of sodium ascorbate 
(1.15 mM) and sodium nitrite (30 mM) in deoxygenated aqueous 200 mM MES buffer at 
pH 5.9, containing: Cu(II)(TRI-H)32+ (0.180 mM) (squares), apo-(TRI-H)3 (90 μM) 
(circles), Cu(II) chloride (0.21 μM) (up triangle), or only ascorbate and nitrite (down 
triangle). Open squares: sodium ascorbate (1.15 mM) in deoxygenated 200 mM MES 
buffer at pH 5.9. (B) Values of -(A-A0) at 265 nm as a function of time for solutions of 
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sodium ascorbate (1.15 mM) and sodium nitrite (30 mM) in deoxygenated aqueous 200 
mM MES buffer at pH 5.9 for increasing concentrations of Cu(II)(TRI-H)32+ (Cu(pep)3; 
filled squares: 0.171 mM, filled triangles: 0.342 mM, filled circles: 0.513 mM) or apo-
(TRI-H)3 (open squares: 86 μM, open triangles: 171 μM, open circles: 257 μM). (C) Rate 
constants for the Cu(II)(TRI-H)32+ - catalyzed reaction as a function of the concentration 
of the metallopeptide. 
Table II-4. Pseudo-first order rate constants for the oxidation of Cu(I)(TRI-H)3+ (k1st,Cu) 
and of oxidation of ascorbate (k1st,Asc) as a function of the pH.  
pH k1st,Cu /10-4 (s-1) k1st,Asc /10-4 (s-1) 
5.3 - 12(3) 
5.5 - 9(1) 
5.8 5.2(3) 4.6(3) 
5.9 - 4.40(16) 
6.0 2.8(3) 2.4(2) 
6.5 0.65(3) 0.68(3) 
7.0 0.22(8) - 
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Figure II-27. (A) Absorbance at 640 nm vs. time for Cu(II)(TRI-H)32+ solutions (0.30-
0.34 mM, 30 mM sodium nitrite) in deoxygenated H2O, added with 1 eq. of sodium 
ascorbate. Circles: pH 5.8; up triangles: pH 6.0; squares: pH 6.5; down triangles: pH 7.0. 
(B) Values of k1st,Cu (crosses) and k1st,Asc (filled circles) as a function of the pH. (C) Values 
of –(A-A0) at 265 nm vs. time for solutions of sodium ascorbate (1.15 mM) and sodium 
nitrite (30 mM) in deoxygenated aqueous 200 mM MES buffer at pH 5.9 containing 
either Cu(II)(TRI-H)32+ (0.180 mM) (filled symbols) or apo-(TRI-H)3 (90 μM) (open 
symbols). Circles: pH 5.3; up triangles: pH 5.5; squares: pH 5.8; down triangles: pH 6.0; 
diamonds: pH 6.5. A0 is the absorbance before the addition of ascorbate. (D) Pseudo-first 
order rate constants (k1st,Asc) values as a function of the pH. 
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Scheme II-2 
Discussion 
 In a recent study, we showed that a de novo design strategy is highly effective for 
providing mimics of carbonic anhydrase using a mononuclear Zn(II)-based hydrolytic 
system.33,64 In this work, I explore the more challenging objective of obtaining a de novo 
designed redox-based assembly that carries out NiR reaction, which occurs at the T2Cu 
site in native CuNiR. Because both Zn(II) and Cu(I) are d10 metals, the latter ion may 
bind to the (His)3 site in a same fashion as Zn(II) in HgSZnN(CSL9PenL23H)3+.33 A 
comparison of this Zn(II) site to that of the T2Cu in CuNiR [R. sphaeroides NiR, Protein 
Data Bank (PDB) ID code 2DY2] is shown in Figure II-3. The metal ions and the atoms 
on the first coordination sphere are well matched in both structures, which serves as a 
starting point for copper-binding studies. To establish fully a structural model for CuNiR, 
I characterized the copper-peptides in both oxidation states. 
Characterization of Cu(I)(TRIW-H)3+ 
 Cu(I) binds to (TRI-H)3 stoichiometrically with 1:1 [Cu(I):3SCC] ratio.34 Unlike 
apo-(TRI-H)3, which has two resonances in the aromatic region in its 1H NMR spectrum, 
at the same pH, Cu(I)(TRI-H)3+ complex has more resonance peaks.34 This suggests that 
the δH and εH on three imidazoles are not chemically equivalent, which could be the 
result of the following scenarios based on different coordination numbers of Cu(I): 1) 
Cu(I) only binds to two of the imidazoles, the third imidazole stays unbound; 2) Cu(I) 
binds to three imidazoles and at least one other ligand (likely a water molecule) in a 
pseudo-tetrahedral geometry; 3) Cu(I) binds to three imidazoles in a distorted trigonal 
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planar geometry. In addition to these possible cases of different Cu(I) coordination 
numbers, the imidazoles might bind Cu(I) with either δN or εN. In order to narrow down 
the available structural possibilities, additional spectroscopic characterization was 
required. 
 Based on the XANES of Cu(I)(TRIW-H)3+ at both pH 5.9 and 7.4, Cu(I) is three-
coordinate. EXAFS fitting shows typical three-coordinate Cu(I)-N bond distances (1.93 
Å, Table II-5), similar to the reported values of three-coordinate Cu(I)-N centers in native 
proteins16,65 and synthetic copper complexes.66–69 In addition, the Debye-Waller factors are 
relatively large in the EXAFS simulations, indicating that the Cu(I) environment is 
somewhat more distorted than that in psAO or in the synthetic Cu(I) complex.65,66 The 
best depiction of the Cu(I) coordination environment in Cu(I)(TRIW-H)3+ based on NMR 
and XAS data is shown in Figure II-28, which describes a three-coordinate Cu(I)N(imid)3 
center in a distorted trigonal plane, possibly with different coordinating nitrogens from 
the imidazoles. These experiments, however, do not provide information of the 
orientation of the imidazole, the imidazole plane could be perpendicular or parallel to the 
helical axis, nor the coordinating imidazole δN or εN atoms, both of which could 
potentially influence the electronic properties of the Cu(I) center. The ascorbate-reduced 
T2Cu in native NiR is also a three-coordinate center, revealed by X-ray crystallography 
and EXAFS, which is the inactive form because it does not bind to exogenous ligands.70–
74  
 Dr. Matteo Tegoni carried out carbon monoxide binding experiments to test 
whether Cu(I)(TRI-H)3+ can coordinate a small molecule inside the helical coiled coils. 
Carbon monoxide is a commonly used small molecule to probe the coordination 
environment of Cu(I) in synthetic small molecules as well as copper proteins,22,75–79 
although my later study on TRI-HL19A peptide shows that CO can induce the binding of 
a third imidazole to a Cu(I)(imid)2 center, forming a Cu(I)(CO)(imid)3 center (See 
Chapter IV). The CO-bound Cu(I)(TRIW-H)3+ shows a typical CO stretching frequency 
when it is terminally bound to a Cu(I)N3 center, which is similar to the reported Cu(His)3 
centers in cuproproteins but different from the situation where CO is bound to a linear 
Cu(I)N2 center (Table II-6). This piece of evidence points to a tetrahedral 
Cu(I)(CO)(imid)3 center. Further 2DIR studies on the vibrational anharmonicity of the C–
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O bond in collaboration with Prof. Kevin Kubarych from the University of Michigan 
support that CO is buried in the hydrophobic interior of the coiled coils.  
Table II-5. Bond lengths of Cu(I)(TRIW-H)3+ in comparison to relevant Cu(I) centers 
 Shell R/Å σ2/Å2 Eo/eV Ref 
Cu(I)(TRIW-H)3+, pH 5.9 3 Nimid 1.93 0.009 -10.88 This 
work Cu(I)(TRIW-H)3+, pH 7.4 3 Nimid 1.93 0.009 -10.62 
Reduced psAO 3 Nimid 1.94 0.006 -13.32 65 
Reduced PHMcc 
(pH 7.5) 
2.5 Nimid 1.92 0.017 -10.34 16 
0.5 SMet 2.24 0.012 
(Met2Im)3Cu(I)a 
2 Nimid 1.89 0.010 - 66 
1 N 2.08 0.003 
aTris(1,2-dimethylimidazole)copper(I) 
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Figure II-28. Possible coordination modes of imidazoles with either Nδ or Nε to Cu(I) 
Table II-6. CO stretching frequency of Cu(I)(CO)(TRIW-H)3+ in comparison to selected 
copper proteins and compounds 
 ν(C-O)/cm-1 ω1/2/cm-1 Ref 
Cu(I)(CO)(TRIW-H)3+ 2063 14 This work 
AfNiR 2050 (T2Cu) 11-15 77 
CuAO 2064/2085  22 
PHM 
2062 (CuH)  78 
2092 (CuM)  
[Cu2(Me3p)(CO)2]2+a 2060  80 
[Cu(I)L5.1(CO)]+b 2073  81 
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[Cu(I)(iPr3TACH)(CO)]+c 2068  75 
[LδCu(I)(CO)]d 2110 5 79 
a, b, ,cThe chemdraw schemes of these compounds are shown in Scheme II-3 
dThe chemdraw scheme of this compound without CO bound is shown in 
Scheme II-4.  
 
 
Scheme II-3 
 
Scheme II-4 
Characterization of Cu(II)(TRIW-H)32+ 
 With the coordination environment of the Cu(I)-peptide well defined, 
spectroscopic studies on Cu(II)(TRIW-H)32+ were next undertaken. The absorption 
spectra of Cu(II)(TRIW-H)32+ show characteristic features of a T2Cu center, with a weak 
visible d-d transition at 643 nm in pH range 5.7–7.5. Based on a spectrum-structure 
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correlation for Cu(II) complexes in aqueous solutions reported by Prenesti et al. 
(Equation II-4, Table II-7),53 for a hypothetic model of a four equatorially coordinated 
Cu(II) center with three imidazoles and one water molecule, the d-d transition is 
predicted to be centered at 634 nm, close to what is observed for Cu(II)(TRIW-H)32+. For 
a Cu(II)(imid)2(OH2)2 center, however, the d-d transition is expected to be at 692 nm. 
Granted that the symmetry of my system might be different from the model, the visible 
spectra support the assignment that all three imidazoles are coordinated to Cu(II), 
however, this analysis does not provide definitive information of the coordination number 
of Cu(II).  
 Cu(II)(TRIW-H)32+ has EPR parameters for a typical T2Cu center, with g tensors 
showing a typical dx2−y2  ground state (gII > g⊥) and AII larger than 14 mT (Table II-8).4,7 
In NiR, three histidine residues and a water molecule bind Cu(II) in a four-coordinate, 
tetrahedral geometry, whereas the EPR spectra of Cu(II)(TRIW-H)32+ indicate that the 
center likely is five-coordinate, especially when compared to Cu(II)N3O2 centers in 
synthetic model compounds for both EPR and UV-Vis parameters (Table II-8). 
Spectroscopies suggest that Cu(II) is bound to three imidazoles from histidine residues on 
a quasi-equatorial plane and one or two water molecules.  
λmax =103 / niν i
i=1
4
∑  
Equation II-4 
Table II-7. Selected coefficient values (ν i ) for the estimation of the λmax values of 
equatorially-coordinated Cu(II) complexes in aqueous solution.53 
Donor group Coefficient (ν i ) 
Imidazole nitrogen 0.427 ± 0.009 
Water oxygen 0.296 ± 0.006 
Hydroxide oxygen 0.39 ± 0.03 
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Table II-8. Spectroscopic parameters of Cu(II)(TRIW-H)32+ compared to similar systems.  
 pH, solvent g⊥ gII AII/mT 
max (ε/M 
cm-1)/nm 
Ref 
Cu(II)(TRIW-H)32+ 6.75, aq. 2.06 2.27 18.58 643 (135) 34 
NiR (T2Cu) Aq.  2.05 2.3 14  82 
PHM pH~6.0, aq. 2.05 2.29 16.81  83 
AO Aq. 2.04 2.25 15.52  84 
[Cu(acac)2trien]NaYa Solid state 2.03 2.21 17.64 
800, 760, 
650 
56 
{Cu[26]py2N4}2+b 
H2O:DMS
O 1:1 
2.06 2.24 17.27 660 57 
[Cu2(tqbd)(H2O)4][S2O6]2c 
Methanol-
DMF 
2.06 2.25 17.6  58 
[Cu(bpba)(MeOH)](ClO4)2d Acetone 2.07 2.25 15.0 640(125) 85 
[Cu(tpy)(H2O)(ClO4)]ClO4e 
Methanol-
water 
2.067 2.277 16.8 693(65) 86 
Mer-[CuL3](NO3)2(H2O)(i-
PrOH)f 
Solid state 2.062 2.255 18.1 715(61) 87 
 The chemdraw schemes of compounds a, b, c, d, e, f are shown in Scheme II-5. 
 
Scheme II-5 
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 The coordination of at least one water molecule to the Cu(II) center is further 
substantiated by a set of pH titration, which partially aims to examine the Cu(II)-bound 
water deprotonation equilibrium reflected by the transformation of Cu(II) d-d band. A 
sharp rise in the d-d band moving from pH 3 until the spectra level out by pH ∼5 is 
observed for Cu(II)(TRIW-H)32+. Two major processes occur over this pH range. The 
first is the conversion of the 2SCCs to 3SCCs through the deprotonation of glutamic 
acids located at the e positions of the heptads. This conversion for the apo-peptide is not 
reflected in these spectroscopic changes. The second process is the binding of Cu(II) to 
the 3SCCs, which is directly reflected by these spectra, as they arise from the d−d 
transition of Cu(II). The UV−vis spectra of all these peptides are consistent with a four- 
or five-coordinate Cu(II) until at least pH 6.0.  
 As shown in Figure II-19B, Cu(II)(TRIW-H)32+ exhibits a second significant 
absorption change at a higher pH with a pKaW of 8.53. This is thought to be associated 
with the deprotonation of the Cu(II)-bound water into a Cu(II)-bound hydroxide because 
the blue shift upon this deprotonation is in accordance with the prediction of the same 
process in an equatorially coordinated Cu(II) complex (Equation II-4, Table II-7).53 
Spectral perturbations over this range are also observed in the EPR spectra of 
Cu(II)(TRIW-H)32+. As the pH increased from 7.80 to 9.14, gII decreased from 2.27 to 
2.26 while AII increased from 18.58 to 19.29 mT (Table II-3). This observed trend is 
consistent with the reported case of copper-bound water deprotonation at the T2Cu center 
in the mercury derivative of laccase.88 This piece of evidence, combined with the 
transformation of the UV−vis spectra in this pH region, supports that the pKaw at 8.53 for 
Cu(II)(TRIW-H)32+ corresponds to a Cu(II)-bound water deprotonation, producing a 
[Cu(II)(His)3(OH)(OH2)0-1]+ species.  
 At this point, although a crystal structure of either oxidation state of this copper-
peptide complex is not available, the spectroscopic data can help me draw a picture of the 
coordination environment of the copper center in this construct (Figure II-29). Going 
from the cuprous form to the cupric form, the copper center experiences a change in 
coordination number from three to four (or five), which would require the copper ion to 
move from the N3 plane to a location above the plane for water coordination. This change 
of copper coordination number also involves the alteration of the orientation of the 
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imidazoles inside the helical coiled coils, if the imidazole planes are perpendicular to the 
helical axis in the cuprous state. In native CuNiR, however, both oxidation levels of 
copper maintain four- or five-coordination during the catalytic cycle.23,4 As a result, there 
is no significant energy barrier due to the change of coordination number, especially the 
in- and out-of-the-plane motion of the copper ion, associated with the catalytic cycle. One 
can expect that the difference between this construct and the T2Cu in native CuNiR in the 
coordination environment of both Cu(I) and Cu(II) might lead to differences in their 
redox properties and reactivity.  
 
Figure II-29. PyMol models of (A) Cu(I)(TRIW-H)3+ and (B) Cu(II)(TRIW-H)32+. Models 
are made based on the crystal structure of Hg(II)SZn(II)N(CSL9PenL23H)3+ (PDB code: 
3PBJ33).  
Binding Affinities and Reduction Potentials for Cu(TRI-H)3n+ 
 After demonstrating that copper binds to 3SCC stoichiometrically, the next step 
was to determine the affinity in both oxidation states. The purpose of these experiments 
was two-fold: 1) binding affinity is an important basis to set up catalytic reactions to 
ensure that there is no free copper ions for either oxidation level; 2) the redox potential of 
the system can be calculated from the affinities based on the Nernst equation (Scheme 
II-1, Equation II-2), which allows one to assess the relationship between NiR activity and 
reduction potential.    
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 The dissociation constants of Cu(I) to (TRIW-H)3 at both pH 5.9 and 7.4 (Table 
II-9) are remarkably close to that of the N-terminal fragment 1–14 of human copper 
transporter hCtr1, which contains three histidine residues90 and much higher than that of 
Aβ4291. Cu(I) affinity to (TRIW-H)3 maintains on a picomolar/sub-picomolar level, 
indicating that the Cu(I) coordination environment is very similar at these two pH 
conditions, consistent with the previous observations. The slight decrease in affinity 
when pH decreases from 7.4 to 5.9 could be attributed to the subtle changes in the 
secondary coordination sphere due to the protonation of the glutamates along the helices. 
Similarly, Cu(II) affinity decreases by approximately one magnitude when pH decreases 
from 7.4 to 5.9. The nanomolar level dissociation constants fall within the range of Cu(II) 
dissociation constants in similar systems (Table II-9). The binding affinities of Cu(I) and 
Cu(II) to (TRIW-H)3 differ by ~four orders of magnitude at each pH condition, which is 
possibly due to the stabilization of a trigonal planar Cu(I) or the unfavorable 
incorporation of a +2 charged ion (Cu2+) as compared to a +1 charged ion (Cu+) into the 
hydrophobic interior of the helical coiled coils.  
 Based on the dissociation constants for both Cu(I) and Cu(II), the reduction 
potentials for Cu(II)(TRIW-H)32+ were calculated to be 400(30) mV at pH 5.9 and 
430(30) mV at pH 7.4. The 30 mV error originates from the reported Eo of Cu(II)/(I)aq 
redox couple, not from experiments. If one takes the experimental error and calculates the 
standard deviation of the reduction potentials, they are less than ±10 mV for both pH 
conditions. This redox potential value is higher than those measured for T2Cu centers in 
NiR (218 mV at pH 6.0 and 137 mV at pH 8.4 for R. sphaeroides, 220–310 mV at pH 7.0 
for A. cycloclastes and A. xylosoxidans).21,92 One possible explanation for this relatively 
high reduction potential for this system is that Cu(I) is strongly stabilized by its distorted 
trigonal planar structure. The coordination number changes from three to five when 
Cu(I)(TRIW-H)3+ is oxidized to Cu(II)(TRIW-H)32+, which requires the change of 
geometry of the site, creating a relatively large energy barrier for oxidation. The T2Cu 
sites in native cuproproteins are coupled with either a T1Cu site or other cofactors to 
function. Although the potential of the T1Cu sites in native proteins spans from 350 to 
790 mV,7,93 those of T2Cu centers are lower. For example, the potential of the T2Cu site 
in laccase (extracted from Rhus vernicifera), is one of the highest (390 mV at pH 7.4), 
! 122 
but still lower than that of our construct.94 The different redox potential between 
Cu(II)/(I)(TRIW-H)32+/+ system and the T2Cu center in CuNiR mainly originates from the 
difference in copper coordination environment. To use the thermodynamic box shown in 
Scheme II-1, the system has to reach an equilibrium for all the species involved, which 
requires the association of water molecule(s) and the re-orientation of imidazoles when 
Cu(I)(TRIW-H)3+ loses one electron.  
Table II-9. Dissociation constants of Cu(n)(TRIW-H)3n+ compared to similar systems 
Cu(I) affinity Kd/M Conditions Ref 
TRIW-H 
3.09(66) × 10-12 pH 5.9 34 
2.00(61) × 10-13 pH 7.4 
Ctr1–14 1.58 × 10-13 pH 7.4 90 
Aβ42 5.3 × 10-8 pH 7.4 91 
Aβ16 1.3 × 10-7 pH 7.4 91 
Cu(II) affinity Kd/M Conditions Ref 
TRIW-H 
4.04(83) × 10-8 pH 5.9 34 
8.69(112) × 10-9 pH 7.4 
Ctr1–14 1.00 × 10-11 pH 7.4 90 
mPrP(90-114) 1.3 × 10-8 pH 7.4 95 
CopC 10-13 pH 7.0 96 
Aβ42 7(2) × 10-7 pH 7.4 97 
Aβ16 1.0(2) × 10-6 pH 7.4 97 
 
Kinetics of nitrite reduction catalyzed by Cu(II)(TRIW-H)32+ 
 Although higher than those of NiRs, these redox potentials suggest that 
Cu(I)(TRIW-H)3+ could have NiR activity [formal E0 of nitrite ∼1.3 V at pH 6.02]. 
Because the redox potential of ascorbate in the pH range 5–7 is ∼100 mV, the bleaching 
of the 643 nm d–d band occurs within the mixing time, forming reduced Cu(I)(TRI-H)3+ 
in situ. The reductive half reaction (the reduction of nitrite to nitric oxide), however, is 
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much slower than the oxidative half (the oxidation of ascorbate to dehydroascorbate), and 
is pH-dependent. The plot of the logarithm of the rate of the reaction against the pH 
shows a linear correlation with a slope of 0.85, indicating that the rate-limiting step of the 
reaction is a one-proton process. The reasons for this pH dependence do not stand, as 
found for the native CuNiR, in the deprotonation of a coordinated water molecule at the 
Cu(II)(His)3 site,21,98 as both the visible absorption and the EPR spectra do not show 
significant changes in the pH range 5.2–7.4. Spectroscopic studies suggest that the pKa of 
coordinated water is 8.53(2) (Figure II-19B), which is out of the pH range that I carried 
out the NiR assay. More likely, this pH dependence is the result of either some changes at 
the Cu(I)(His)3 active site in that pH range [as suggested by changes in the NMR spectra 
of Cu(I)(TRI-H)3+]34 or the involvement of H+ in the reduction step of nitrite to NO 
(Scheme II-2).  
 Under catalytic conditions, Cu(II)(TRIW-H)32+ undergoes five turnovers after 220 
min, expressed as moles of electrons per mole of Cu(II). No catalyst decomposition is 
observed as the progress curve for absorbance vs. time remains in the linear regime 
throughout the 220 min reaction time. Hence, the turnover number is limited by the 
amount of the electron donor rather than the stability of the catalyst. The rate constants 
for the oxidation of ascorbate by Cu(II)(TRI-H)32+ (kfirst,Asc, Table II-4) under catalytic 
conditions match the first-order rate constants kfirst,Cu for the oxidation of Cu(I)(TRI-H)3+ 
by nitrite (both kfirst values refer to samples containing 30 mM nitrite) reasonably well. 
This demonstrates that the electron transfer from Cu(I)(TRI-H)3+ to nitrite with the 
formation of Cu(II)(TRI-H)32+ is the rate-determining step of the overall catalytic process, 
and rules out the possibility of ascorbate consumption by the NO formed from the 
reaction, which should lead to the observed values for kfirst,Asc significantly larger than 
those of kfirst,Cu.  
 One should be cautious that the mechanism of this model may differ from that of 
the native CuNiR because the oxidation states for copper under turnover conditions are 
not the same. In CuNiR, nitrite binds to Cu(II) followed by electron transfer, which 
initiates the reduction of the substrate.20,73,99 Dr. Matteo Tegoni demonstrated the binding 
of a diatomic molecule carbon monoxide to Cu(I)(TRI-H)3+, which mimics the product-
enzyme intermediate in the catalytic cycle of native CuNiR. I examined the possibility of 
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binding NO2- to Cu(II)(TRIW-H)32+ as a model for the substrate-enzyme complex. The 
addition of NO2- induces changes in both gII and AII values, which are comparable to 
those reported for native CuNiRs (Table II-10). Nitrite can bind to a copper center in a 
few possible modes (Figure II-30). Based on DFT calculations for small molecule 
models, η2 – O, O Cu(II)-NO2– has the lowest energy, although not much lower than the 
other two forms.100 This lowest-energy mode is consistent with the crystal structure for 
nitrite-bound CuNiR (PDB code: 1AS6).70 Similar to nitrite binding to native T2Cu in 
CuNiR, the nitrite-bound form of the Cu(II)(TRIW-H)32+ still has the commonly observed 
dx2−y2  as its ground state, which corresponds to an symmetric η2 – O, O binding mode. 
Further interrogation of the binding modes and metric parameters of the substrate-bound 
form is necessary to understand the mechanistic details of this system.  
 
 
Figure II-30. Possible binding modes of nitrite to copper 
Table II-10. EPR parameters of Cu(II)(TRIW-H)32+ with/without NO2- compared to the 
T2Cu center in NiR 
  g⊥ gII AII/mT Organism Ref 
Cu(II)(TRIW-
H)32+ 
Without NO2- 2.050 2.270 18.6 - 
This 
work With 50 eq. NO2- 2.034 2.282 16.4 
NiR (T2Cu) 
Without NO2- 2.038 2.355 9.0 Alcaligenes 
xylosoxidans 
101 
With 2 eq. NO2- 2.045 2.290 11.0 
NiR (T2Cu) 
Without NO2- - 2.34 12.5 Rhodobacter 
sphaeroides 
54 
With 12 eq. NO2- - 2.30 11.2 
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 Under turnover conditions in this system, however, the rapid reduction of Cu(II) 
by ascorbate ensures that the resting form of the enzyme is Cu(I). Thus, the interaction of 
nitrite with the reduced Cu(I) likely initiates catalysis. On the other hand, in the synthetic 
small molecule studies, nitrite prefers binding Cu(I) via the nitrogen atom, adopting η1 – 
N binding mode (Figure II-30).102–104 If this is true for this de novo designed system, the 
actual chemical conversion may not follow the same pathway as that in the native NiR. 
Cu(II)(TRI-H)32+ exhibits a pseudo-first-order rate constant kfirst,Asc of 4.40 × 10−4 s−1 at pH 
5.9 (Table II-4) with five turnovers in 3.7 h (pH 5.8), which is not very efficient as 
compared to native CuNiR (∼1500 s−1 at pH 5.8 for Alcaligenes faecalis NiR with 
Pseudoazurin as the electron donor).98 Nonetheless, these alternate reaction schemes 
suggest that the de novo designed Cu(II)/(I)(TRIW-H)32+/+ may provide a unique approach 
to evaluate both types of chemistry within the same framework. For example, one may 
evaluate nitrite reduction from the cuprous form using existing protocols, but probe the 
chemistry of nitrite reduction from the cupric enzyme by photoinduced electron transfer 
after the nitrite has bound to Cu(II).  
 Numerous other mononuclear models that examine NiR reactivity have been 
explored so far.102,104–108 These compounds are split into those whose activities have been 
investigated in nonaqueous solutions48,107,108 and those that have been examined in 
aqueous solutions102,106,109–112. In the case of nonaqueous systems, the reaction rates are 
higher than those observed in aqueous solutions, and the ligands in some cases model the 
tris-His environment of NiR relatively well.107,108,113 Although the nonaqueous conditions 
allow the control of the number of coordinating water, the use of these complexes does 
not account for several features of the NiR reaction, such as the different dielectrics 
between the exterior and the enzyme pocket and the hydrogen bonding network close to 
the T2Cu site. There are only a few examples of functional copper complexes that can 
reduce nitrite in aqueous solutions, and in general these systems have far lower rates that 
those observed in nonaqueous conditions. In some cases, these complexes produced N2O 
rather than NO,102,112 whereas the systems in which multiple turnovers were observed 
have been associated mostly with electrocatalytic reactions, particularly heterogeneous 
systems (i.e., catalyst linked to the electrode surface).102,106,109,112 For example, a bis(6-
methyl-2-pyridylmethyl)amine copper complex (CuMe2bpa) has been reported that is 
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capable of at least four turnovers in 15 min using photoactivated [Ru(II)(bpy)3]2+ as the 
electron donor. This complex saw a significant decrease in nitric oxide generation after 
two turnovers.110 Once this complex is attached to an electrode surface coated with a 
collagen film, the nitric oxide production rate goes up at the expense of the stability of 
the complex.106 In contrast, our data demonstrate that Cu(n)(TRIW-H)3n+ is robust and 
carries out multiple turnovers with no decrease in efficiency. Equally important, the 
product of our reaction is dominantly NO as opposed to other homogeneous catalysts, 
which also form N2O.102,112 The latter point may reflect the steric constraints and the 
proper matching of the coordination geometry for Cu(I) and Cu(II) in our system. 
 I have described in this chapter the first generation of a de novo designed CuNiR 
model based on the TRI family peptide. This is a good, although not exact, structural 
model for the T2Cu center. It is also functional in catalyzing the reduction of nitrite into 
nitric oxide with modest rates. I have incorporated some of the most important features of 
this T2Cu center (protein environment, native histidines as binding residues, coordinated 
water molecule(s), stable oxidation states, etc.). This first generation of design is focused 
on the first coordination sphere, establishing a “reference point” for the properties of a 
Cu(His)3 center, although there is still chemical space for improvement. Other key 
features that contribute to the activity in the native CuNiR include: 1) appropriate local 
environment (geometry, orientation of the imidazoles, local dielectrics) to achieve a 
relatively low redox potential of the copper center for nitrite reduction; 2) proper access 
and positioning of the substrate aided by a few important residues (Asp98, His255, 
Ile257) close to the copper center (Figure II-31); 3) an extended hydrogen bonding 
network proposed to be the proton transfer chain (Figure II-32). The effect of the 
important residues responsible for fixing nitrite can be most clearly seen if one compares 
the nitrite affinity to Cu(II)(TRIW-H)32+ (1.5 ~ 2.1 mM) to that for the T2Cu in CuNiR 
(52 μM) from Nitrosococcus oceani.114 The following two chapters will focus on a few of 
these features to tune the reduction potentials and improve the activity.  
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Figure II-31. Important residues involved in positioning nitrite. (PDB code: 1SJM)99  
 
Figure II-32. Proposed proton transfer chain close to the T2Cu in CuNiR. (PDB code: 
1HAU)115  
Conclusion 
 The work discussed in this chapter demonstrates the first de novo designed 
functional CuNiR model. Utilizing a well understood scaffold TRI, we have previously 
! 128 
shown the design of a hydrolytic center that exhibits CA activity, which is one of the 
fastest designed models.33 Designing a redox-active metal center in the helical coiled 
coils is arguably more challenging because a stable complex on both oxidation levels 
needs to be achieved. Compared to numerous small molecule mimics, this system 
represents an advanced stage of model chemistry. The hydrophobic/hydrophilic interface 
in the 3SCC mimics well the situation in native NiR, where the macromolecule is soluble 
in aqueous solutions while the interior is not necessarily hydrophilic. In addition, the 
isolation of the T2Cu center from native CuNiR to a designed protein environment 
excludes the interference from other chromophores. Not only is our construct stable on 
both oxidation levels, but its spectroscopic parameters are highly similar to the Cu(His)3 
centers in many copper proteins, establishing a foundation for expanding its reactivities. 
Although the current construct Cu(II)/(I)(TRIW-H)32+/+ has a redox potential that is higher 
than most reported cases of Cu(His)3 centers in a protein matrix, the in situ cyclic 
reduction/oxidation of the system is still achieved by adding sodium ascorbate/nitrite. 
More importantly, Cu(II)/(I)(TRIW-H)32+/+ is a functional mimic for CuNiR, catalyzing 
the reduction of nitrite exclusively into nitric oxide. Using this first generation model, I 
can really start to address the question of how much NiR activity a Cu(His)3 center can 
confer, then build extended structures (H-bonding, altered side-chain packing) upon this 
model to improve the activity. The highly modular nature of the TRI family peptides 
allows for designs beyond the first coordination sphere of the metal center. In summary, 
Cu(II)/(I)(TRIW-H)32+/+ is an advanced structural and functional NiR model in aqueous 
solutions.   
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Chapter III . Modifications of charged residues at the helical 
interface to modulate the redox properties and NiR rates
Introduction 
 Understanding the relationship between structure and function has always been a 
major goal of biomimetic studies. Redox-active enzymes are critical in many biological 
processes, with metal cofactors accounting for many of the redox-related reactions.1–5 For 
these metalloproteins, the redox-properties of the metal centers are highly sensitive to 
their protein environment. The influence of the coordinating ligands on the redox 
properties of the metal centers is evident.6,7 Besides the first coordination sphere, factors 
on the outer coordination spheres also play an important role in fine-tuning the redox 
potentials. For example, the hydrophobicity of the environment could modulate the 
stability of the relevant oxidation states; the bulkiness of the amino acid residue side 
chains close to the active site could regulate the solvent/substrate access, changing the 
coordination number of different oxidation states; polar residues around the metal center 
can H-bond to metal-bound water molecules or coordinating ligands. All of these effects 
would influence the redox potential of a particular metal center. In addition, electrostatic 
interactions around the metal site are recognized to influence the redox properties. 
Charged amino acid residues, e.g. Glu, Lys, both in the interior and on the surface of the 
proteins, can participate in fine-tuning the potentials of redox-active metal sites.8–11 
Considerable effort has been devoted to understanding these interactions in native 
proteins, however, due to the complexity of native systems, it is always challenging to 
disentangle the contribution of each potentially influential factor.  
 A de novo design strategy provides an opportunity to generate biologically 
relevant models to understand structure-function relationships using a minimal 
construct.12–15 In the previous chapter, I described the first generation of a NiR model 
based on a de novo design strategy, which represents one of the most efficient model 
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systems for NiR in aqueous solutions.16 Prior to this work, there were very few cases of 
Cu(His)3 sites in de novo designed peptides with controlled copper coordination.17–19 
Cu(II)/(I)(TRIW-H)32+/+ is the first to have relatively well-characterized, stable Cu(I) and 
Cu(II) oxidation states that exhibits NiR activity in aqueous solutions. This initial design 
was focused solely on the first coordination sphere of copper, yielding a modest catalyst. 
To design a model with higher rates, the next logical step was to explore systematically 
secondary coordination sphere modifications around the copper. Of course, such studies 
are potentially relevant to understanding how solely electron transfer centers as found in 
PHM20–23 are influenced by the same secondary coordination sphere modifications. 
 With a simplified polypeptide sequence, the local environment of metal centers 
may be modified rationally in order to investigate the important factors that govern the 
properties and functions of a specific site. After examining the sequence of TRI peptide, 
one realizes that the copper-binding His residues are in between two Lys residues, and 
there are a few Glu residues farther along the sequence. The role of these charged 
residues is to form salt bridges in a neutral pH range to stabilize the 3SCC. In the context 
of designing a redox-active center, the electric field framed by these charged residues can 
influence the redox potential of a metal center embedded in helical coiled coils. This 
prompted me to design a series of peptides to investigate how the charged residues 
influence the properties of Cu(His)3 center. The sequences of the peptides involved in this 
chapter are shown in Table III-1. The work described in this chapter is based on reference 
24.  
 The initial thought behind these designs was to decrease the local positive charge 
imparted by the Lys residues close to the His site. Since Lys as 22nd position is the closest 
to the copper-binding site, I replaced it with a Glu residue, leading to the parent peptide 
of the TRIW-EH series. Modifications are then applied to the other charged residues 
close to the copper binding site, yielding a series of peptides with 0, -3, -6, -9, and -12 
charge differences from the first generation TRIW-H (Table III-1). In addition, TRIW-
HK22Q, TRIW-HK24E, and TRIW-EMH were designed as a comparison to the TRIW-
EH series of peptides to examine the effect of Glu22.  
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Figure III-1. PyMol models of I. TRIW-EHE27K; II. TRIW-EHE27Q; III. TRIW-EH; 
IV. TRIW-EHK24Q; V. TRIW-EHK24E; VI. TRIW-H; VII. TRIW-HK22Q; VIII. 
TRIW-HK24E; IX. TRIW-EMH. These models are made based on the crystal structure of 
Zn(II)NHg(II)S(CSL9PenL23H)3 (PDB code: 3PBJ).25 The same colored texts represent 
the same Δcharge. Going from the left to the right, Δcharge is 0, –3, –6, –9, and –12 in a 
neutral pH range.  
Materials and methods 
 The sequences of the peptides used in this work are shown in Table III-1, with 
each heptad repeat given as abcdefg. Variations were made at the b, e, g positions of the 
heptad in addition to the L23H mutation.  
General procedures.  
 The copper-peptide complexes were prepared by adding a solution of Cu(I) 
tetra(acetonitrile) tetrafluoroborate or Cu(II) chloride into a (buffered) solution of apo-
peptide. Since the Cu(I)-peptide complexes undergo slow oxidation under aerobic 
conditions, all reactions concerning Cu(I) or nitrite reduction were carried out in an inert 
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atmosphere box. The procedures to determine the concentrations of both Cu(I) and Cu(II) 
solutions are described in Chapter II.  
Peptide synthesis and purification.  
 All peptides in this work were synthesized on an Applied Biosystem 433A 
peptide synthesizer using standard protocols26 and purified and characterized as 
previously reported.27 The apo-peptide solution was prepared by dissolving purified dry 
peptides in doubly distilled water or buffer solutions. The peptide concentration was 
determined based on the tryptophan (Trp) absorbance at 280 nm (ε = 5500 M-1cm-1).28  
Ultraviolet-Visible (UV-Vis) and fluorescence spectroscopy.  
 UV-Visible spectra were collected in quartz air-tight cuvettes at 25 oC on a 
Cary100 Bio UV-Vis spectrophotometer. Emission spectra were recorded on a Fluomax-
2 Fluorimeter at 25 oC.  
Circular Dichroism (CD) Spectroscopy.  
 CD spectra were collected on an AVIV 62DS spectrometer at 25 oC using 1 cm 
quartz cuvettes. Guanidine hydrochloride (GuaHCl) titrations were carried out using an 
automated titrator with a Microlab 500 series syringe pump based on previously reported 
procedures.29  
pKa determination for Cu(II)-peptides.  
 The visible spectra of a solution containing 0.27 mM Cu-3SCC and 0.03 mM apo-
3SCC (to ensure that > 99 % of Cu(II) is bound to the peptide) at various pH conditions 
were collected and pKa fitted to Equation II-3.  
Binding constants determination.  
 The binding constants of Cu(I) and Cu(II) were determined using the same 
procedure as described in Chapter II.  
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Redox potentials.  
 The redox potentials of Cu(II)/(I)-3SCC were calculated as described in Chapter 
II.  
X-ray absorption spectroscopy (XAS).  
 Samples were made based on the same procedure as described in Chapter II. Data 
collection parameters follow those described in Chapter II. A detailed data fitting 
procedure is described in Chapter II. 
EPR spectroscopy.  
 X-band EPR spectra were collected on a Bruker EMX electron spin resonance 
spectrometer with a Varian liquid nitrogen cryostat at 77 K. A sample of ~1mM 
Cu(II)(3SCC)3 was prepared in a 50 mM buffer solution, and the pH was adjusted by 
adding concentrated HCl or KOH solution into the sample. An extra 0.5 mM apo-3SCC 
was added to ensure that the free Cu(II) is less than 0.1 %. 50% glycerol was used as a 
glassing agent. The EPR parameters were extracted by fitting the collected spectra to the 
simulated spectra using the EPR data fitting software SpinCount. 
NiR activity.  
 NiR rates. 30 mM NaNO2 was mixed with 0.18 mM Cu(II)(3SCC) and 0.09 mM 
apo-3SCC (to ensure that over 99% of Cu(II) is bound to the peptide). The reaction was 
initiated by adding 6 equivalents of sodium ascorbate (NaAsc) with respect to Cu(II). The 
consumption of sodium ascorbate (NaAsc) was monitored by UV-Visible spectroscopy. 
The control was a mixture of 30 mM NaNO2 and 0.09 mM apo-3SCC with the same 
amount of NaAsc. The rates of the reaction were calculated by two times the different 
rates of NaAsc consumption (decrease of absorbance at 251 nm) between the sample and 
the control. The production of nitric oxide was examined using the method previously 
reported.16  
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 Production of nitric oxide. A solution of 0.18 mM Cu(I), 0.27 mM 3SCC and 1.1 
mM NaAsc in 50 mM potassium phosphate buffer was prepared in an inert atmosphere in 
a gas-tight reaction vessel. The pH was adjusted to 5.8 using small aliquots of KOH. The 
reaction was initiated by injecting a solution of NaNO2 ([NO2-] = 30 mM). The reaction 
mixture was stirred for 2-3 h. A 0.01 M pH 5.0 [Fe(EDTA)]2- solution was prepared by 
mixing 0.01 M FeSO4 and 0.01 M H2EDTA solution in a 1:1 ratio in an air-tight cuvette 
with a septum attached. The gas in the headspace of the reaction vessel was cannula-
transferred to the cuvette. The absorption spectra were collected. [Fe(NO)(EDTA)]2- was 
quantified by the absorbance at 432 nm (ε = 780 M-1cm-1).16,30  
Results 
CD spectra of apo-peptides.  
 The CD spectra were collected for a solution of 20 μM apo-peptide monomer, 10 
mM potassium phosphate at pH 7.0 (Figure III-2, Figure III-3). The double-well at 208 
and 222 nm for all of the peptides involved in this study indicates the formation of helical 
coiled coils. Due to the lack of an initial plateau in the denaturation curves, I cannot 
extract a free energy of folding because the curves cannot be fitted to a two-state model.  
 
Figure III-2. (A) CD spectra of apo-peptides in the TRIW-EH series at pH 7.0. Black 
spectrum: TRIW-EHE27K; red spectrum: TRIW-EHE27Q, magenta spectrum: TRIW-
EH; blue spectrum: TRIW-EHK24Q; green spectrum: TRIW-EHK24E. (B) GuaHCl 
denaturation titration for the above-described peptides at pH 7.0. The same color coding 
applies.  
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Figure III-3. (A) CD spectra of other peptides involved in this study at pH 7.0. Red 
dashed line: TRIW-EMH; black dashed line: TRIW-HK24E; blue dashed line: TRIW-
HK22Q. (B) GuaHCl denaturation titration for these peptides. The same color coding 
applies.  
XAS of Cu(I)(TRIW-EH)3+ and its derivatives.  
 The XANES spectra of Cu(I)(TRIW-EHK24E)3+, Cu(I)(TRIW-EH)3+, and 
Cu(I)(TRIW-EHE27K)3+, all show a modest intensity peak at ~8983 eV, similar to that of 
Cu(I)(TRIW-H)3+ at pH 5.9 (Figure III-4). This is typical of Cu(I) in an approximately 
trigonal environment.16,31 The near identity of these spectra shows that there are only 
minor structural differences between the copper sites.   
 The EXAFS data for Cu(I)(TRIW-EH)3+ and its derivatives support this structural 
interpretation.  The Fourier transform is dominated by a peak at R + a ≈ 1.5 Å typical of 
Cu-N or Cu-O nearest neighbor scattering, with pronounced outer-shell scattering typical 
of rigid ligands such as imidazole.  Quantitative fitting (Figure III-5, Table III-2) 
confirms this structure.  The nearest-neighbor distance of 1.93 Å is typical of three-
coordinate Cu(I), and the outer-shell scattering can be modeled using three imidazole 
ligands, results that are quantitatively consistent with structural parameters reported 
previously for Cu(I)(TRIW-H)3.16 Attempts to fit the data with a Cu-O shell in addition 
to, or in place of one of the Cu-imidazole interactions did not give any improvement in 
the fit. The three peptides investigated here include the parent peptide of the TRIW-EH 
series, the peptide with the largest and the smallest Δcharge in the series. They all bind 
Cu(I) in a trigonal planar environment. One might notice that there are small differences 
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in the fitting parameters for these peptides (Debye-Waller factors, outer-shell distances), 
which could be reflective of subtle geometry changes of the first coordination sphere or 
the orientation of the imidazole ring. These changes, however, do not exceed the 
difference between the TRIW-EH series peptides and TRIW-H. For example, for TRIW-
EH series of peptides, the Debye-Waller factors are between 0.0067 and 0.0072, ~0.002 
smaller than that of TRIW-H, suggesting a more ordered environment for TRIW-EH 
peptides. Since the two ends of the TRIW-EH series as well as the “mid-point” peptide 
TRIW-EH are examined, it is a logical assumption that the other two peptides TRIW-
EHK24Q and TRIW-EHK24E also adopt the same Cu(I) coordination.  
 
Figure III-4. XANES of Cu(I)(TRIW-H)3+ (black spectrum), Cu(I)(TRIW-EHE27K)3+ 
(green spectrum), Cu(I)(TRIW-EH)3+ (red spectrum), and Cu(I)(TRIW-EHK24E)3+ (blue 
spectrum) at pH 5.8.  
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Figure III-5. EXAFS and FT data (solid line) and fitting (dashed line) for (A)(B) 
Cu(I)(TRIW-EHE27K)3+, (C)(D) Cu(I)(TRIW-EH)3+, (E)(F) Cu(I)(TRIW-EHK24E)3+ at 
pH 5.8. 
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XAS of Cu(I)(TRIW-HK24E)3+.  
 XANES of Cu(I)(TRIW-HK24E)3+ (Figure III-6) indicate that Cu(I) is three-
coordinate, the same coordination number as the Cu(I) centers described above. The 
metrical parameters are similar to those of the TRIW-EH series of peptides as well as 
TRIW-H peptide (Table III-2, Figure III-7).  
 
Figure III-6. XANES of Cu(I)(TRIW-HK24E)3+ at pH 5.8 (black spectrum) and 7.4 
(dashed blue spectrum).  
 
Figure III-7. EXAFS (A) and Fourier transform (B) of Cu(I)(TRIW-HK24E)3+. 
Experimental data are represented in solid lines and fittings are shown in dashed lines.  
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pKa of Cu(II)-peptides.  
 As shown in Chapter II, Cu(II)(TRIW-H)32+ has a deprotonation equilibrium 
reflected by the change of Cu(II) d-d band, which is most likely to be associated with the 
deprotonation of the Cu(II)-bound water molecule. The pKa of this equilibrium is 8.53(2), 
corresponding to a one-proton process. Interestingly, the pH titration of Cu(II)(TRIW-
EH)32+ results in a pKa distinctively different from the parent peptide (Table III-3). 
Similar to Cu(II)(TRIW-H)32+, from the pH region 2.97-5.57, the increase of absorbance 
at 659 nm is indicative of copper binding to the peptide (Figure III-8A). However, when 
the pH is raised from 5.33 to 7.87, the absorbance at 659 nm decreases slightly (Figure 
III-8B), resulting in a pKa = 6.33. This deprotonation event fits best to a 1.65(23) proton 
process (Figure III-8D), which suggested that the nature of this deprotonation might be 
different from the one for Cu(II)(TRIW-H)32+. In a higher pH region, another set of 
spectral transformation is observed, which resembles that of Cu(II)(TRIW-H)32+ (Figure 
III-8C). Similar effects are also observed for Cu(II)(TRIW-EHK24E)3 (Figure III-9).  
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Figure III-8. pH titration spectra of Cu(II)(TRIW-EH)32+ at (A) pH 2.92 to 5.57; (B) pH 
5.33 to 7.87; (C) pH 7.59 to 10.65; (D) d-d band absorbance in pH 5–8.5 fitted to 
Equation II-3, pKa = 6.33(4), n = 1.65(23).  
500 600 700 800
0
40
80
120
A
Wavelength/nm
ε/
M
-1
cm
-1
500 600 700 800
0
50
100
150
200
C
Wavelength/nm
ε/
M
-1
cm
-1
500 600 700 800
0
40
80
120
B
Wavelength/nm
ε/
M
-1
cm
-1
5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5
80
90
100
110
120
D
pH
ε 6
59
 n
m
/M
-1
cm
-1
! 150 
 
Figure III-9. pH titration spectra of Cu(II)(TRIW-EHK24E)32+ at (A) pH 2.99-5.75; (B) 
pH 5.97-7.87;  (C) d-d band absorbance fitted to Equation II-3, pKa = 6.76(6), n = 
1.37(25).  
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Figure III-10. pH titration spectra of Cu(II)(TRIW-EHE27K)32+ at (A) pH 2.96-6.54; (B) 
pH 7.83-10.72; (C) d-d band absorbance fitted to Equation II-3, pKa = 9.59(15), n = 
1.10(31) 
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 Different from the spectral evolution for Cu(II)(TRIW-EH)32+ and Cu(II)(TRIW-
EHK24E)32+, the pH-dependent d-d absorption spectra for Cu(II)(TRIW-EHE27K)32+ do 
not have a decrease in absorbance in the pH range of 5.8-7.4 (Figure III-10A and B). 
Only one deprotonation event is observed at a higher pH range, which is reminiscent of 
the Cu(II)-bound water deprotonation process (Figure III-10B).   
 pH titrations were also carried out for Cu(II)(TRIW-EMH)32+ and Cu(II)(TRIW-
HK24E)32+ as a comparison to peptides within the TRIW-EH series (Figure III-11, Figure 
III-12). These titrations share the common feature of increased d-d band absorption at pH 
below 5.5 and unvaried extinction coefficients when pH increases from 5.8 to 7.4.  
 
 
Figure III-11. pH titration for Cu(II)(TRIW-EMH)32+. (A) titration spectra at pH 2.89-7.81. 
(B) d-d band extinction coefficient at pH below 7.5, showing no decrease going from 5.8 
to 7.4. 
500 600 700 800
0
20
40
60
80
100
A
Wavelength/nm
ε/
M
-1
cm
-1
2.5 3.5 4.5 5.5 6.5 7.5
0
20
40
60
80
100
B
pH
ε 6
89
 n
m
/M
-1
cm
-1
! 153 
 
Figure III-12. pH titration spectra for Cu(II)(TRIW-HK24E)32+. (A) pH 2.92 ~ 6.07; (B) 
pH 6.07 ~ 10.85; (C) d-d band absorbance fitted to Equation II-3, pKa = 9.18(1), n = 
0.91(3) 
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 The Cu(II) d-d band evolves differently upon pH increase for different peptides 
within the pH region (5.8–7.4) that we are interested in (Figure III-13). In summary, 
Cu(II) d-d band appears when bound to different peptides and the transformations of the 
spectra are pH-dependent due to various deprotonation events.   
 
Figure III-13. Changes in Cu(II) d-d band absorbance when bound to TRIW-H (Δcharge = 
0),  filled circles; TRIW-EHE27K (Δcharge = 0), hollow circles; TRIW-EH (Δcharge = -6), 
filled squares; and TRIW-EHK24E (Δcharge = -12), hollow squares; insert: differences 
between the evolution of Cu(II)-peptide d-d band reveal different pKa values (same 
symbols) 
Table III-3. pKa values and spectroscopic parameters of selected Cu(II)-peptides 
Peptide pKaE pKaW 
λmax(ε/M-1 cm-1)/nm 
at pH 5.8 
λmax(ε/M-1 cm-1)/nm 
at pH 7.4 
TRIW-H - 8.53(2) 644(143) 644(143) 
TRIW-EHE27K  9.59(15) 671(80) 671(79) 
TRIW-EH 6.33(4) 9.86(5) 659(110) 659(89) 
TRIW-EHK24E 6.76(6) 9.81(5) 665(101) 657(81) 
The two pKa values correspond to two different deprotonation processes. pKaE is 
associated with Glu22 and pKaw is associated with the Cu(II)-bound water. 
 
3.0 4.0 5.0 6.0 7.0 8.0
0.00
0.01
0.02
0.03
0.04
0.05
pH
d-
d 
ba
nd
 a
bs
or
ba
nc
e
5.0 5.5 6.0 6.5 7.0 7.5
Ab
s
pH
! 155 
Cu(I) and Cu(II) affinities, the free energy of binding and calculated reduction 
potentials.  
 Dissociation constants for the complexation of either Cu(I) or Cu(II) at pH 5.8 
and 7.4 for the peptides studied in this work are provided in Table III-4. The first point to 
recognize is that the reversal of the position of the Lys and Glu groups going from 
TRIW-H to TRIW-EHE27K leads to a marked change in the Cu(I) affinity (a factor of 
100 in favor of the reversed peptide), while the corresponding Cu(II) affinities are higher 
for the original parent peptide. In an effort to isolate the effects, peptides solely with 
modifications at the 22 position, which is much closer to the copper site than the 27 
position (Table III-1) were examined. At pH 7.4, for the series TRIW-EH, TRIW-
HK22Q, and TRIW-H corresponding to Δcharge = -6, -3, and 0, respectively, the Cu(I) 
affinity changed only modestly (a factor of 5 less stable for TRIW-HK22Q  and 
essentially identical for TRIW-EH) and the Cu(II) affinities were essentially invariant. At 
pH 5.8, the mutated peptides TRIW-HK22Q, TRIW-EH have very similar affinities and 
reduction potentials (Table III-5), although they have higher Cu(I) affinities and lower 
Cu(II) affinities compared to the parent peptide TRIW-H. It is worth noticing that TRIW-
H behaves quite differently compared to the mutated peptides at pH 5.8, possibility due to 
the lower pKa that the mutated peptides have; however, it appears that Δcharge of the 
residues at the 22nd position (one residue above the binding site His23) does not have a 
dramatic influence on the affinities and redox properties of the peptide. Based on these 
observations, I chose to examine a series of peptide substitutions that occur below the 
copper-binding site (positions 24 and 27) using the K22E derived peptides as this would 
allow for the widest range of Δcharge (from 0 to -12). 
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 As shown in Figure III-14A, the Cu(I) affinities for the series of peptides 
containing a K22E substitution are related to the total charge around the copper binding 
site at both pH 5.8 and 7.4. As the total negative charge is increased, going from Δcharge = 
0 (TRIW-EHE27K) to Δcharge = -12 (TRIW-EHK24E), the Cu(I) affinity decreases by 
about two orders of magnitude, which occurs under both pH conditions. However, the 
Cu(II) affinities seems to be relatively immune to the change of total charge. As shown in 
Figure III-14B, at both pH 5.8 and pH 7.4, the change of Cu(II) affinities to the peptides 
is minimal at a particular pH across the series of peptides with different total charge. It is 
interesting to notice that unlike Cu(I), whose affinities remains essentially the same for a 
particular peptide at different pH conditions with dissociation constants ranging from 
picomolar to femtomolar, Cu(II) is destabilized by at least two orders of magnitude when 
the pH decreases from 7.4 to 5.8, as shown in Figure III-14B. The difference between 
Cu(I) and Cu(II) can be described more clearly when one compares the free energy of 
binding at a particular pH (Figure III-15, Table III-6). The free energy of binding is 
calculated using the equation ΔGo = 2.303RTlgKd.  
! 159 
 
Figure III-14 (A) Cu(I) dissociation constants and (B) Cu(II) dissociation constants with 
respect to Δcharge at pH 5.8 and pH 7.4. Peptides: 1) TRIW-EHE27K; 2) TRIW-EHE27Q; 
3) TRIW-EH; 4) TRIW-EHK24Q; 5) TRIW-EHK24E. Note: the y-axis is on log scales. 
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Figure III-15. The free energy of binding for both Cu(I) and Cu(II) at (A) pH 5.8; (B) pH 
7.4. Peptides: 1) TRIW-EHE27K; 2) TRIW-EHE27Q; 3) TRIW-EH; 4) TRIW-EHK24Q; 
5) TRIW-EHK24E 
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 While reduction potentials for metalloproteins and small molecules are often 
determined by direct electrochemical methods, one may extract the same information by 
determining the binding affinities of the metals in both oxidation states to the proteins 
and applying the Nernst Equation. This approach has the added benefit that it allows one 
to track directly the behavior of interest (e.g., reaction rates) not only against the 
reduction potential, but also to see if correlations exist associated with a specific 
oxidation level. The reduction potentials of the Cu(II)/Cu(I)-peptide system are 
calculated using the methodology shown in Scheme 2-1 and Equation II-1, where Eo(Cu, aq) 
= 0.159 V vs. NHE is utilized (Table III-5).16,32 Since the free energy of binding for Cu(I) 
varies with amino acid substitution more than that of Cu(II) (Figure III-15), the change in 
the calculated reduction potential is dominated by the variation of Cu(I) affinities. This is 
true at both pH conditions; however, the change in potential between pH conditions is 
due to the stabilization of the Cu(II) upon acidification. The linear regressions for the 
trends following amino acid substitutions result in two parallel lines, the distance 
between which is about 100 mV. This value corresponds to a 1 H+ per electron change in 
potential, which is consistent with a difference of 1.6 pH units for these measurements. 
(Figure III-16) 
 
Figure III-16. Calculated reduction potentials in relation to the changes of the local 
charge at pH 5.8 and 7.4. Peptides: 1) TRIW-EHE27K; 2) TRIW-EHE27Q; 3) TRIW-
EH; 4) TRIW-EHK24Q; 5) TRIW-EHK24E 
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EPR analyses of Cu(II) peptides.  
 The EPR parameters of Cu(II)(TRIW-EHE27K)32+, Cu(II)(TRIW-EH)32+, and 
Cu(II)(TRIW-EHK24E)32+ at both pH 5.8 and 7.4 are in the same range as the parent 
peptide complex (Table III-7). The g⊥ is smaller than the gII, representing a typical dx2−y2  
ground state, and the AII of all these complexes are in the range of 17 – 19 mT, indicative 
of an axial type 2 copper center with a high coordination number (4 or 5), which is 
consistent with the observed d-d band absorption spectra.  
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NiR activity.  
 The copper-peptide complexes exhibit NiR activity with different rates (Figure 
III-17), all of which are pH dependent. As the total negative charge goes from 0 to –12, 
the rates of the reaction increase by about four fold. Moreover, the rates are also 
correlated to the calculated reduction potentials at pH 5.8, as shown in Figure III-18: as 
the calculated reduction potentials increase, the rates decrease. The turnover numbers 
(TONs) for these reactions, expressed as moles of electrons per mole of copper, were 
obtained. The TONs in one hour are linearly correlated to the local negative charge 
(Figure III-19). As Δcharge goes from 0 (TRIW-EHE27K) to -12 (TRIW-EHK24E), the 
TONs at pH 5.8 increase by one. For all of the NiR reactions, no degradation of the 
enzyme is observed 1.5 h after the reaction is initiated, which indicates that neither the 
copper center nor the protein undergoes degradation during this time period.  
 Nitric oxide production is examined for the peptides showing the lowest and 
highest rates [Cu(II)(TRIW-EHE27K)32+ and Cu(II)(TRIW-EHK24E)32+, respectively] at 
pH 5.8. The reaction catalyzed by Cu(II)(TRIW-EHE27K)32+ produced 8.19 × 10-7 mol 
NO and that catalyzed by Cu(II)(TRIW-EHK24E)32+ produced 1.53 × 10-6 mol NO 
(Figure III-20). 
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Figure III-17. pH dependence of nitrite reduction rate constants. Peptides: ! TRIW-
EHK24E (Δcharge = -12),  TRIW-EHK24Q (Δcharge = -9),  TRIW-EH (Δcharge = -6),  
TRIW-EHE27Q (Δcharge = -3),  TRIW-EHE27K (Δcharge = 0). 
 
Figure III-18. Rates at pH 5.8 in relation to the calculated reduction potentials at pH 5.8. 
Peptides: 1) TRIW-EHE27K; 2) TRIW-EHE27Q; 3) TRIW-EH; 4) TRIW-EHK24Q; 5) 
TRIW-EHK24E 
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Figure III-19. Turnover numbers of NiR reactions by Cu-peptides related to Δcharge. 
Peptides: 1) TRIW-EHE27K; 2) TRIW-EHE27Q; 3) TRIW-EH; 4) TRIW-EHK24Q; 5) 
TRIW-EHK24E 
 
Figure III-20. Spectra of a 0.01 M [Fe(EDTA)]2- solution before (dashed line) and after 
(dashed dot line) the cannula transfer of the headspace gas from the reaction vessel. The 
difference spectrum is shown in solid lines. (A) Enzyme: Cu(II)(TRIW-EHE27K)32+, 3 h; 
(B) Enzyme: Cu(II)(TRIW-EHK24E)32+, 2.5 h. 
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multiple factors exert influence on the reduction potential simultaneously, complicating 
the understanding of the structure-function relationship of a particular system. In general, 
the energy associated with the redox process can be conceptualized as the sum of the 
inner-sphere contributions, which directly point to the energy needed to add or remove an 
electron to the redox site, outer-sphere contributions, which are related to the interaction 
of the redox site with the protein and solvent environment during the redox process, the 
relative distances between the redox centers, and the solvating/desolvating of the metal 
cetners.33 In reality, more often than not, one change around the active site may lead to a 
cascade of events that will eventually modify the redox properties, but it is challenging to 
track down the specific roles of each event.  
 A significant amount of work has been done to understand the redox property 
modulations on systems containing heme cofactors or cupredoxin sites. It was reported, 
as early as 1989, that mutating the valine (Val) residue into charged or polar residues 
such as Glu, aspartate (Asp) and asparagine (Asn) led to a decrease in the mid-point 
redox potential of recombinant myoglobin at 25 oC, which demonstrated that changing 
the electric field around the redox center resulted in a substantial change in the redox 
thermodynamics of a particular system.10 The substitution of Val68 close to the distal site 
of the heme center into a Glu or an Asp led to about 200 mV decrease in the reduction 
potential whereas Val68Asn resulted in an 80 mV decrease.  Furthermore, the Dutton and 
Gibney groups showed that by varying the burial of heme in the hydrophobic core, heme 
peripheral substituents, heme-hydrophobic amino acids, et al., they were able to modulate 
rationally the heme-protein redox potential over a range of a few hundred mV.34–37 More 
recently, Yi Lu and coworkers demonstrated that the redox potential of a cupredoxin site 
in azurin could be tuned by modifying two important secondary coordination sphere 
interactions: hydrophobicity and H-bonding. Their work showed an astounding shift in 
redox potentials, in some cases by as much as 700 mV, which extended even beyond the 
natural redox potential range of the protein.38,39 Despite its importance in the electron 
transfer or catalytic functions in native proteins, there had been no systematic studies on 
the redox property modulations of Cu(His)3 site in a protein environment until this work 
was published in 2013.  
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Design rationale.  
 Taking advantage of a de novo protein design approach, I took a known functional 
peptide Cu(TRIW-H)3 (Chapter II), and modified the local charge in a stepwise manner 
in order to observe changes in the reduction potentials and NiR rates of a series of 
peptides (Table III-1). The rationale of the design is first to invert the charged residues 
Glu27 and Lys22, yielding TRIW-EHE27K. Compared to the parent peptide TRIW-H, 
the change in the overall charge, or Δcharge, of this peptide is 0. While this double mutation 
leads to a significant shift in potential, no perturbation in the reduction potentials is 
observed between copper complexes of TRIW-H and TRIW-EH at pH 7.4. I used the 
K22E mutation (TRIW-EH scaffold) to evaluate a broader range of charge effects than 
would be available with TRIW-H. The residues below the copper-binding site of TRIW-
EH are substituted in a stepwise manner from positively-charged residues into neutral and 
then negatively-charged residues. Since three strands of peptides self-assemble in 
aqueous solutions above pH 5,40 the resulting series of peptides have a Δcharge of 0, -3, -6, -
9, and -12.  
 None of the residues (Lys22, Lys24 and Glu27 in TRIW-H) involved in the 
mutations are inside the helix bundle, neither can they directly coordinate to the copper 
center (according to the pymol models shown in Figure III-1), hence the first 
coordination sphere effects on the properties of the copper center are not expected. This 
de novo design strategy allows one to vary the charge systematically in order to probe the 
subtle influence of surface charged residues on the stability constants of Cu(I) and Cu(II)-
peptides and, subsequently, upon the redox properties and catalytic activities of these 
type 2 copper centers.  
Coordination environment of Cu(I).  
 To my expectation, the first coordination sphere of Cu(I)(TRIW-EH)3+ is not 
modified when the residues at the helical interface are mutated. The XAS data of 
Cu(I)(TRIW-EHE27K)3+, Cu(I)(TRIW-EH)3+, and Cu(I)(TRIW-EHK24E)3+ indicate that 
Cu(I) still binds to three imidazoles in a trigonal planar coordination with typical trigonal 
Cu(I)-N bond distances.22,41,42 Since the EXAFS data do not provide information on the 
orientation of the imidazole rings (whether they are perpendicular or parallel to the 
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helical axis), it is possible that the aromatic rings might adopt different orientations based 
on other types of interactions such as H-bonds or salt bridges. As shown in Scheme III-1, 
assuming that all three imidazoles bind Cu(I) with their εN, Cu(I) is in the same plane as 
the three εN, which is true for all three peptides investigated here. As marked by the red 
arrows, the orientations of the imidazoles can be different for these peptides, depending 
on the packing of the aromatics and the potential interactions between the proton on the 
δN with the charged residues. The differences in the orientations, consequently, would 
influence the orbital overlap between the εN and Cu(I), which might have an effect on the 
energetics of Cu(I) binding.  
 
Scheme III-1 
Deprotonation equilibria of Cu(II)(3SCC). 
 I then characterized the binding of the Cu(II) ion to the peptide as a function of 
pH using UV-Vis spectroscopy. As demonstrated in the last chapter, for Cu(II)(TRIW-
H)32+, the rise in the visible region when pH goes from ~3 to ~5 corresponds to the 
binding of Cu(II) to (TRIW-H)3 and the spectral transformation in a higher pH range 
(7.5~10) relates to the deprotonation of Cu(II)-bound water. Besides these two equilibria, 
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the copper binding ligand can undergo deprotonation of the cationic imidazolium form, 
which does not bind copper, to a neutral imidazole, which binds copper.43 A 1H NMR 
titration of (TRIW-H)3 has shown that this deprotonation event occurs over the pH range 
5.5-8.0 in the absence of metal (Chapter II). Most likely, the presence of a Lewis Acid 
shifts the imidazolium to imidazole equilibrium in favor of the neutral metal binding 
ligand as has been reported for both zinc and copper complexes with (TRIW-H)3.16,25 
Under higher pH conditions the imidazole may be converted to the negatively charged 
imidazolate form, which also binds copper efficiently. It is generally believed, however, 
that this equilibrium occurs at much higher pH values than investigated here. Additional 
carboxylic acid deprotonation events would be expected when Lys is substituted to Glu at 
the 22 and/or 24 positions for the mutated peptides. One would expect this deprotonation 
chemistry to occur in the general range of the pre-existing carboxylic acids at the e 
positions of the peptide. At very high pH conditions (again above pH 8), the 
deprotonation of the Lys side chain may become relevant, which could disrupt the 
3SCCs; however, the conditions used in this study are unlikely to enter this basic range. 
The pKa values involved are depicted in Figure III-21.  
 
Figure III-21. Deprotonation events involved in the pH region of interest in this study 
 Similar to the first generation peptide TRIW-H, in the presence of Cu(II), TRIW-
EHE27K, TRIW-EH, and TRIW-EHK24E all exhibit a sharp rise in absorbance moving 
from pH 3 until the spectra level out by ~pH 5 (Figure III-8, Figure III-9, Figure III-10). 
Again, this process corresponds to the binding of Cu(II) to the peptides, forming a Cu(II) 
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center with a high coordination number (vide supra). As the pH is raised to neutral 
conditions, peptides containing additional Glu (TRIW-EH, and TRIW-EHK24E) show an 
additional pH-dependent conversion (pKa~6.5). Since this pKa is about 2 pH units 
different from the that of Cu(II)-bound water deprotonation discussed in Chapter II, it is 
unlikely that this pKa corresponds to the same equilibrium. This process could be due to 
either the complexation of Glu22 to Cu(II) or the deprotonation of the carboxylic acid on 
Glu22. Based on PyMol models, the position of Glu22 on the helix places it too far from 
the metal center to bind directly to the copper or to form a hydrogen bond with a Cu(II)-
bound water. This observation leaves the most likely explanation for the pKa in the 6~7 
range for peptides containing the K22E mutations as the deprotonation of the glutamic 
acid leading to an H-bond formation between Glu22 and His23.  
 In the previous chapter, I presented the EPR spectra of Cu(II)(TRIW-H)32+ at pH 
5.2~7.8 (Figure II-12). showing that the EPR parameters are the same for a peptide 
without the K22E mutation in this pH range. In contrast, for the TRIW-EH series of 
peptides, the EPR parameters at pH 5.8 and 7.4 are different, signifying the perturbation 
derived from the K22E mutation. Specifically, for the charge “flipped” peptide 
Cu(II)(TRIW-EHE27K)32+, gII stayed the same, maintaining the dx2−y2  ground state, while 
AII increased by 0.14 mT and the isotropic hyperfine splitting constant Aiso increased by 
0.31 mT (Table III-7). Similar changes of gII and Aiso occurred for Cu(II)(TRIW-EH)32+. 
For Cu(II)(TRIW-EHK24E)32+, however, both gII and AII decreased significantly while A⊥ 
increased, leading to an increased Aiso. In summary, the Aiso of the TRIW-EH series of 
copper-peptide complexes increased when pH rises from 5.8 to 7.4, indicating a higher 
spin-density at the copper center. The changes of the other EPR parameters are dissimilar 
to those of Cu(II)(TRIW-H)32+ in a higher pH region (7.8~9.1, Figure II-20), which also 
supports the proposition that this equilibrium (corresponding to pKa ~6.5) is not a Cu(II)-
bound water deprotonation.  
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Scheme III-2. A possible scenario for the formation of an H-bond between Glu22 and 
His23 upon the deprotonation of the carboxylic acid for Cu(II)(TRIW-EH)32+. Residues 
from the same helix are shown in the same color. Only key residues proposed to be 
involved in this deprotonation process are shown.  
 Considering the combined observations, the pKa at ~6.5 for some of the TRIW-
EH peptides is assigned to a deprotonation equilibrium of a glutamic acid side-chain 
(probably at the 22 position) which can become an H-bond acceptor for the imidazole 
proton at the 23 position or a bridging water molecule (Scheme III-2). This H-bond leads 
to the variance of both UV-Vis and EPR spectral parameters of the Cu(II) center when 
the pH increases from 5.8 to 7.4. Two control experiments were carried out to assess 
further whether this protonation equilibrium (pKa~6.5) is associated with both Glu22 and 
His23. When the same pH titration was carried out for Cu(II)(TRIW-HK24E)32+, where 
the Glu is placed at the 24th, instead of the 22nd position, no perturbation of the Cu(II) d-d 
band absorption is seen in this pH range (Figure III-12).  As shown in the PyMol models 
(Figure III-1), the side chain of Glu at the 24th position in TRIW-HK24E is almost at the 
opposite side of the helix with regard to the His side chain, so it is very unlikely for 
Glu24 to form an H-bond with His23 (or with bridging water molecules). Even if there is 
deprotonation of the carboxylic acid side chain on Glu24, it is not reflected on the Cu(II) 
d-d absorption, which supports the conclusion that the Glu has to be placed at the 22nd 
position to interact with His23 (Scheme III-3). In other words, Glu22 is necessary for this 
observed deprotonation event. The second control involves the substitution of the proton 
on the Nδ of the imidazole with a methyl group while Glu22 retains, yielding TRIW-
EMH. The d-d band absorption stays the same when pH increases from 5.5 to 7.5 (Figure 
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III-11), which indicates that the presence of the proton on the imidazole is a must for one 
to observe this deprotonation event (pKa~6.5). Again, even if there is a deprotonation 
within this pH range, it is not reflected on the Cu(II) absorption spectra (Scheme III-4).  
 
Scheme III-3. Possible deprotonation of Glu24, forming an H-bond with Lys22 for 
Cu(II)(TRIW-HK24E)32+. Residues from the same helix are shown in the same color.  
 
Scheme III-4. 
 Consistent with this assignment, For the charge “flipped” peptide Cu(II)(TRIW-
EHE27K)32+, one might have expected it to behave more similarly to the other TRIW-EH 
peptides having a lower pKa; however, models suggest that Glu22 can interact with Lys27 
in TRIW-EHE27K which would weaken the H-bonding interaction of Glu22 with His23 
(Scheme III-5). This putative H-bond would lead to a less acidic Cu(II), which would 
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increase the pKa for the Cu(II)-bound water deprotonation in these peptides. 
Correspondingly, a higher pKa (9.6-9.8) for the TRIW-EH series of peptides is observed, 
which is assigned to the deprotonation of the Cu(II)-bound water (Table III-3).  
 
Scheme III-5. Possible deprotonation scheme for Cu(II)(TRIW-EHE27K)32+. Residues 
from the same helix are shown in the same color.  
Affinities and reduction potentials.  
 At pH 5.8 and 7.4, the binding affinities of Cu(I) and Cu(II) to the TRIW-EH 
series of peptides are determined in order to evaluate the reduction potentials and the 
impact of protein mutations at both oxidation levels (Table III-4, Figure III-14, Figure 
III-16). These peptides are prepared in order to examine the effect of increased local 
negative charge on the stabilities of Cu(I) and Cu(II) within the hydrophobic core. It was 
originally thought that the Cu(II) state would be more greatly stabilized by higher 
negative charge, decreasing the reduction potential of the system. While the reduction 
potentials (Table III-5) were made less positive by increasing the local negative charge, 
contrary to this expectation, the shift occurred as a result of Cu(I) destabilization rather 
than Cu(II) stabilization. These results are most clearly visualized when comparing the 
free energy of binding shown in Figure III-15.  
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 In contrast, Rorabacher and coworkers have reported a series of potentially 
tetradentate copper complexes which vary neutral nitrogen or sulfur donors over the 
range N4 to NS3 (Figure III-22). The reduction potentials of these compounds are strongly 
influenced by the stability constants of the Cu(II) oxidation level rather than those of the 
Cu(I) complexes.44,45 In particular, an increase in the stability constants of Cu(II) 
complexes by as much as 104 ~ 105-fold was observed when substituting thioether sulfurs 
for unsaturated nitrogens; at the same time, the stability constants of Cu(I) complexes 
were maintained in the range 1014 ~1016 M-1. These changes lead to differences in the 
reduction potentials (Figure III-23).44 The reduction potentials were also shown to be pH-
dependent below pH 5 (and invariant above this pH) due to the acid-base chemistry of the 
ligand.46 Important differences between these models and our system include the choice 
of ligands (neutral thioethers and pyridyl groups), the lack of potential H-bond acceptors 
(such as glutamate), the lack of charge variation across the series and the possibility of a 
tertiary amino nitrogen atom that could serve as a fourth ligand. Hence, our system 
provides a more biologically relevant example to assess how electrostatic and H-bonding 
influence copper protein reduction potentials.  
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Figure III-22. Tetradendate ligands involved in Rorabacher’s investigation. The numbers 
in red are the reduction potentials of the corresponding copper complexes (vs. NHE).  
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Figure III-23. Reduction potentials of the synthetic complexes investigated by 
Rorobacher and coworkers in relation to the Cu(II) and Cu(I) dissociation constants. 
Filled circles represent Cu(II) and hollow circles represent Cu(I). Note: the dissociation 
constants are on log scales.  
 As shown in Figure III-14, the relative Cu(I) or Cu(II) affinity change across the 
series of designed protein mutants is independent of pH as demonstrated by the invariant 
slopes of the lines for either oxidation state. This statement is not intended to suggest that 
the pH is not important in this system, as marked effects are seen both on Cu(II) stability 
and reduction potential. The Cu(I) stability is more sensitive to protein modification 
(Δ(ΔGaCu(I))~ 2 kcal/mol versus  Δ(ΔGaCu(II))~ 0.7 kcal/mol), whereas one sees that the 
Cu(II) affinities are more sensitive to pH adjustment ((ΔGaCu(I))pH 7.4 – (ΔGaCu(I))pH 5.8 ~ 0.5 
kcal/mol versus  (ΔGaCu(II))pH 7.4 – (ΔGaCu(II))pH 5.8 ~ 3.5 kcal/mol). Thus, the trend is that as 
the negative charge around the copper center is increased via protein modification, Cu(I) 
is destabilized and the reduction potential becomes less positive. In contrast, as the pH is 
lowered, the Cu(II) affinity decreases and the reduction potential becomes more positive. 
Within the series there is an ~100 mV shift in potential from pH 7.4 to 5.8 for any 
peptide, providing a slope of ~ 60 mV/pH unit that indicates that the change in potential 
is dependent upon a single proton per electron. The differences between the copper 
affinities lead to the two parallel lines shown in Figure III-16. Thus, by controlling the 
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peptide sequence and the pH, one can systematically vary the reduction potential in this 
system by nearly 200 mV. 
 The observed trends can be explained by the change of H-bonding and salt bridge 
interactions around the copper center upon protein mutations under different pH 
conditions. The mutation of Lys at the 22 position into a Glu would likely lead to an H-
bonding interaction between the carboxylic acid/carboxylate from Glu and the imidazole 
from His, therefore, pH-dependent Cu(II) affinities and reduction potentials are observed. 
Variations on the other charged residues would alter the salt-bridging interactions, 
leading to differences in the electron-donating abilities of the imidazoles or structural 
perturbations to the Cu(I) center, likely involving the change of the orientations of the 
imidazole ring. Consistent with this idea, TRIW-H only exhibits a modest shift to a less 
positive potential (Δ = - 30 mV) from pH 7.4 to 5.9 while all of the peptides with Gln or 
Glu in the 22 position show significant shifts to more positive potentials (Δ = + 60 to + 
140 mV) as the pH is decreased (Table III-5). One possible H-bonding scheme that 
supports both the pH trends in Cu(II) binding and the impact of side chain mutations of 
the Cu(I) affinities is provided in Figure III-24.  
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Figure III-24. Proposed H-bonding network formation in the mutated peptides compared 
to the parent peptide viewed from the C-terminus. (A) Parent peptide TRIW-H; (B) 
TRIW-EH when Glu22 is in its deprotonated state; (C) TRIW-EHE27K when Glu22 is in 
its deprotonated state; (D) TRIW-EHK24E when Glu22 is deprotonated. Water 
molecules are omitted for clarity; however, it is possible that a water molecule might 
exist between any of the salt bridges shown in the scheme. These PyMol models were 
made based on the crystal structure of Hg(II)SZn(II)N(CSL9PenL23H)3– (PDB code: 
3PBJ). With the 23rd position His as a reference point, mutations were made in the 
models into the real sequence of the corresponding TRI peptides. Specifically, the 
relevant amino acid sequence close to the His site in CSL9PenL23H is KHEALE (22–
27). To make this short fragment the same sequence at the corresponding location in 
TRIW-H, Lys22 was mutated into a Glu and Glu24 was mutated into a Lys, yielding the 
sequence EHKALE (22–27). Additional mutations were then carried out to visualize the 
possible H-bonding and salt bridge interactions in the TRIW-EH family peptides.   
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 The pymol models of TRIW-H, TRIW-EH, TRIW-EHE27K and TRIW-EHK24E 
illustrate the changes that may occur in salt bridge interactions as one modifies Glu and 
Lys residues in the b, e and g positions of the heptads. It appears that a neutral or charged 
acceptor side chain (Gln or Glu) can form an H-bond to the imidazole of His23 or having 
a water molecule bridging the two residues. One would expect that as the acidity of the 
solution increases, the negatively charged residue would decrease in charge and become a 
poorer H-bond acceptor. In addition, for some of the mutated peptides (TRIW-EH and 
TRIW-EHK24E), going from pH 7.4 to 5.8, Glu22 should experience protonation, which 
leads to the perturbation of the putative H-bond between Glu22 and His23. This effect 
will lead to less electron density on the imidazole of His23, thus result in a lower affinity 
for Cu(II). The extent of this influence though, varies for different peptides depending on 
the other possible interactions with Glu22, for example, the interaction between Lys24-
Glu22 or Lys27-Glu22 for some of the mutated peptides. In contrast, Lys22 in TRIW-H 
cannot form such H-bonds with His23. 
 The likely key interactions in this system are the inter-helical H-bonds between 
Glu22 and His23 (or a water molecule bridging the two residues), salt bridges between 
Glu22 and Lys24, Lys24 and Glu27. The TRIW-EH peptide has available all three 
possibilities, meaning that Lys24 can spend part of its time salt bridged to either Glu22 or 
Glu27. When Lys24 is interacting with Glu27 with an average donor-acceptor distance of 
3.0 Å based on the pymol model (Figure III-25), the Glu22 is free to H-bond with His23 
(average donor-acceptor distance <2.7 Å, Figure III-25). This leads to an intermediate 
imidazole H-bonding situation (Figure III-24B). If Glu27 is converted to a Lys (TRIW-
EHE27K), Lys27 would interact with Glu22 with an average donor-acceptor distance of 
2.6 Å (Figure III-26), which would weaken the Glu22-His23 H-bond (Figure III-24C). 
For both situations, other rotamers of Lys24 can also interact with Glu20, Glu21 on the 
same strand with distances of <2.8 Å, which might also occur in the parent peptide 
TRIW-H. For residues above Glu22, The intra-helical salt-bridging interaction could 
happen between Glu20 and Lys15, Glu13 and Lys8. On the other hand, when Lys24 is 
converted to Glu24 (TRIW-EHK24E), Glu22 can then H-bond to His23 (average donor-
acceptor distance <2.7 Å, Figure III-27), without the competition from the other potential 
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H-bond contributors (Figure III-24D). The situation with Gln substitution is expected to 
be intermediate between Lys and Glu substitution as is seen to be the case.  
 
Figure III-25. PyMol models of TRIW-EH H-bond scheme (A, B, C represent the 
interactions on the three strands; the numbers represent distances measured directly from 
the pymol models in Å) 
 
Figure III-26. PyMol models of TRIW-EHE27K H-bond scheme (A, B, C represent the 
interactions on the three strands; the numbers represent distances measured directly from 
the pymol models in Å) 
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Figure III-27. TRIW-EHK24E helical wheel model representing the local negative charge 
around the binding site. The Glu22-His23 from the neighboring strands distances are 1.8, 
2.2, 2.3 Å (Ave. < 2.7 Å).  
 Alteration of the amino acid residue in the layer above the copper site (22) has 
virtually no effect on the reduction potential of the system (at pH 7.4: TRIW-H E0 = 433 
mV; TRIW-HK22Q E0 = 450 mV; TRIW-EH E0 = 440 mV).  In general, with peptides 
containing the K22E modification (i.e., those where mutations are made to TRIW-EH), 
one observes that increasing the side chain positive charge below the metal site causes 
significant stabilization of the Cu(I) oxidation level, while the Cu(II) state is mildly 
stabilized by the same mutation. Thus, if we take TRIW-EH as the parent peptide, 
replacing Lys at the 24 position with Gln and Glu progressively destabilizes Cu(I) 
binding, whereas converting Glu27 into Gln or Lys yields much higher Cu(I) affinities. If 
this were solely an electrostatic effect, one might expect the opposite trend for Cu(I) 
affinity (as more positive charge around the positive metal should destabilize binding) 
and that the greater effect would be observed for the Cu(II) level (as charge repulsion 
would be greater). These observations suggest an alternative explanation is required. The 
best explanation is that this may again reflect H-bonding and salt bridging interactions 
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between the different surface residues. In the case of Cu(I)-peptides, the dominant factor 
may be structural perturbations around the metal center.  
 In order to form an effective geometry for directional H-bonding and salt bridging 
interactions, the imidazoles may need to reorient to minimize the conformational changes 
on the peptide backbone. Cu(I) still adopts a trigonal planar coordination when bound to 
the TRIW-EH series of peptides. However, as shown in Scheme III-1, the orientations of 
the imidazoles might vary depending on the interactions between the charged residues 
and the imidazole protons. One may notice that the Debye-Waller factors of the TRIW-
EH series are consistently smaller than that of TRIW-H (by 0.002 Å2), which indicates 
that the Cu(I) trigonal environment in the TRIW-EH series of peptides is slightly less 
distorted than that for Cu(I)(TRIW-H)3+. This could be the result of the interactions 
described above, which would constrain the motions of the imidazole rings.   
 It seems that a more ordered trigonal plane possibly exists for TRIW-EHE27K 
because of the inter-helical H-bonding network formed, connecting His23-Glu22-Lys27 
from the adjacent strands that would hold the copper coordinating ligand His in a 
relatively constrained environment (Figure III-24C). This is of great relevance to the 
rack-induced binding hypothesis proposed for blue copper electron transfer centers in 
native proteins.47 This hypothesis suggests that the protein matrix is responsible for 
maintaining a proper metal coordination environment and fine-tuning the redox potential 
to facilitate electron transfer processes. A previous report demonstrates the importance of 
an H-bond close to the type 1 copper center in plastocyanin, which contributes to the 
rigidity of the coordinating environment of the type 1 copper center.48 The higher 
reduction potential of Cu(II)(TRIW-EHE27K)32+, is reflective of the rigidity at the copper 
centers that favors a trigonal Cu(I).  
  For TRIW-EHK24E, while Glu22 forms an H-bond with His23, the charge 
repulsion between Glu22, Glu24 and Glu27 on the neighboring helices might force the 
imidazoles to adopt a tetrahedral geometry. Such perturbations in geometry are not 
required for the Cu(II) site as it is believed that this ion is already five-coordinate with the 
imidazoles no longer planar. So for Cu(II), the influence of salt-bridging and H-bonding 
effects are not as pronounced. This point may be understood most simply. Cu(II) being 
much more Lewis acidic should lead to acidification of the coordinated imidazole proton. 
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Thus, regardless of competing salt bridges, the Glu22 substitution may lead to an H-bond 
of sufficient stability not to be diminished significantly by salt bridging effects and 
protein mutations. 
NiR activity.  
 How side chain modifications would affect the known catalytic activity of this 
system is examined. The nitrite reductase (NiR) activity of these peptides is expressed as 
the rates of ascorbate consumption. The influence of reduction potential on the NiR rates 
is clearly revealed when examining the rates at a constant pH. At pH 5.8, for the TRIW-
EH series of peptides, the higher the reduction potentials, the lower the rates (Figure 
III-18). The reduction potential changes from 597 mV (TRIW-EHE27K) to 491 mV 
(TRIW-EHK24Q), leading to a 3.5 fold increase in the rates (from 9.94(60) × 10-5 s-1 to 
3.48(71) × 10-4 s-1). While there is an impressive linear correlation between rates and 
reduction potential, one must use caution to ascribe this effect to electron transfer since 
our studies show that the rapid reduction of Cu(II) to Cu(I) by ascorbate can not be rate 
limiting. More likely, the significant reorganization energy due to the change of 
coordination geometry from Cu(I) (3-coordinate) to Cu(II) (5-coordinate) limits the 
observed rates.  
 The nitrite reduction rates also increase markedly with decreasing pH, which was 
observed for both the parent peptide16 and the mutated peptides (Table III-8). The native 
CuNiR is also reported to exhibit pH-dependent activities that are proposed to be closely 
related to both the electron transfer process and the nitrite binding step at the catalytic 
site.49 In this case, since a type 1 electron transfer site does not exist, and the reduction of 
the Cu(II) by ascorbate is much faster than the catalytic reaction, the observed pH-
dependence is likely correlated to steps during the nitrite reduction catalytic cycle. It is 
not surprising to see that at a lower pH, the reaction rates are higher, as the full chemical 
reaction requires two equivalents of protons. Quantitatively, when the pH decreases from 
7.0 to 5.8, the proton concentration in the solution [H+] increases by about 16 times; the 
rates of the reaction, if directly proportional to [H+]2, should have increased by 256 fold. 
Instead, an increase in rate of ~10-fold is observed for TRIW-H.  The rates for the TRIW-
EH series of peptides similarly increased by about 10-16 fold when the pH changed from 
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7.0 to 5.8 (Table III-8). If one plots Log(Initial rate) = a -b·pH for TRIW-H, the b co-
efficient which corresponds to the proton order of the reaction is 0.85. Thus, while the 
stoichiometric reaction requires two protons, the rate-limiting step is dependent on a 
single proton. The second proton is necessary once the hydroxide leaving group is 
formed.50–52 Similar linear correlations are observed for peptides in the TRIW-EH series 
as well (Figure III-28), with a slope of 0.85~0.98.  
 
Figure III-28. The correlation between NiR rates and the pH. The rates are on log scales. 
For a clear presentation, the data points for different peptides are nudged, so there are no 
absolute values on the y-axis. Peptide: 0. TRIW-H; 1. TRIW-EHE27K; 2. TRIW-
EHE27Q; 3. TRIW-EH; 4. TRIW-EHK24Q; 5. TRIW-EHK24E.  
 For all the TRIW-EH peptides, when the pH decreases from 7.4 to 5.8, the 
reduction potential increases by about 100 mV. If this is the only factor influencing the 
rates, the NiR reaction rate should have decreased. It is worth noticing that the rates are 
very low at pH 7.0, so the NiR rates are only analyzed at pH 5.8. As a result, for a 
specific peptide, when pH decreases from 7.0 to 5.8, the participation of a proton in the 
rate-limiting step directly enhances the rate, while the significant structural change upon 
5.7 6.0 6.3 6.6 6.9
pH
-L
og
(r r
xn
)
0
1
2
3
4
5
! 188 
converting from Cu(I) to Cu(II) (reflected as an increased reduction potential) impedes 
the reaction.  This is consistent with the trends observed when comparing the peptides at 
a fixed proton concentration. Combining these two opposite effects, a 10-16 fold rate 
increase is observed when the pH decreases from 7.0 to 5.8.  
 It should be noted that the NiR rate vs. reduction potential correlation at a 
constant pH should be interpreted with caution as it only compares peptides within the 
TRIW-EH series. If one compares the parent peptide TRIW-H and the charge “flipped” 
peptide TRIW-EHE27K at pH 5.8 the situation is different. The reduction potential of 
TRIW-EHE27K is about 200 mV more positive than that of TRIW-H, but its NiR rate is 
only 2 times less than that of the parent peptide. Using the correlation in Figure III-18, 
one would have expected a 6-fold differential between these two peptides if reduction 
potential alone were the determining factor. In general, despite the TRIW-EH peptides 
having much more positive reduction potentials, they have, as a group, comparable rates 
to TRIW-H. In the next chapter, I will discuss a few peptides that that involve the K22E 
mutation and demonstrate that Glu22 either does not influence or lowers the reaction 
rates. Among the TRIW-EH series of peptides presented in this chapter, interactions of 
Glu22 with other charged residues at the helical interface (vide supra) moderate the 
impact on catalysis of Glu22.  
Conclusion 
 I have presented here a systematic approach of modulating the reduction 
potentials and NiR activity within a self-assembled peptidic framework by stepwise 
modifications that influence the local charge. These modifications are carried out for 
residues at the helical interface. Varied deprotonation equilibria of Cu(II)-peptides are 
observed, which have a direct impact on the Cu(II) affinities to the apo-peptide at 
different pH conditions. At a specific pH, the influence of the mutations is reflected from 
the linearly correlated Cu(I)-peptide affinities and Δcharge. Reduction potentials are 
calculated based on the Cu(I) and Cu(II) affinities to the apo-peptides. For a particular 
peptide, the difference of reduction potentials at different pH conditions originates from 
the change in Cu(II) affinities; at a specific pH, the difference of reduction potentials for 
TRIW-EH series of peptides is dominated by the variance in Cu(I) affinities, which could 
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be the result of the variation in the orientations of imidazole rings upon the alteration of 
charged residues. Moreover, all of these copper-peptides exhibit pH-dependent NiR 
activities. Within the TRIW-EH series, the NiR rates are governed by the proton 
concentration and the reduction potentials. At a specific pH, the reduction potential 
correlates to the observed rates, however, other factors, such as the formation of 
substrate-enzyme complex, product-enzyme complex and product release, may also play 
a role in determining the NiR rates. The effects on the processes described above are 
likely the result of an H-bond between Glu22 and His23 (or a water molecule bridging 
the two residues), together with salt-bridging interactions of Glu22 with other charged 
residues.   
 This study demonstrates that even in highly simplified scaffolds, attempts to 
change the local charge around the active site may cause multiple interactions that can 
vary the redox properties and activities in distinct ways. Nevertheless, this de novo design 
approach allows one to begin to peel the onion layer by layer. One can isolate different 
factors (pH, affinities, reduction potentials, et al.) and to compare and analyze the effects 
in a multi-dimensional way. In conclusion, this work showcases the strength of de novo 
protein design to anchor the in-depth understanding of fundamental interactions that 
modulate the redox properties and NiR rates for a type 2 copper center, which provides 
interesting directions for future work on model chemistry in general.  
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Chapter IV . Modifications of the interior of the coiled coils to 
achieve a better NiR model
Introduction 
 The fine-tuning of activities of a metal center involves interactions beyond the 
coordinating atoms. As discussed in Chapter I, the second coordination sphere 
interactions have an impact on the reactivity of metal centers through H-bonding, salt-
bridges, packing patterns, and hydrophobicity in both redesigned and de novo designed 
systems. Significant efforts have been made to understand how the above-described 
interactions influence the activity of hydrolytic centers such as the zinc center in CA,1–5 
and electron transfer centers such as a cupredoxin center.6 Again, no such study on a 
Cu(His)3 center was precedent before this thesis work was begun. The crystal structure of 
NiR reveals a few important residues that are responsible for solvent and substrate 
binding, shaping the active site, as well as facilitating proton/electron transfer at the 
T2Cu center.7–13 Mutagenesis studies have been carried out to probe the roles of these 
residues. For example, Asp98 in Achromobacter cycloclastes CuNiR forms an H-bond 
with the copper-coordinating water14 or nitrite, playing a direct role in the protonation of 
intermediates. The mutation of Asp into an Asn significantly decreases the activity 
attributed to the loss of this H-bond or an alternative substrate binding mode due to a 
different orientation of the Asn side chain.7,8 An Ile residue at position 257 is highly 
conserved in native NiRs. When Ile257 is mutated to Ala, Gly, Thr, and Met, nitrite binds 
to the T2Cu center in a monodendate mode revealed by crystal structures, leading to the 
decrease of specific activity of up to 100-fold.9 Therefore, the residues beyond the first 
coordination sphere are essential for efficient nitrite reduction to occur at this copper site.   
 In the context of this thesis, I have constructed a model for the first coordination 
sphere of the T2Cu center in NiR as described in Chapter II. The cuprous state of this 
model is three-coordinate, the same coordination number as the ascorbate-reduced T2Cu 
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center in CuNiR.15 The cupric state might have a higher coordination number than seen in 
the native T2Cu center. Although possessing a higher redox potential as compared to 
native CuNiR, this model can still catalyze nitrite reduction with 5 turnovers over 3.7 h. 
Then I explored the modification of the charged residues on the helical interface that 
yielded a series of peptides with reduction potentials spanning ~200 mV and NiR rates 
varying 4-fold (Chapter III). These modifications are thought to alter the electrostatics 
around the copper center, the H-bonding interactions, and the salt-bridges, which are all 
important facets of second coordination sphere interactions.16 In this chapter, I will take a 
different design approach to modify the residues in the interior of the helical coiled coils 
in order to utilize a few other second coordination sphere interactions to tune the 
reactivity.  
 Two general strategies are undertaken: 1) the modification of the hydrophobic 
residues around the copper center; 2) the modification of the electronic environment of 
the imidazole ring by incorporating an unnatural amino acid N-methyl-histidine. In 
addition, the K22E mutation is also introduced combined with the two strategies 
mentioned above.  Table IV-1 shows the peptide sequences involved in this chapter. The 
potential consequences of these modifications include the change of the coordination 
environment on either or both oxidation levels, the alteration of solvent/substrate access, 
the change of the H-bonding scheme around the copper center, and the variation of the 
Lewis acidity of the copper ions. All these possible effects might lead to altered 
reactivity.   
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Material and methods 
 All the general procedures and methods are the same as reported in the the 
previous chapters.  
NiR rates at pH 5.8.  
 30 mM NaNO2 was mixed with 19.4 μM Cu(II)(3SCC) and 80.6 μM apo-3SCC 
(to ensure that over 99% of Cu(II) is bound to the peptide) in 50 mM potassium 
phosphate buffer. The pH was adjusted to 5.8 by adding small amount of concentrated 
KOH or KHSO4. The reaction was initiated by adding 1.1 mM sodium ascorbate 
(NaAsc). The consumption of sodium ascorbate (NaAsc) was monitored by UV-Visible 
spectroscopy. The control was a mixture of 30 mM NaNO2 and 80.6 μM apo-3SCC with 
the same amount of NaAsc. The rates of the reaction were calculated by two times the 
different rates of NaAsc consumption (decrease of absorbance at 251 nm) between the 
sample and the control. To compare to the peptides presented in the previous chapters, 
the rates were then calibrated based on the first order dependence between peptide 
concentrations and rates.  
Correlation between peptide concentrations and rates at pH 5.8.  
 A series of reactions with different Cu(II)(3SCC) concentrations were set up to 
establish the relationship between enzyme concentration and NiR rates. The samples 
contain 30 mM NaNO2, varied concentrations of Cu(II)(3SCC) (0.5, 1, 5, 10, 15, and 20 
μM), and corresponding concentrations of apo-peptides (3.5, 7, 35, 70, 105, 140 μM). 
The controls contain 30 mM NaNO2 and apo-peptides (3.5, 7, 35, 70, 105, 140 μM). The 
pH of the solution was adjusted to 5.8 by adding concentration KOH/KHSO4. The 
reactions were initiated by adding a solution of NaAsc. The final NaAsc concentration in 
the cuvette was 1.5 mM. The rates of the reaction were calculated the same way as 
discussed previously. 
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Michaelis-Menten kinetics.  
 Different concentrations of NaNO2 (0.5, 1, 2.5, 5, 10, 20, 30, 40, 50, 100, 150, 
200, 300 mM) were incubated with the peptides. Samples contained 10 μM 
Cu(II)(3SCC), 70 μM apo-peptide in 50 mM potassium phosphate buffer. Controls 
contained 70 μM apo-peptide. The pH was adjusted to 5.8. The reactions were initiated 
by injecting NaAsc to the reaction mixture. The final NaAsc concentration was 1.5 mM. 
The rates of the reactions were calculated the same way as discussed previously.. The 
rates were correlated to the substrate concentrations through fits to the Michaelis-Menten 
equation in Prism 5 (GraphPad software).  
Results 
Characterization of apo-peptides.  
 The CD spectra of apo-peptides are shown in Figure IV-1A. These peptides all 
have characteristic double-well spectra at 208 and 222 nm, signifying formation of coiled 
coils. It is worth noticing that with the introduction of the L19A mutation, the helical 
content of the apo-peptide decreases from ~70% to ~60%. In addition, the introduction of 
a methyl group on the imidazole does not alter the helical content or the stability of the 
peptide as compared to TRIW-H ([GuaHCl]midpoint = 2 M for both denaturation titrations). 
Since there is no plateau at the beginning of the titration curve, the unfolding process 
cannot be fitted to a two-state model.  
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Figure IV-1. (A) CD spectra of TRIW-EHL19A (cyan spectrum), TRIW-HL19A (black 
spectrum), TRIW-MH (red spectrum), and TRIW-MHL19A (blue spectrum). (B) GuaHCl 
denaturation titration monitored by CD. The color-coding for peptides is the same as (A).  
XAS of Cu(I)(TRIW-HL19A)3+.  
 The L19A mutation leads to a different Cu(I) coordination environment at pH 5.8. 
The XANES of Cu(I)(TRIW-HL19A)3+ has a relatively high intensity at ~8984 eV, 
typical of a two-coordinate Cu(I) center. As pH is increased from 5.8 to 7.4, this feature 
gradually decreases. At pH 7.4, the XANES resembles that of a three-coordinate Cu(I). 
The EXAFS fittings of Cu(I)(TRIW-HL19A)3+ at these two pH conditions are consistent 
with the change of coordination numbers (Figure IV-3, Table IV-2). Going from pH 5.8 
to 7.4, the Cu-Nimid distance increases by 0.05 Å, which is smaller than one might expect 
for an increase of one in coordination number (~0.07-0.1 Å).  
 
Figure IV-2. XANES of Cu(I)(TRIW-HL19A)3+ at pH 5.8 (black spectrum), 6.5 (red 
spectrum), and 7.4 (blue spectrum).  
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Figure IV-3. EXAFS of Cu(I)(TRIW-HL19A)3+ at pH 5.8 (A) and pH 7.4 (C). The 
Fourier transform of the EXAFS at pH 5.8 (B) and pH 7.4 (D). Experimental data are 
shown in solid lines and fittings are shown as dashed lines.  
XAS of Cu(I)(TRIW-MH)3+.  
 The XANES of Cu(I)(TRIW-MH)3+ overlays very well with that of Cu(I)(TRIW-
H)3+, indicating that Cu(I) is still three-coordinate. Subtle differences in the edge 
structures might reflect minimal geometrical perturbations. Also similar to Cu(I)(TRIW-
H)3+, when the pH increases from 5.8 to 7.4, there is essentially no change in the XANES 
of Cu(I)(TRIW-MH)3+ (Figure IV-4). EXAFS fitting results corroborate the assignment of 
coordination numbers. A typical three-coordinate Cu-Nimid distance is seen (1.935 Å) with 
a smaller Debye-Waller factor as compared to that for Cu(I)(TRIW-H)3+ (Figure IV-5, 
Table IV-2). 
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Figure IV-4. XANES of Cu(I)(TRIW-MH)3+ at pH 5.8 (black solid line) and 7.4 (blue 
solid line) compared to that of Cu(I)(TRIW-H)3+ at pH 5.8 (red dashed line).   
 
Figure IV-5. EXAFS (A) and Fourier transform (B) of Cu(I)(TRIW-MH)3+. Experimental 
data are shown in solid lines and fittings are represented as dashed lines.  
XAS of other peptides involved in this study.  
 The XANES of other peptides involved in this chapter are shown in Figure IV-6. 
They are presented in three groups. Group 1 (Figure IV-6A) includes two types of 
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pH 5.8, Cu(I)(TRIW-H19A)3+ is two-coordinate while Cu(I)(TRIW-MH)3+ is three-
coordinate. One sees an intermediary spectrum for Cu(I)(TRIW-MHL19A)3+. Group 2 
(Figure IV-6B) focuses on K22E and L19A mutations and a peptide combining these two 
features (TRIW-EHL19A). Cu(I) binds to three His in a distorted trigonal plane in 
TRIW-EH (Chapter III), however, when the L19A mutation is introduced, the 
coordination number of Cu(I) decreases from 3 to 2, as the XANES of Cu(I)(TRIW-
EHL19A)3+ is the same as that of Cu(I)(TRIW-HL19A)3+. Group 3 (Figure IV-6C) 
contains peptides with only an MH feature, K22E mutation with MH, and L19A mutation 
with MH feature. Again, one sees the tendency of forming a two-coordinate Cu(I) once 
L19A is introduced to TRIW-MH. Interestingly, in the presence of a methyl group on 
imidazole, it seems that K22E mutation drives toward the formation of a two-coordinate 
Cu(I) as well. The EXAFS fittings of these peptides are mostly consistent with the 
assignment of coordination numbers, resulting in typical two- or three-coordinate Cu(I)-
Nimid distances (Table IV-2, Figure IV-7, Figure IV-8, and Figure IV-9).  
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Figure IV-6. (A) XANES of Cu(I)(TRIW-HL19A)3+ (solid blue line), Cu(I)(TRIW-MH)3+ 
(solid black line), and Cu(I)(TRIW-MHL19A)3+ (solid red line) at pH 5.8; (B) XANES of 
Cu(I)(TRIW-HL19A)3+ (solid blue line), Cu(I)(TRIW-EHL19A)3+ (dashed red line), and 
Cu(I)(TRIW-EH)3+ (dashed black line) at pH 5.8; (C) XANES of Cu(I)(TRIW-MH)3+ 
(solid black line), Cu(I)(TRIW-MHL19A)3+ (solid red line), and Cu(I)(TRIW-EMH)3+ 
(dashed purple line) at pH 5.8.  
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Figure IV-7. Cu(I)(TRIW-MHL19A)3+ at pH 5.8 [EXAFS (A) and Fourier transform (B)] 
and 7.4 [EXAFS (C) and Fourier transform (D)]. Experimental data are shown in solid 
lines and fittings are shown as dashed lines.  
 
Figure IV-8. EXAFS (A) and Fourier transform of EXAFS of Cu(I)(TRIW-EMH)3+ at pH 
5.8. Experimental data are shown in solid lines and fittings are shown as dashed lines. 
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Figure IV-9. EXAFS (A) and Fourier transform of EXAFS of Cu(I)(TRIW-EHL19A)3+ at 
pH 5.8. Experimental data are shown in solid lines and fittings are shown as dashed lines. 
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CO adduct of Cu(I)(TRIW-HL19A)3+ at pH 5.8.  
 In Chapter II, I presented the characterization of the CO adduct of Cu(I)(TRIW-
H)3+. As a probe molecule, CO is widely used to study the coordination environment of 
Cu(I) in synthetic small molecules and native copper centers.17–23 If this method can be 
applied to the case of Cu(I)(TRIW-HL19A)3+ (pH 5.8), one would expect to see a very 
different CO stretching frequency (~2100 cm-1)20 since Cu(I) is two-coordinate at this pH. 
Surprisingly, the CO adduct of Cu(I)(TRIW-HL19A)3+ exhibits a C-O stretching 
frequency of 2064.6 cm-1, suggesting the formation of a tetrahedral Cu(I) center where 
Cu(I) is coordinated to three His and a CO in a terminal binding mode (Chapter II).19,22 
The XANES of Cu(I)(CO)(TRIW-HL19A)3+ is different from those of Cu(I)(TRIW-
HL19A)3+, which has a two-coordinate Cu(I), and from Cu(I)(TRIW-H)3+ with a three-
coordinate Cu(I). The decreased intensity of the ~8984 eV peak indicates the formation 
of a four-coordinate Cu(I) center, consistent with the FTIR analysis.  
 
Figure IV-10. FTIR spectrum of the CO adduct of Cu(I)(TRIW-HL19A)3+ at pH 5.8.  
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Figure IV-11. XANES of Cu(I)(TRIW-HL19A)3+ (blue spectrum), Cu(I)(CO)(TRIW-
HL19A)3+ (black spectrum), and Cu(I)(TRIW-H)3+ (green spectrum) at pH 5.8.  
Spectroscopies of Cu(II)-peptides.  
 The absorption spectra of Cu(II)(3SCC) exhibit typical T2Cu features, with broad 
absorption bands and low extinction coefficients (Table IV-3). These absorption features 
are typical of N2-3O2-3 coordination to Cu(II). Together with EPR parameters (Table 
IV-4), Cu(II) spectroscopy studies indicate that Cu(II) is coordinated to multiple nitrogen 
atoms (presumably from imidazoles) and oxygen atoms (from solvent) with a relatively 
high coordination number (4~5).  
Table IV-3. d-d absorption features of Cu(II)(3SCC) 
Peptide max(ε/M-1 cm-1)/nm, pH 5.8 max(ε/M-1 cm-1)/nm, pH 7.4 
Cu(II)(TRIW-HL19A)32+ 652(94) 646(100) 
Cu(II)(TRIW-MH)32+ 670(67) 666(72) 
Cu(II)(TRIW-MHL19A)32+ 659(74) 645(82) 
Cu(II)(TRIW-EMH)32+ 689(71) 657(76) 
Cu(II)(TRIW-EHL19A)32+ 677(75) 664(74) 
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Table IV-4. EPR parameters of selected Cu(II)(3SCC) at pH 5.8 
Peptide gx gy gz Az/mT 
Cu(II)(TRIW-HL19A)32+ 2.050 2.060 2.278 18.93 
Cu(II)(TRIW-MH)32+ 2.054 2.058 2.292 18.65 
Cu(II)(TRIW-MHL19A)32+ 2.048 2.058 2.285 18.93 
 
 
Figure IV-12. EPR spectra of Cu(II)(TRIW-HL19A)32+ (black spectrum), Cu(II)(TRIW-
MHL19A)32+ (blue spectrum), and Cu(II)(TRIW-MH)32+ (red spectrum).  
pKa of Cu(II)(3SCC).  
 pH titrations were carried out for Cu(II)(3SCC) to probe how the Cu(II) 
coordination environment changes upon changing pH and to understand the nature of the 
coordination environment based on the deprotonation events observed for a specific 
peptide. For each system, as pH is increased from ~3 to ~5, a d-d band grows in at 650 – 
690 nm. After this conversion, the d-d band evolves differently for different peptides.  
 For Cu(II)(TRIW-HL19A)32+, from pH 5.60 to 7.95, the d-d band is essentially 
unvaried (Figure IV-13A).  As the pH keeps increasing, the spectra transform into 
2400 2800 3200 3600
Field/G
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another set with a maximum centered at 516 nm (Figure IV-13B). This conversion can be 
fitted into a protonation equilibrium with a pKa = 9.08(3), n = 0.99(7) (Figure IV-14).  
 
Figure IV-13. pH titration of Cu(II)(TRIW-HL19A)3+. (A) pH 2.94 – 7.26; (B) pH 7.26 – 
9.93.  
 
Figure IV-14. The d-d band extinction coefficient of Cu(II)(TRIW-HL19A)3+ fitted to 
Equation II-3 at pH 7 – 11.  
 When a methyl group is introduced onto the imidazole, one more protonation 
equilibrium is observed in the neutral pH range. When the pH is raised from 5.99 to 9.07, 
the Cu(II) d-d band shifts from 660 nm to 625 nm, with an increased extinction 
coefficient (Figure IV-15A). This conversion can be fitted to Equation II-3, yielding a 
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pKa = 7.53(5), n = 1.18(14). Furthermore, in an even higher pH range (9.07 – 10.79), a 
similar transformation is observed.  
 
Figure IV-15. (A) pH titration spectra of Cu(II)(TRIW-MH)32+. Red spectrum: pH 2.89; 
green spectrum: pH 5.99; blue spectrum: pH 9.07; magenta spectrum: pH 10.79. (B) 
Cu(II) d-d band extinction coefficient fitted toEquation II-3.   
 Cu(II)(TRIW-MHL19A)32+, the peptide combining the two features described 
above, i.e. L19A mutation and MH, shows similar behavior as Cu(II)(TRIW-MH)32+ 
(Figure IV-16A). However, the equilibria in this case are not well-defined, as one sees an 
increased absorbance going from pH ~3 to ~10, without distinct steps as seen in other 
Cu(II)(3SCC). The titration curve cannot be fitted properly toEquation II-3.  
 
Figure IV-16. (A) pH titration spectra of Cu(II)(TRIW-MHL19A)32+. Red spectrum: pH 
2.97; glue spectrum: pH 5.83; green spectrum: pH 9.01; magenta spectrum: pH 10.24. (B) 
the change of εd-d band upon pH change.  
 The spectral evolution of Cu(II)(TRIW-EHL19A)32+ as a function of pH is shown 
in Figure IV-17. Two equilibria are observed after the formation of Cu(II)(3SCC) 
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complex. At pH 6.98 – 8.73, the absorption maximum shifts from 664 nm to 625 nm. An 
isosbestic point is observed, indicating a conversion from one species to another (Figure 
IV-17B). As pH is raised above 9, a few new species show up in a higher energy region 
(~510 nm) (Figure IV-17C). Since the pKa values of these deprotonation equilibria are 
too close to each other, they cannot be defined by fitting the titration curve to Equation 
II-3.  
! 213 
 
Figure IV-17. pH titration of Cu(II)(TRIW-EHL19A)32+. (A) pH 2.91 – 6.19; (B) pH 6.98 
– 8.73; (C) pH 8.73 – 10.10.  
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NO2- titration monitored by EPR.  
 NO2- titrations were carried out for Cu(II)(TRIW-HL19A)32+, Cu(II)(TRIW-
MH)32+, and Cu(II)(TRIW-MHL19A)32+ at pH 5.8 monitored by EPR. No spectral change is 
observed for Cu(II)(TRIW-HL19A)32+ or  Cu(II)(TRIW-MHL19A)32+ after 20 eq. of NO2- 
is added (Figure IV-18, Figure IV-19). For Cu(II)(TRIW-MH)32+, however, as NO2- is 
titrated in small aliquots, AII decreases (Figure IV-20). The correlation of AII to the 
concentration of NO2- yields a NO2- dissociation constant of 8.8 mM (Figure IV-21).  
 
Figure IV-18. NO2- titration of Cu(II)(TRIW-HL19A)32+ at pH 5.8 ([Cu(II)] = 1 mM, 
[3SCC] = 1.5 mM, 50 mM MES). The numbers on the right side of the spectra represent 
the equivalents of NO2- with respect to Cu(II).  
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Figure IV-19. NO2- titration of Cu(II)(TRIW-MHL19A)32+ at pH 5.8 ([Cu(II)] = 1 mM, 
[3SCC] = 1.5 mM, 50 mM MES). The numbers on the right side of the spectra represent 
the equivalents of NO2- with respect to Cu(II). 
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Figure IV-20. NO2- titration of Cu(II)(TRIW-MH)32+ at pH 5.8 ([Cu(II)] = 1 mM, [3SCC] 
= 1.5 mM, 50 mM MES). The numbers on the right side of the spectra represent the 
equivalents of NO2- with respect to Cu(II). 
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Figure IV-21. AII of Cu(II)(TRIW-MH)32+ with solid line representing the fit to Equation 
II-2.  
Azide binding to Cu(II)(3SCC).  
 Azide binding titrations monitored by UV-Vis spectroscopy were carried out for 
selected peptides in this study. When azide is titrated into a solution of Cu(II)(TRIW-
HL19A)32+, a peak at 382 nm starts to grow when azide is below 30 eq. with respect to 
Cu(II). After 30 eq., the peak shifts to a higher wavelength (Figure IV-22A). A red-
shifted d-d band is observed for both processes. This is tentatively conceived as 
sequential azide binding, the chemical reactions of which are represented by:  
  
The Kd1N3
−  and K fN3
− values can be extracted by fitting the titration spectra into these 
equilibria, and Kd2N3
−  is calculated from the equation Kd2N3
−
=
1
K fN3
−
•Kd1
N3−
 (Table IV-5). 
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Figure IV-22. Azide titration of Cu(II)(TRIW-HL19A)32+ monitored by UV-Vis 
spectroscopy. (A) Titration spectra. The blue, red, green, magenta, cyan, purple, and 
orange spectra correspond to 1, 10, 30, 120, 200, 300, and 460 eq. of azide with respect to 
Cu(II). (B) The absorption spectra of two types of azide-Cu(II)(TRIW-HL19A)32+ adduct. 
Insert: fitting of the two species. Dots: data points; solid lines: calculated titration curves. 
The colors of the calculated curves correspond to the color of the specific spectrum, 
representing the formation of that species.  
 For Cu(II)(TRIW-MH)32+, only one type of azide adduct is produced when azide is 
added (Figure IV-23A). This species corresponds to an absorption maximum at 390 nm. 
With a model of one azide binding to the Cu(II)-peptide complex, the absorbance at 390 
nm can be fitted to yield a dissociation constant of 26.3 mM (Table IV-5).   
 
Figure IV-23. Azide titration of Cu(II)(TRIW-MH)32+ monitored by UV-Vis spectroscopy. 
(A) Titration spectra. The blue, red, green, magenta, cyan, purple, and orange spectra 
correspond to 1, 10, 30, 120, 200, 300, and 460 eq. of azide with respect to Cu(II). (B) 
Calculated titration curve (solid red line) and experimental data (black dots, absorbance 
at 390 nm).  
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 Azide also binds to the peptide with combined features of L19A and MH 
mutations. A slight shift of absorption maximum is observed as azide reaches higher 
equivalents (Figure IV-24A). The titration spectra can be fitted to two equilibria as shown 
for Cu(II)(TRIW-HL19A)32+ (Table IV-5).  
 
Figure IV-24. Azide titration of Cu(II)(TRIW-MHL19A)32+ monitored by UV-Vis 
spectroscopy. (A) Titration spectra. The blue, red, green, magenta, cyan, purple, and 
orange spectra correspond to 1, 10, 30, 120, 200, 300, and 460 eq. of azide with respect to 
Cu(II). (B) The absorption spectra of two types of azide-Cu(II)(TRIW-MHL19A)32+ 
adduct. Insert: fitting of the two species. Dots: data points; solid lines: calculated titration 
curves. The colors of the calculated curves correspond to the color of the specific 
spectrum, representing the formation of that species. 
Affinities and reduction potentials.  
 The affinity of Cu(I) to selected peptides were determined based on the 
procedures described in the previous chapters (Chapter II, Experimental section). For the 
peptide Cu(I)(TRIW-HL19A)3+, when small aliquots of Na2BCA were first added to the 
solution, a peak centered at 508 nm grew in. With the addition of more BCA2–, the 
absorption spectra gradually transformed to a new set centered at 562 nm, which is 
consistent with the reported Cu(BCA)23- species. The titration spectra can be fitted to a 
model with two equilibria:  
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where . 
 
 Data fitting was carried out in the global fitting program Hyperquad.24 As shown 
in Figure 25B, both processes contribute to the increase in absorbance simultaneously. 
The dissociation constants and reduction potentials are listed in Table IV-6. TRIW-
MHL19A experiences slow kinetics for BCA2- chelation. As a result, the competition 
assay cannot be used for this peptide.  
  
 
Figure IV-25. BCA2– competitive chelation titration of Cu(I)(TRIW-HL19A)3+ at pH 5.8. 
(A) Titration spectra. (B) Two species extracted from spectral fitting. Red spectrum: 
Cu(BCA)23-; blue spectrum: CuP(BCA)–. Insert: data points and fitting curves for the two 
colored species.  
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Table IV-6. Cu(I) and Cu(II) dissociation constants and reduction potentials of selected 
peptides at pH 5.8 
Peptide Kd(Cu(I))/M Kd(Cu(II))/M E/mV vs. NHE 
TRIW-HL19A 
Kdternary = 6.12(10) × 10-18 1.33(19) × 10-5 559(8) 
KdCuP = 2.28(68) × 10-12 
TRIW-MH 1.70(23) × 10-12 3.29(100) × 10-6 530(8) 
TRIW-MHL19A - 5.66(38) × 10-6 - 
 
NiR activity.  
 NiR rates at pH 5.8. It has been demonstrated in the previous chapters that NiR 
rates increase as the pH decreases. At pH 5.8, the rates are the highest for all the peptides 
presented so far. Herein, I collected data on NiR rates at pH 5.8 for the peptides involved 
in this chapter. In general, the peptides containing the L19A and MH features exhibit 
much higher NiR rates than the previous generations (Figure IV-26). Compared to 
TRIW-H, the L19A mutation introduced ~150-fold increase in rates, the MH mutation 
~500-fold, and the peptide with both features ~1300-fold. The K22E mutation, on the 
other hand, tends to decrease the rates, as is seen for the cases of TRIW-EHL19A versus 
TRIW-HL19A, and TRIW-EMH versus TRIW-MH. The peptides on the right side of the 
plot (from TRIW-EHL19A to the right) have significantly higher rates than the ones on 
the left side of the plot, suggesting that the modifications of the interior of the helical 
coiled coils might be more effective in influencing the NiR rates.  
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Figure IV-26. NiR pseudo-first order rate constants at pH 5.8 for Cu(II)(3SCC). The y-
axis is on a logarithmic scale. Insert: the same plot on a linear scale.  
 Since the rates are much higher for some of the peptides in this chapter, for a 
direct comparison to TRIW-H and TRIW-EH series of peptides, I would have to decrease 
the enzyme concentration to obtain a valid initial rate, and proportionally scale up the 
rates to compare to the other peptides. The NiR rates are linearly dependent on the 
peptide concentrations (Figure IV-27), allowing me to carry out this process for 
comparison.  
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Figure IV-27. Linear correlations between peptide concentrations and NiR rates at pH 
5.8. Filled triangles: TRIW-MHL19A; filled squares: TRIW-MH; filled circles: TRIW-
HL19A. 
 Michaelis-Menten kinetics. Michaelis-Menten kinetic studies were carried out for 
TRIW-HL19A, TRIW-MH, and TRIW-MHL19A. The parameters are shown in Table 
IV-7.  
Table IV-7. Kinetic parameters at pH 5.8 
Peptide vmax (M min-1) KM (M) kcat (min-1) kcat/KM (min-1 M-1) 
Cu(II)(TRIW-
HL19A)32+ 
1.4(2) × 10-4 0.24(5) 14(2) 60(15) 
Cu(II)(TRIW-MH)32+ 8.9(7) × 10-4 0.18(2) 89(7) 4.9(7) × 102 
Cu(II)(TRIW-
MHL19A)32+ 
8.8(3) × 10-4 0.13(1) 88(3) 6.8(6) × 102 
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Figure IV-28. Michaelis-Menten kinetics of Cu(II)(TRIW-HL19A)32+ at pH 5.8.  
 
Figure IV-29. Michaelis-Menten kinetics of Cu(II)(TRIW-MH)32+ at pH 5.8. 
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Figure IV-30. Michaelis-Menten kinetics of Cu(II)(TRIW-MHL19A)32+ at pH 5.8. 
 
Discussion 
 To obtain a desired metal coordination environment, protein designers can either 
directly change the first coordination sphere of the metal center or the area immediately 
surrounding the catalytic center (second coordination sphere). In the first case, one may 
incorporate an exogenous ligand or modify/add a coordinating residue. The second 
coordination sphere may be controlled by changing the packing of the hydrophobes, 
including H-bonding, changing local dielectric, building channels and even altering the 
grand topology of the protein. In native metalloenzymes, the complex architecture of 
substrate channel, proton-electron transfer chain, and the proper shaping and packing of 
amino acid side chains is responsible for the outstanding efficiency and selectivity which 
is observed. It is generally believed that the modification of the second coordination 
sphere only leads to a limited level of influence on the metal center; however, sometimes, 
changes in the second coordination sphere directly gives rise to alterations of the first 
coordination sphere, as is the case described here.  
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 The designs introduced in this chapter focus on the interior of the helical coiled 
coils. The first strategy is to mutate a Leu a layer above the copper-binding site into an 
Ala in order to change the substrate/solvent access to the copper center. It has been 
demonstrated that the peptide TRIL16C binds Cd(II) with three sulfurs from the Cys 
residue. This Cd(II)-peptide complex contains a mixture of a four-coordinate Cd(II)S3O, 
where the oxygen presumably comes from a coordinating water molecules, and a three-
coordinate Cd(II)S3. The mutation of a d site (a site versus d site, see Chapter I) right 
above the Cd(II)-binding site (TRIL12AL16C) leads to a 100% four-coordinate 
Cd(II)S3O species.25,26 This change of coordination number is attributed to the smaller 
side chain of Ala, which opens a “hole” above the Cd(II)-binding site to accommodate 
the coordinating solvent molecule. My design is similar to this in the distance between 
the Ala mutation site and the metal-binding residue, but the residues involved here are 
one heptad repeat closer to the C-terminus. Based on the known effect of having an Ala 
residue one hydrophobic layer above the Cd(II)-binding residue, L19A mutation is 
introduced with the intention of modifying the solvent/substrate access to the copper 
center (Figure IV-31). 
 The second strategy is to replace the copper-binding His by Nδ-methyl-histidine 
in order to utilize the steric bulk introduced by the methyl group. The intention was to 
increase the coordination number of Cu(I) by forcing the copper ion out of the trigonal 
plane (3Nimid) (Figure IV-32), so as to decrease the reorganizational energy upon electron 
transfer. In addition, the electronic effect of the methyl group can potentially influence 
the binding properties of both cuprous and cupric forms, thus changing the redox 
properties and activity.  
 Based on these two strategies and the K22E mutation introduced in Chapter III, I 
then prepared a few peptides that have two features incorporated in the same peptide: 
TRIW-EHL19A, TRIW-EMH, TRIW-MHL19A. Basic characterizations such as copper 
binding and spectroscopic studies were carried out for all of these peptides to investigate 
how these changes influence copper coordination on both oxidation levels.  
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Figure IV-31. Space-filling model of TRIW-H (A) and TRIW-HL19A (B) illustrating 
that the L19A mutation opens space above the copper-binding site. The PyMol models 
are made based on the crystal structure of Hg(II)SZn(II)N(CSL9PenL23H)3– (PDB code: 
3PBJ). 
 
Figure IV-32. Predicted coordination of Cu(I) in TRIW-MH (B) compared to the TRIW-H 
(A). The PyMol models are made based on the crystal structure of 
Hg(II)SZn(II)N(CSL9PenL23H)3– (PDB code: 3PBJ). 
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Cu(I) coordination. 
 The modifications directly influence Cu(I) coordination, possibly through the 
change of packing of the side chains and H-bonding scheme around the copper center. 
Contrary to the expectation of potentially increasing the coordination number, Cu(I) is 
only coordinated to two His when bound to TRIW-HL19A at pH 5.8, as XANES shows a 
typical two-coordinate Cu(I) edge structure and EXAFS fitting parameters are consistent 
with those of the reported two-coordinate Cu(I) sites (Table IV-8, blue blocks). When the 
pH is increased to 6.5 and 7.4, a gradual decrease in the pre-edge peak intensity is 
observed, while the peak positions do not shift. This indicates that the pH change is 
directly correlated to the change of coordination numbers of Cu(I), the pKa of which is 
between 5.7 to 6.3 depending on whether it is a one- or two-proton related process. This 
transformation is linked with either the association of 2SCC into 3SCC (Figure IV-33A) 
or the deprotonation of His (Figure IV-33B). As shown in Figure 3-21, the pKa 
corresponding to route Figure IV-33A is generally smaller than 5.5 and an isolated His 
imidazole has a pKa of ~6, so route B (Figure IV-33) is a more favored explanation. At 
pH 5.8, Cu(I) is coordinated to two His residues, the third His is in its protonated form, 
i.e. imidazolium form. When the pH is increased, the remaining imidazolium is 
deprotonated into an imidazole, which then binds Cu(I), forming a trigonal cuprous 
center (Scheme IV-2). 
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Table IV-8. Two-coordinate and three-coordinate Cu(I) centers  
Sample Shell R(Å) σ2(Å2) Ref 
Cu(I)(TRIW-HL19A)3+, pH 5.8 2 Nimid 1.86 0.007 This work 
Aβ16Cu(I), pH 7.2 2 Nimid 1.88 0.006 27 
Lε-Cu(I)a 2 Nimid 1.86 0.009 20 
(Met2Im)2Cu(I)b 2 Nimid 1.86 0.003 28 
Cu(I)(TRIW-HL19A)3+, pH 7.4 3 Nimid 1.91 0.010 This work 
Cu(I)(TRIW-H)3+, pH 5.9 3 Nimid 1.93 0.009 29 
Reduced psAO 3 Nimid 1.94 0.006 30 
Reduced PHMcc 
(pH 7.5) 
2.5 Nimid 1.92 0.017 
31 
0.5 SMet 2.24 0.012 
(Met2Im)3Cu(I) 
2Nimid 1.89 0.01 
28 
1N 2.08 0.003 
The Chemdraw schemes for compound a and b are shown in Scheme IV-1.  
 
Scheme IV-1. (a) Lε; (b) (Met2Im)2Cu(I) 
 Based on this analysis, at pH 5.8, the linear coordination of Cu(I) possibly reflects 
the change of packing patterns in the interior of the helical coiled coils. For example, it is 
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possible that the extra space created by Ala19 can accommodate an imidazolium from 
His23, leaving two imidazoles from the other strands coordinated to Cu(I) (Figure 
IV-34A). It is also reasonable that the linear Cu(I)(imid)2 center shifts to the N-terminus, 
packing into the extra space from Ala19 (Figure IV-34B). I cannot distinguish one model 
versus the other without a crystal structure. Whichever is the case, the results here 
possibly allude to the preference for a linear coordination of Cu(I). As shown in the 
previous chapters, the peptides without the L19A mutation all bind Cu(I) into a trigonal 
planar geometry, which might attribute to the bulky Leu side chains that would not 
accommodate either an imidazolium or a Cu(I)(imid)2 center. Once this layer of Leu is 
removed, Cu(I) readily adopts a linear coordination geometry, as seen in the case of 
TRIW-HL19A.  
 It is worth noticing that at pH 7.4, the Cu-Nimid distance is 0.02 Å shorter than 
those from the previous chapters (1.91 Å for Cu(I)(TRIW-HL19A)3+ versus 1.93 Å for 
peptides presented in the previous chapters), and the Debye-Waller factor is 20~30% 
larger than the previous cases. This could be due to either the incomplete deprotonation 
of imidazolium (a mixture of two- and three-coordinate Cu(I)) or a T-shaped structure. 
XAS data at a higher pH condition can help clarify this.  
 
Figure IV-33. Two possible routes for the transformation from linear Cu(I) to trignoal 
Cu(I).  
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Scheme IV-2 
 
Figure IV-34. Possible packing model of Ala19 (space-filling spheres) directing the 
formation of a linear Cu(I)(imid)2 center. (A) Imidazolium filling in the extra space 
created by Ala19; (B) linear Cu(I)(imid)2 filling the space.  
 The peptide TRIW-MH, involving the introduction of a methyl group on the 
imidazole, is expected to also modify the Cu(I) coordination. Contrary to this 
expectation, both the XANSE and EXAFS data are consistent with a three-coordinate 
Cu(I) center. Notably, in the EXAFS fitting process, if one fixes the coordination number 
to four, the fitting still yields Cu-Nimid distances at around 1.93 Å, which is too short for a 
four-coordinate Cu(I)-N distance (Table IV-9). The Debye-Waller factor of the best fit 
(Table IV-2) is 0.002 Å2 smaller than that of Cu(I)(TRIW-H)3+ at the same pH, indicating 
that the introduction of the methyl group reduces the dynamic motions of the copper 
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center. There are two facets that can contribute to the decreased Debye-Waller factor. 
The incorporation of the methyl group eliminates Nδ from binding to Cu(I) in the case of 
TRIW-MH, whereas in TRIW-H, there are potentially four possible binding modes 
depending on whether it is Nε or Nδ of the imidazole that binds to Cu(I)  (Figure 2-28). 
The sterics of the methyl group may also limit the wobbling motion of the imidazole 
plane along the Cu(I)-Nε axis, creating a less dynamic Cu(I) site.   
Table IV-9. Relevant distances in four-coordinate Cu(I) complexes 
Complex Cu(I)-N distance/ Å 
Geometry 
description 
Ref 
[Cu(Meim)4]+[ClO4]–a 2.054 Tetrahedral 32 
[OP(3-t-
Bupz)3Cu(NCMe)]+[PF6]–b 
2.101, 2.135, 2.089,  
1.910 (Cu-NCMe) 
Pyramidal 33 
[Cu(dbp)(dmp)]+c 2.087, 2.087, 2.052, 2.095 Pseudo-tetrahedral 34 
The Chemdraw schemes of compounds a, b, and c are shown in Scheme IV-3 
 
 
Scheme IV-3 
 TRIW-MHL19A contains both the L19A and the MH mutations, exhibiting 
combined Cu(I) coordination features. The pre-edge peak of Cu(I)(TRIW-MHL19A)3+ is 
in between those of Cu(I)(TRIW-HL19A)3+ and Cu(I)(TRIW-MH)3+, and is more similar 
to that of Cu(I)(TRIW-HL19A)3+, indicating that there might be a mixed two- and three-
coordinate species or a pure species with a T-shaped Cu(I) center. In an effort to solve 
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this ambiguity, in the multi-scattering EXAFS fitting process, I let the coordination 
number of the imidazoles float, with the intention of resolving the best fitted coordination 
number. The best fit yielded a coordination number of 3 (Table IV-2). Considering that 
there is ~25% error in coordination number for EXAFS fittings, the coordination number 
alone cannot distinguish whether this site is a two- or three-coordinate mixture or a three-
coordinate T-shaped pure species. The Cu(I)-Nimid distance of 1.890 Å can also be derived 
from both cases. If this is a pure T-shaped species with Cu-N distances of 1.86, 1.86, and 
1.95 Å, the averaged bond distance is 1.89 Å. If, for example, this is a 50/50 mixture of 
two- and three-coordinate Cu(I), with linear Cu(I)-Nimid distance of 1.86 Å and trigonal 
Cu(I)-Nimid distance of 1.93 Å, the averaged bond distance is 1.90 Å, within the error of 
the fitting parameters. However, if this site is a mixture of two- and three-coordinate 
species, when the pH is increased, the uncoordinated methyl-imidazolium is expected to 
bind Cu(I), with a pKa possibly similar to that of Cu(I)(TRIW-HL19A)3+ for the same 
process. So I examined the EXAFS of Cu(I)(TRIW-MHL19A)3+ at pH 7.4. With the 
coordination number set to float freely, a coordination number and bond distances 
essentially the same as those of pH 5.8 were obtained from a multi-scattering fitting, 
suggesting that it is unlikely that 50% of the Cu(I) center changed from two-coordinate 
two three-coordinate. Based on these analyses, the best description of the Cu(I) 
coordination so far is T-shaped three-coordinate, with Cu(I)-Nimid distances of ~1.86, 
~1.86, and ~ 1.95 Å.  
 At this point, I have analyzed peptides with K22E, L19A, and MH mutations. One 
might have noticed that the L19A mutation tends to drive the formation of linear or T-
shaped (possessing a linear component) Cu(I) centers at pH 5.8. For example, going from 
Cu(I)(TRIW-H)3+ to Cu(I)(TRIW-HL19A)3+, a trigonal to linear coordination change is 
observed; from Cu(I)(TRIW-MH)3+ to Cu(I)(TRIW-MHL19A)3+, there is a change from a 
trigonal to arguably a T-shaped  Cu(I) center; from Cu(I)(TRIW-EH)3+ to Cu(I)(TRIW-
EHL19A)3+, the coordination number also changes from three to two. Both K22E and MH 
mutations tend to maintain the trigonal coordination environment of Cu(I), however, 
when these two features are present together, both XANES and EXAFS indicate a two-
coordinate Cu(I) center in Cu(I)(TRIW-EMH)3+ (Figure IV-6C, Table IV-2). The best 
possible explanation for the coordination environment and H-bonding scheme around the 
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Cu(I) center is shown in Scheme IV-4. It is possible that the formation of an H-bond 
between Glu22 and MHis23 lowers the total energy of this structure, making it a more 
favored coordination than Cu(I)(MHis)3.  
 
Scheme IV-4. Possible coordination environment of Cu(I)(TRIW-EMH)3+ at pH 5.8. 
Residues of the same color are from the same strand.  
Cu(II) coordination.  
 Similar to the effects on the Cu(I) coordination environment, the modifications 
introduced here might change the primary coordination sphere of Cu(II). Spectroscopic 
parameters all point to a typical T2Cu center with slight differences in the coordination 
environment. As compared to Cu(II)(TRIW-H)32+, the d-d bands of the Cu(II)-peptide 
complexes introduced here shift to lower energy, with smaller extinction coefficients. 
Although I do not have crystal structures of any of these complexes, I will use a five-
coordinate Cu(II) center as the basis for my analyses here for these two reasons: 1) in 
copper literature, pentacoordinate Cu(II) complexes are just as abundant as the 
hexacoorindate rhombically elongated stereochemistry; 2) based on my discussion in the 
previous chapters, it is unlikely that the coordination number of these Cu(II) centers is 
less than four, so I will use coordination number five as a starting point.  
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 In general, the geometry of pentacoordinate Cu(II) centers range from trigonal 
bipyramidal (D3h) to square pyramidal (C4v). The conversion between these two forms is 
usually follows a distortion coordinate along the Berry pseudorotation.35 Due to the 
structural plasticity and the variety of donor ligands of Cu(II), researchers have 
experienced significant difficulties trying to establish a structure-spectroscopy 
correlation.36–39 Taking the approach adapted by Addison et al.,40 in a pentacoordinate 
metal center, τ is introduced to measure the degree of square pyramidal versus trigonal 
bipyramidal stereochemistry, which is defined as the (β – α)/60o (angle α and β are 
shown in Scheme IV-5). The closer τ is to zero, the more square pyramidal character the 
metal center possesses; the closer τ is to one, the more trigonal bipyramidal character. 
Again, since I do not have crystal structure of these Cu(II)-peptide complexes, my 
analyses will be qualitatively based on spectroscopic parameters.  
 
 
Scheme IV-5. A pentacoordinate metal center. A is the axial ligand. Angle α = DME, 
β = BMC. When α = β = 180o, this center has square pyramidal geometry. When α = 
120o and β = 180o, BMC becomes the principle axis, so that it adopts trigonal 
bipyramidal geometry.  
 As lower extinction coefficients are observed for Cu(II)(TRIW-HL19A)32+, 
Cu(II)(TRIW-MH)32+, Cu(II)(TRIW-MHL19A)32+, Cu(II)(TRIW-EMH)32+, and 
Cu(II)(TRIW-EHL19A)32+, an inversion center is introduced as a symmetry component. 
A possible scenario of Cu(II) coordination is shown in Table IV-10. Cu(II)(TRIW-H)32+ 
is most likely to be square planar as compared to all the other peptides as it has the largest 
extinction coefficient, so it has the smallest τ value, probably close to zero. Within the 
group of Cu(II)(TRIW-HL19A)32+, Cu(II)(TRIW-MHL19A)32+, and Cu(II)(TRIW-
MHL19A)32+, Cu(II)(TRIW-HL19A)32+ has the most similar spectroscopic parameters as 
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Cu(II)(TRIW-H)32+. A smaller extinction coefficient of Cu(II)(TRIW-HL19A)32+ 
indicates that there is an axial component of another ligand that points to the opposite 
direction from the axial OW (Table IV-10). This is a case where the Cu(II) geometry is in 
between square planar and trigonal bipyramidal (0 < τa < 1). Cu(II)(TRIW-MH)32+ has the 
smallest extinction coefficient and the lowest energy d-d band within these three 
peptides. The significant decrease in extinction coefficient and a slight decrease in d-d 
band energy of Cu(II)(TRIW-MH)32+ as compared to that of Cu(II)(TRIW-H)32+ suggests 
Cu(II)(TRIW-MH)32+ that might have an (elongated) octahedral center. The absorption 
parameters of Cu(II)(TRIW-MHL19A)32+ lie in between the above-described two cases in 
both the absorption wavelength and extinction coefficient, which indicates that the Cu(II) 
geometry is probably between these two cases. The coordination in Table IV-10 shows 
one possibility: Cu(II) adopts a geometry close to trigonal bipyramidal so that the 
integration is small when one applies the dipole transition operator on the d-orbitals, 
although this effect is not as pronounced as the case of an octahedral Cu(II). Using 
similar analogies, the possible Cu(II) coordinations for Cu(II)(TRIW-EHL19A)32+ and 
Cu(II)(TRIW-EMH)32+ are provided in Table IV-10. The EPR parameters of selected 
Cu(II)-peptide complexes further indicate that the they have a dx2−y2  ground state, 
consistent with the geometric assignments here.  
 The pH titrations of these Cu(II)-peptide complexes show different deprotonation 
equilibria, only some of which have pKa values that can be defined. Considering the Jahn-
Teller effect of Cu(II) centers, one would expect that the equatorial water oxygens (OW) 
to have more orbital overlap than the axial OW, so the equatorially coordinated water 
would have a lower pKa than the axial water. After inspecting the pKa values (Table 
IV-10), one realizes that the pKa difference between Cu(II)(TRIW-HL19A)32+ and 
Cu(II)(TRIW-MH)32+ (first deprotonation equilibrium) is 1.5 pH unit. The difference in 
pKa values might derive from the position of the coordinated water that is deprotonated. 
In the case of Cu(II)(TRIW-HL19A)32+, it is possible that the deprotonation occurs at the 
axial water with a larger pKa while in Cu(II)(TRIW-MH)32+, an equatorial water might be 
deprotonated when the pH is increased. A spectral conversion at a higher pH region is 
observed for Cu(II)(TRIW-MH)32+, which might correspond to the combined effects of 
axial water deprotonation and Lys side chain deprotonation. One might wonder about the 
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equatorial water in Cu(II)(TRIW-HL19A)32+. My current best explanation is that the 
equatorial water might have already been deprotonated along with Cu(II) binding. If one 
were to fit the titration points below pH 6 for Cu(II)(TRIW-HL19A)32+, a pKa of 4.47 (n = 
1.57) is observed. This pKa might correspond to combined effects of Cu(II) binding to 
3SCC and equatorial water deprotonation because it is larger than the previously 
observed pKa for Cu(II) binding (~3.8). The other peptides involved in this study do not 
yield well-defined deprotonation equilibria, possibly because the energies of the two 
coordinated water molecules are very similar or the involvement of carboxylic acid 
deprotonation, which might occur for the peptides containing K22E mutation.   
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NO2- binding.  
 EPR is used to monitor NO2- binding to Cu(II)-peptide complexes. No spectral 
change was observed for Cu(II)(TRIW-HL19A)32+ or Cu(II)(TRIW-MHL19A)32+, which 
means either nitrite does not bind to these two peptides or the binding cannot be detected 
by EPR spectroscopy. I favor the latter but cannot rule out the former possibility. The 
introduction of L19A mutation is likely to induce easier access of the substrate, if it 
changes the substrate binding at all. The fact that no spectral change is observed possibly 
means that the symmetry of the site does not vary upon NO2- binding. In particular, the 
O-Cu-O (Scheme IV-6) angle might or might not change depending on the peptides and 
the geometry of the Cu(II) center prior to NO2- binding. One can infer that the orbital 
overlap between the oxygen p-orbitals and copper d-orbitals changes upon the variation 
of this angle (Scheme IV-6).  
 
Scheme IV-6. A possible scheme to explain the EPR spectral evolution upon NO2- 
binding. For TRIW-H and TRIW-MH, upon binding to NO2-, the O-Cu-O angle varies, 
leading to the change of symmetry, thus the EPR spectra change. It is possible that due to 
the altered packing around the copper center, the O-Cu-O angle in TRIW-HL19A does 
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not vary much, so that EPR spectroscopy cannot detect the binding. TRIW-MHL19A 
might be similar to TRIW-HL19A in this regard.  
Azide binding.  
 Azide is widely used as a structural and mechanistic probe for copper enzymes 
and synthetic copper complexes.41–47 Due to the potential for a Jahn-Teller distortion, 
there are potentially two different binding sites for azide: equatorial and axial, although 
that some of the Cu(II) centers in this study might not have a strictly defined equatorial 
plane. Usually, the equatorial coordination of azide anion to a Cu(II) center results in a 
LMCT with moderate intensity and a blue-shifted d-d band, and the axially coordinated 
azide-Cu(II) adduct has a LMCT with reduced intensity and red-shifted d-d band.44 
Casella and coworkers have investigated azide binding to a series of Cu(II) complexes 
with tridentate ligands (N2O to N3 donor set). They observed that when the equatorial 
donors are dinegatively charged, azide prefers to bind at the axial position; while it binds 
at the equatorial position when the donors are neutral or mononegatively charged.44 Of 
course, the spectroscopic features of Cu(II)-azide adducts are markedly influenced by the 
nature of other coordinating ligands and the special arrangements of the ligands, so the 
trend cannot be generalized in all the cases.   
 For Cu(II)(TRIW-MH)32+, the binding of azide leads to a d-d band with increased 
intensity, but the position of the peak remains the same, which suggests that azide weakly 
interacts with the Cu(II) center, most likely by binding at the axial position. A relatively 
large dissociation constant is consistent with this assignment. The relatively large 
extinction coefficient for LMCT indicates the significant orbital overlap between the 
Πnb(π), Πnb(σ) from azide with dx2−y2  of Cu(II).46 In contrast, two binding events are 
observed for both Cu(II)(TRIW-HL19A)32+ and Cu(II)(TRIW-MHL19A)32+. Take 
Cu(II)(TRIW-HL19A)32+ as an example, the second equivalent of azide seems to be 
competitive with the first equivalent, which might be due to the formation of a neutral 
complex after binding to two azide anions. The first equilibrium involves 1:1 binding of 
azide to Cu(II), which occurs at the axial position (less intense LMCT band and red-
shifted d-d band) with weaker affinity. The second equivalent of azide binds almost 
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simultaneously at a position that is not strictly axial or equatorial. Both N3– interact with 
the dx2−y2  orbital of Cu(II),  resulting in an increased intensity of LMCT.  
NiR activity.  
 The NiR rates of peptides with modifications inside the helical coiled coils are 
compared to those presented in the previous chapters (Figure IV-26). A few general 
trends are observed: 1) L19A mutation introduces rate enhancements. Three groups of 
peptides [(TRIW-H, TRIW-HL19A), (TRIW-EH, TRIW-EHL19A), and (TRIW-MH, 
TRIW-MHL19A)] all have higher rates for those with L19A mutation than those without; 
2) MH helps increase the rates, which is seen by comparing the rates of TRIW-H with 
TRIW-MH, TRIW-EH with TRIW-EMH, and TRWI-HL19A with TRIW-MHL19A; 3) 
K22E mutation tends to decrease the rates, possibly through the interference of the proton 
transfer process by Glu22.  
 Based on the previous discussions on the possible mechanism (Chapter II), the 
reaction is likely to be initiated at the Cu(I) state, which is different from native 
NiRs.10,12,48 The rate enhancement described for the peptides involved in this chapter is 
likely related to the change of the binding modes of Cu(I)-NO2– adduct. Nearly all of the 
reported Cu(I)-NO2– complexes are N-ligation nitrites (η1-N mode),49–55 indicating that 
this form has a relatively low energy. In some of the synthetic complexes, Cu(I)-η1-N and 
Cu(I)-η1—O linkage isomers are observed in the same crystal structure, consistent with 
the DFT calculation results, which suggest that the energies of these two isomers are 
similar, although the η1–N linkage seems to be slightly more favorable.54 In my case, 
possible different binding modes of NO2– to Cu(I) can explain the enhanced reactivity for 
the mutants discussed in this chapter.  
 At the beginning of the reaction, since the Cu(II)-peptide complex is incubated 
with NO2–, under the conditions that I carried out the assay, almost all the Cu(II) is bound 
to NO2–. When NaAsc is injected to initiate the reaction, the first equivalent of NaAsc 
directly reduces Cu(II)(NO2–)(3SCC)+ complex into Cu(I)(NO2–)(3SCC), followed by 
inner-sphere electron transfer between Cu(I) and NO2–. With the dissociation of nitric 
oxide aided by a proton, the copper-peptide complex goes back to the 
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Cu(II)(3SCC)(OH2)x state (Scheme IV-7, route 1). This sequence of substrate-binding, 
electron transfer is similar to one of the proposed mechanisms for the native T2Cu center 
in CuNiR and is thought to be a fast process.56 After the first equivalent of NaAsc is 
consumed, the peptide goes back to the cupric form. As there is excess NaAsc in the 
system and electron transfer step is fast, the reduction of Cu(II)-peptide occurs before the 
binding of NO2– to Cu(II), producing the corresponding cuprous form. For different 
peptides, depending on the coordination environment of Cu(I), they might go through 
different routes, which differentiate the reaction rates. A copper-nitrosyl complex is 
proposed to be an important intermediate in the final stage of nitric oxide production in 
native CuNiR.11,48,57,58 The fate of these Cu(I)-NO2– adducts is the formation of the 
corresponding copper-nitrosyl complexes, thus the binding modes of NO2– and the 
energetics of the adducts are important determinants for the reaction rates.  
 
Scheme IV-7 
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 For peptides that have three-coordinate Cu(I) centers, the reaction may follow 
route 2 (Scheme IV-7), with NO2– then coordinating to Cu(I), forming η1-N, η1-O, or η2-
N, O adduct, which might go through different processes to yield the product. Again, 
based on synthetic small molecule models, the η1-N mode adduct is the most stable,52,55,58–
60 however, the possibility of η1-O binding mode should not be eliminated since it has a 
similar energy based on DFT calculations. The bidendate η2-N, O adduct, in the presence 
of protons, is higher in energy than the monodendate adduct, and the energy gap between 
the η2-N, O adduct and the copper-nitrosyl complex is smaller than that between the 
monodendate Cu(I)-NO2– adduct and the copper-nitrosyl complex.55 For those peptides 
with MH mutation that have trigonal Cu(I) coordination, it is possible that a bidentate η2-
N, O binding mode is adopted by NO2–. This assignment is consistent with the fact that 
the rate of the nitrite reduction catalyzed by MH-containing mutants is not as high as that 
of native CuNiR (not in a η2-O, O mode), but much higher than those without MH 
(monodendate binding mode).  
 On the other hand, for peptides with linear Cu(I) coordination (or T-shaped with a 
weakly coordinating imidazole), NO2– may also bind in a bidentate η2-O, O mode, 
forming a four-coordinate Cu(I)(Nimid)2(η2-O, O) center, which then follows route 3 
(Scheme IV-7). A larger KM is observed for TRIW-HL19A (Table IV-7), suggesting that 
the increase in coordination number upon NO2– binding might not be preferred by this 
Cu(I) center, which leads to elevated energy of the Cu(I)-NO2– adduct. Since the resulting 
adduct is still a four-coordinate Cu(I) complex, it is expected to have similar energy as 
the other four-coordinate adducts (Scheme IV-8). The unbound imidazolium at pH 5.8 
might also contribute to the rate enhancement in the case of TRIW-HL19A. The 
protonation of nitrite when bound to the copper center is important for the elongation of 
the HO-NO bond, therefore efficient proton transfer to the active site is a crucial factor to 
maintain the high activity of nitrite reduction.10,58,61 The imidazolium in TRIW-HL19A 
can serve as a general acid catalyst, assisting the protonation of the Cu(I)-NO2– adduct, 
thus increasing the nitrite reduction rate. For TRIW-MHL19A, since Cu(I) forms a T-
shaped coordination, the effect of general acid catalysis from imidazolium is not 
available. As a result, the effect of rate enhancement cannot simply be added. The Cu(I)-
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NO2– adduct might be more energetically favorable than that of TRIW-MH, possibly more 
similar to the η2-O, O form due to the extra space created by the L19A substitution.  
 
Scheme IV-8. A relative energy diagram of the possible Cu(I)-NO2– adduct in relation to 
the copper-nitrosyl complex.  
 The rate for TRIW-EMH is ~2-fold lower than that of TRIW-MH, and the rate for 
TRIW-EHL19A is ~5-fold lower than that of TRIW-HL19A. This is tentatively attributed 
to the interference of the proton transfer process by Glu22. At pH 5.8, for peptides with 
K22E mutation, due to the existence of multiple Glu residues, the pKa for the carboxylic 
acid spans a wide range (Figure 3-21). The glutamate might compete with the Cu(I)-NO2– 
adduct for protons, leading to lower rates. For TRIW-EMH, one of the imidazoles 
possibly forms an H-bond with Glu22 (Scheme IV-4), however, the other two Glu22 can 
still interfere the protonation of NO2–. As a result, the rate of TRIW-EMH is lower than 
that without Glu22. In the case of TRIW-EHL19A, it is possible that since Cu(I) adopts a 
linear coordination, the way that the imidazole plane orients makes it difficult to form an 
H-bond with Glu22, thus glutamates compete with NO2– for protons. This effect is not as 
evident in the case of TRIW-EH and TRIW-H possibly because Glu22 forms an H-bond 
with the imidazole δN (Chapter III), which elevated the pKa of of the carboxylic acid to ~ 
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6.5, so most of the Glu22 is in its protonated form. Granted that this is the pKa for the 
cupric form, one can still expect a similar influence on the cuprous form.  
 It has been demonstrated that in native NiR, the reaction goes through a step-wise 
mechanism.10,48,56 The timing of substrate-binding and electron transfer is crucial for this 
reaction to occur efficiently. The order of these two steps has originated two different 
proposed reaction pathways: Suzuki/Hasnain mechanism11,48,62 and Averill 
mechanism57,63. The energetics of different reaction intermediates might lead to distinct 
pathways. A recent study using protein film voltammetry revealed that the three-
coordinate Cu(I) is an inactive reduced state in native CuNiR, the reactivation of which is 
still possible.64 As analyzed above, the major portion of the reaction (other than the first 
equivalent) in my system goes through the less-active Cu(I) state as the starting point, 
which might explain why this system has rates that are much lower than the native T2Cu 
center. The protein design strategies described here change the Cu(I) coordination or 
possibly the Cu(I)-NO2– adduct to influence the reaction rates, which has proved to be 
successful. Another approach can be taken by properly timing the influx of electrons to 
make sure that the reaction always starts with the substrate-bound cupric form. This will 
be discussed in Chapter 4.  
 Compared to the best model CuNiR in the literature, the copper-peptide model 
has a comparable catalytic efficiency (Table IV-11). The higher efficiency of the 
synthetic small molecule mainly originates from a relatively low KM, which could be 
explained by the heterogeneous catalytic nature of this system that leads to easy access of 
substrate. It was estimated that if the same reaction were to be carried out in a 
homogeneous solution, the efficiency would decrease by three orders of magnitude,65 
much lower than my model. The current methods for setting up the reaction yield 
catalytic efficiencies that are six-orders of magnitude smaller than that of the native 
CuNiR (Table IV-11). The discrepancy of the catalytic efficiency reflects the importance 
of the sequence of Cu(II) reduction and substrate binding in this particular system, and 
the crucial role of the proton-electron transfer chain around the T2Cu center. Laser flash-
photolysis experiments have been employed to investigate the efficacy of several residues 
around a native T2Cu center in CuNiR in the proton-coupled electron transfer (PCET) 
process.66 It was demonstrated that Asn90 route is the main proton delivery channel for 
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AxNiR, but even if this channel is disrupted, there are other possible routes for proton 
delivery.66 This is one of the most profound benefits of possessing an extended H-
bonding network in native metalloenzymes, which has not been assimilated in de novo 
designed system quite yet.  
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Conclusion 
 I have presented in this chapter a series of peptides with modifications on the 
interior of the helical coiled coils. Parallel to the designs described in Chapter 3, the 
approach taken here is focused on altering the packing of the hydrophobic residues and 
the putative H-bonding schemes, in order to achieve higher NiR activity. Two mutations, 
L19A and L23MH, have been described, along with the K22E mutation introduced in 
Chapter III, lead to the third generation of CuNiR models. Although the modifications are 
carried out on the second coordination sphere, the alteration on the first coordination 
sphere of the copper centers is observed, especially for peptides with the L19A mutation, 
which tend to bind Cu(I) into a linear coordination at pH 5.8. Additional insight into the 
coordination environment of both oxidation levels is obtained by small molecule binding 
studies monitored by FTIR, EPR, or UV-Vis spectroscopies.  
 Based on the previous analysis of the possible reaction routes, one realizes that 
the cuprous state is likely the starting point of the catalytic reaction. This generation of 
models exhibits NiR rates up to ~1300-fold better than TRIW-H, which is tentatively 
explained by the alternative binding modes of NO2– to Cu(I)-3SCC, forming 
intermediates that are energetically more accessible to facilitate the intramolecular 
electron transfer. The higher rates allow me to carry out Michaelis-Menten kinetic studies 
for these peptides. They are by far the best CuNiR models in homogeneous aqueous 
conditions with high enzyme stability. Overall, this work suggests that modifying the 
interior of the helical coiled coils is an effective design strategy to achieve a better 
CuNiR model. Future work will focus on the timing of electron flux and substrate 
binding, as well as building a H-bonding network to facilitate PCET.   
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Chapter V . X-ray absorption spectroscopy and its applications 
on de novo designed metallopeptides  
An overview of X-ray absorption spectroscopy 
 X-ray absorption spectroscopy (XAS) has become one of the most important tools 
to understand the structural details of metal centers in metalloproteins. In the X-ray 
absorption process, a core electron is ejected to an outer empty orbital or the continuum, 
absorbing certain energy of X-ray radiation. Although this phenomenon has been known 
since the 1920s,1,2 the interest in X-ray absorption reoccurred in the 1970s when the 
Stanford Positron Electron Accelerating Ring (SPEAR) was first employed as a 
synchrotron radiation source. Unlike X-ray crystallography, which requires a well-
defined periodic structure of the sample, this technique can be used to study non-
crystalline materials thus making it very convenient to investigate the metal coordination 
environment in diluted protein samples. In addition, XAS techniques are element 
specific, which is especially important for the study of heterometallic systems. The two 
most commonly used spectroscopic techniques are X-ray absorption near-edge structure 
(XANES) and extended X-ray absorption fine structure (EXAFS), both of which are 
based on the scattering of the X-ray photoelectrons by the surrounding atoms.3 In my 
previous data chapters, I used XAS techniques to determine the Cu(I) coordination 
environment in an NiR model. I present herein a brief overview of this technique and my 
data fitting procedures for future reference. Two other de novo designed systems using 
XAS for structural assignment will also be presented.  
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Figure V-1. Experimental setup for XAS 
 An X-ray beam goes through a monochromator and three ionization chambers 
(Figure V-1). The reference sample and experimental sample are placed in between I1 and 
I2, I0 and I1, respectively. Data are collected as fluorescence exciation spectra and 
transformed to desired formats depending on the specific technique. An electron can be 
ejected from an atom by X-ray. The mathematical description of X-ray absorption 
process is discussed in an exhaustive review by de Groot.4 When core electrons are 
ejected, there is an abrupt increase in the absorption, which is called an absorption 
“edge”. The nomenclature of the X-ray absorption derives from its core orbital. The most 
common XAS experiments focus on the K-edge of the sample, which refers to the 
excitation of an electron from the innermost s orbital. For first row transition metals, the 
K-edge energy is in the hard X-ray region (5 – 10 keV, or ca. 2 – 1 Å).3  
 XANES refers to the range of the X-ray absorption spectrum within about 30 eV 
of the energy threshold where scattering is very strong and inelastic losses are relatively 
weak.5 The edge structure provides information on the geometry and oxidation state of 
the metal center. Recent advancement in the theoretical aspects and quantitative 
interpretation of XANES is reviewed by Rehr et al.5 In this dissertation, I use XANES to 
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investigate the geometry and coordination number of spectroscopically silent metal such 
as Zn(II) and Cu(I).  
 For X-ray energy beyond the initial ~30 – 50 eV threshold, the photoelectron 
kinetic energy increases as described in Equation V-1 
E = Eo + Ek = Eo + 1/2mev2,  
Equation V-1 
The wavelength of the ejected photoelectron can be expressed as Equation V-2.  
λ =
h
mev
=
h
2me(E −Eo ) ,  
Equation V-2  
 The energy is converted into k space (photoelectron wave-vector), which refers to 
the inverse photoelectron wavelength described in Equation V-3.   
k = 2π
λ
=
2π 2me(E −Eo )
h =
2me(E −Eo )
 ,  
Equation V-3  
 The ejected electron interacts with the neighboring atoms (back-scatterers), 
creating backscattered waves, which interfere with the original electrons, creating 
oscillating patterns. EXAFS is defined as the oscillatory part of the absorption 
coefficient, which is described by the difference between the observed absorption 
coefficient and the free-atom absorption coefficient, normalized to the free-atom 
absorption coefficient, as shown in Equation V-4.   
χ (k) = µ(k)−µ0 (k)
µ0 (k) ,  
Equation V-4. 
 Quantitatively, between a single absorber-backscatterer, EXAFS can be written as 
Equation V-5, where Ns stands for the number of scattering atoms; As(k) stands for the 
contribution of this specific interaction to the amplitude; Ras is the distance between the 
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absorber and the backscatterer; σas2 is the mean-square disorder of the distance between 
the absorber and the backscatterer, usually referred to as the Debye-Waller factor, which 
accounts for disorder, both thermal and structural, of the relevant scattering paths;6   
ϕas(k) is the phase component.  
χ i (k) =
NsAs (k)
Ras2
exp(−2k2σ as2 )sin(2kRas +φas (k))
,  
Equation V-5 
For systems with multiple components of backscatterers, the total EXAFS is the sum of 
all these components, as shown in Equation V-6.  
χ (k) = χ i (k)i=1
n
∑ ,  
Equation V-6. 
Single scattering and multiple scattering fitting procedures.  
 The XAS data are collected on line 7-3 at Stanford National Accelerator 
Laboratory (SLAC). The program for data collection was written by Martin J. George at 
SSRL and the user manual can be downloaded at http://ssrl.slac.stanford.edu/~xas/xas-
man.html. The same file can also be found in the Pecoraro group D-drive under “XAS 
documents” folder. The raw XAS data are viewed, calibrated, averaged, baseline 
subtracted, and normalized using the EXAFSPAK program suite, which can be 
downloaded at http://www-ssrl.slac.stanford.edu/exafspak.html with a user manual. 
Scheme V-1 shows the general procedure for the EXAFS data fitting process. The steps 
for single scattering fitting are described in details in the EXAFSPAK manual, so I will 
omit the description here and focus on multiple scattering fitting.  
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Scheme V-1. EXAFS data fitting process. Blue blocks represent files; gray blocks 
represent the commands. 
 For metal centers with ligands such as imidazoles, significant Fourier transform 
peaks from the outer shells are observed, which is attributed to the multiple scattering 
processes occurring within the atoms from the imidazole ring and the metal center. 
Multiple scattering effects are sensitive to the geometry of the ligands. Atoms closer to a 
180o angle with respect to the axis created by the metal center and the primary scatterer 
have greater contributions to the scattering amplitude. To map out the multiple scattering 
paths, a model has to be built based on the known crystal structures of similar 
coordination environments. For example, based on XANES and single scattering fitting, 
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Cu(I)(TRIW-H)3+ has a coordination number of 3 (maybe 4), so I searched for three- or 
four-coordinate Cu(I) centers with imidazoles as ligands, averaged the bond distances and 
angles,  and built a model of Cu-imidazole into Cartesian coordinates (Figure V-2).  
 
Figure V-2. The Cu-imid model. Red spheres represent atoms.  
 The coordinates of relevant atoms are then written into a text file, which is named 
as “*.inp”. This *.inp file is used as an input file for ATOMS, a program for generating a 
list of atomic coordinates from crystallographic data. The primary use of ATOMS is to 
create input files suitable for running the ab initio program FEFF. An online version of 
ATOMS can be found at http://cars9.uchicago.edu/cgi-bin/atoms/atoms.cgi. There is a 
copy of ATOMS on the Pecoraro lab computer. For installation on personal computers, 
the relevant files can be downloaded at http://cars9.uchicago.edu/ifeffit/Downloads. The 
file that ATOMS creates is named feff.inp by the program.  
 The phase and amplitude calculation for multiple scattering fitting is carried out 
on a remote server (brd-ts2.adsroot.itcs.umich.edu). A remote desktop app can be used to 
access this server. For this calculation, one needs the feff.inp file that is generated by 
ATOMS. Once this file is downloaded onto the remote server, one can find the JFEFF 
program on the desktop, and load the feff.inp file into the program for calculations. It is 
worth mentioning that for different versions of ATOMS and JFEFF, the coding might not 
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necessarily be the same. So there might be errors in the assignment of potentials for 
different atoms. One needs to double-check the potential surface as well as the 
coordination by clicking the “Edit” tab in the JFEFF program. In addition, one can 
monitor what specific files to generate after the calculation by changing the numbers 
under “print level”. The manual of the GUI version of JFEFF is under the same folder on 
the Pecoraro lab computer. 
 After the JFEFF calculation, one should see a group of files including paths, chi, 
as well as specific path files (feff0001, 0002, etc.) under the same folder as the initial 
feff.inp file. These files can then be used to carry out multiple scattering fitting. The 
JFEFF calculation is the only step that requires the biophysics server. After this step, one 
can copy these files into a local folder, and continue the multiple scattering fitting from a 
personal computer or the lab computer. It is essential that all the files generated from 
JFEFF and the data file (*.ave) are in the same folder before any further pursuit. Under 
Command Prompt (or terminal), type “feff_hld825 *.ave”, where “*.ave” is the averaged, 
processed EXAFS data file to fit. This operation will generate a file called “paths.hld” 
under the same directory as all the other files. Now a command needs to be executed to 
change the name of this “paths.hld” file into “*.hld”, where the * should be the same as 
that in “*.ave” to ensure that the program can correctly extract the right .hld file. After all 
these files are taken care of, one can type “opt *.ave” to carry out multiple scattering 
fitting. The operations under the opt program are similar to those for single scattering 
fitting. I have written a multiple scattering fitting protocol, which is in the “XAS 
documents” folder on the Pecoraro lab computer.   
De novo designed copper-peptides as a model for a key intermediate in copper 
transfer by metallochaperones 
 Copper is an important trace metal that is indispensible for essentially all aerobic 
organisms. The hallmark of copper reactivity in biological systems are its redox 
properties, which leads to a variety of copper proteins that catalyze oxidoreductase 
reactions or carry out electron transfer.7–17 These reactions are critical for many cellular 
functions; however, copper is a potential toxin if not regulated properly. Free copper ions 
carry out Fenton-type reactions that produce deleterious reactive oxygen species, which 
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can cause lipid, nucleic acid, and protein damage.18,19 These effects demand a tight 
homeostatic regulation of copper acquisition, distribution and use. For example, the most 
common copper deficiency disorders in humans are Menkes and Wilson diseases, which 
are related to defects of human P1B-type ATPase ATP7A and ATP7B, respectively.20–25 
The uptake and transport of copper ions involve cell surface transporters (Ctr1)26 and 
copper chaperones. Three pathways with three distinct metallochaperones have been 
proposed to deliver copper to the mitochondria (Cox17 pathway), the Golgi (Atx1 
pathway), and the cytosolic superoxide dismutase (CCS pathway).27–30 The Cu(I) binding 
sites of these metallochaperones are generally cysteine rich with a highly conserved 
CXXC motif. Intracellular copper trafficking is achieved through ligand exchange of 
these metallochaperones with their delivery target via thermodynamic and kinetic control. 
The mechanistic details of transfer, however, are not completely understood on the 
molecular level. Over the years, two- and three-coordinate copper-thiol/thiolate species 
have been proposed to be key intermediates,29–32 but the protonation states of the 
coordinating cysteine residues have not been elucidated experimentally.  
 De novo protein design has been utilized to understand the interactions between 
metal ions and proteins.33–38 The Pecoraro group has demonstrated the design of thiolate 
environments amenable for Hg(II), Pb(II), Cd(II), and As(III) binding to address heavy 
metal selectivity, specificity, and coordination preferences in a protein environment.39–53 
Cu(I)-thiol/thiolate interactions under physiologically relevant pH conditions in a 
peptidic environment are investigated here. A thiol-rich site is embedded in a de novo 
designed scaffold TRIW-C (sequence: Ac-G WKALEEK LKALEEK CKALEEK 
LKALEEK G-NH2). Cu(I) is then introduced to study its coordination preference in a 
thiol-rich environment. The resulting Cu(I)SxOy (x, y ≥ 0) center serves as a model for the 
intermediates in the copper transfer process, providing key insight into the delivery 
mechanism. XAS data were collected at pH 6.5, 7.5, and 9.0 for Cu(I)(TRIW-C)3x (x = –1 
or –2 depending on the protonation state of the Cys). Sample preparation and data 
collection were carried out according to the previously described procedures.  
 A relatively intense pre-edge peak is observed for the XANES at all three pH 
conditions (Figure V-3). Subtle variations in the edge structure are observed: the ratio of 
the normalized intensity of the pre-edge peak and edge peak increases as the pH is raised 
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from 6.5 to 9.0. One should use caution when interpreting this set of XANES data based 
on the previous experience for the Cu(I)-Nimid coordination environment. Since the pre-
edge of Cu(I) corresponds to a 1s ! 4p transition, the intensity of this peak is influenced 
by the geometry (orbital degeneracy) and the nature of the ligand (energy level). Due to 
different ligand field created by Nimid and SCys, the relative ratio of the pre-edge/edge 
intensity to determine the coordination number of Cu(I)(Nimid)x does not apply to the 
Cu(SCys)y environment. Compared to reported CuSx centers (Table V-1), the Ia/Ib ratio of 
Cu(I)(TRIW-C)3x falls in between those of the linear and trigonal Cu(I) centers. This, 
however, does not exclude the possibility of Cu(I) binding to other coordinating atoms 
such as an oxygen from solvent water.  
 
 
Figure V-3. XANES of Cu(I)(TRIW-C)3x at pH 6.5 (black line), pH 7.5 (red line), and pH 
9.0 (blue line). Insert: detail of the edge. The dashed lines indicate the positions of the 
pre-edge and edge peaks.  
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Table V-1. Ratio of pre-edge/edge intensity for Cu(I) XANES 
Complex Ia/Ib Comments Ref 
Cu(I)(TRIW-C)3x 0.8–0.9 Ia/Ib increases slightly as the pH goes up This work 
[Cu(SC10H12)2]2– ~1.1 Digonally coordinated by two sulfurs 54 
[Cu4(SPh)6]2– 0.5–0.6 Trigonally coordinated cuprous cluster 
Cu-CueR ~1.1 Digonal coordination 55 
Cu-HAH1 ~1.1 Linear CuS2 center 56 
[Cu(SC6H5)3]2– ~0.7 Trigonal Cu(I)S3 30 
Cu-CopZ ~0.7 Three coordinate 57 
Ia, Ib represent the normalized intensity of the pre-edge and edge peaks, respectively 
 
 EXAFS data were collected for all three pH conditions and Fourier transformation 
was carried out. A transition is observed when the pH is raised from 6.5 to 9.0. Two 
major peaks are observed for pH 6.5 and 7.5 samples; at pH 9.0, a shoulder at R + α ~2.3 
Å is observed (Figure V-4). Plotting the ratio of the intensities corresponding to the two 
major peaks, one sees an increasing trend as the pH increases. This, together with 
XANES data, suggests a transition between two species that is correlated with pH 
change. At pH 7.5, it is highly likely that the sample contains a mixture of two species. 
Since EXAFS can only provide information of an “averaged” coordination, fitting 
EXAFS data at pH 6.5 and 9.0 is more likely to yield useful metric parameters.  
 Table V-2 and Figure V-5 show the current best fits. At pH 6.5, the fitting model 
suggests that Cu(I) is coordinated to sulfur at two short distances [R(Cu-S) = 2.24 Å], one 
sulfur at a longer distance [R(Cu-S) = 2.45 Å], and a low Z scatter such as an oxygen or 
nitrogen atom [R(Cu-O) = 1.96 Å]. During the fitting process, the Debye-Waller factor of 
Cu-O/N and long Cu-S components have to be fixed, otherwise the simulation generates 
unphysical parameters. As shown in Figure V-5B, the component at R + a ~2.3 Å is not 
well-simulated. At pH 9.0, the current best model is a Cu(I) center that coordinates to 
three sulfurs at short distances (consistent with thiolates) and an oxygen, however, the 
comparison between this model and copper centers in a similar coordination environment 
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(Table V-3) reveals that the Cu-S distance of 2.13 Å is too short for such a copper center. 
All of these observations reflect the inherent inconsistency of the data, possibly due to 
impurity in the samples, which could lead to an incorrect chemical interpretation. At this 
point, before we can reproduce this experiment, further analysis on this set of XAS data 
is unwarranted.  
 
 
 
Figure V-4. Fourier transform of the EXAFS at pH 6.5 (black spectrum), 7.5 (red 
spectrum), and 9.0 (blue spectrum). Insert: Ic/Id in relation to the pH.  
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Table V-2. EXAFS parameters of Cu(I)(TRIW-C)3x.  
pH Component CN R/Å σ2/Å Eo/eV F Nvar F2/(Nfree) × 10-2 
6.5 
Cu-O 1 1.96 0.0010 
-10 69 4 4.0 Cu-S 2 2.24 0.0032 
Cu-S 1 2.45 0.0010 
9.0 
Cu-O 1 2.08 0.0010 
-10 157 3 19 
Cu-S 3 2.13 0.0051 1. CN:!coordination!number;!R:!distance;!σ2:!Debye9Waller!factor;!2. Variable!parameters!in!red;!!3. Assuming!Nidp!=!2ΔkΔR/π!~!16!and!Nfree!=!Nidp!9!Nvar;!4. The!goodness!of!the!fit! is!evaluated!by!F’!=!F2/(Nfree)!×!1092.!The!smaller!the!value,!the!better!the!fit.!!
 
 
Figure V-5. EXAFS and Fourier transforms of Cu(I)(TRIW-C)3x at (A)(B) pH 6.5; (C)(D) 
pH 9.0. Solid lines: data; dashed lines: fitting.  
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Table V-3. Bond distances in relevant complexes 
Complex R(Cu(I)-S)/Å R(Cu(I)-O)/Å Ref 
[Cu(1, 4-TOX)3OH2]BF4a 
2.291, 2.261, 
2.272 
2.235 60 
[Cu(Vn3S3)(CH3OH)]O3SCF3"MeOHb 
2.299, 2.300, 
2.279 
1.980 61 
[Cu(L1)(OH2)(ClO4)]ClO4"acetonec 
2.344, 2.271, 
2.329 
1.956(OH2), 2.759(ClO4) 62 
[Et4N]2[Cu{S(p-tBuC6H4)}3]d 
2.234, 2.244, 
2.257 
- 63 
The Chemdraw scheme of complexes a, b, c, d are shown in Scheme V-2 
 
 
Scheme V-2 
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 The Cu(I) affinities to TRIW-C were determined using the previously described 
procedures.64,65 As expected, Cu(I) binds to this peptide with a high affinity, with Kd in 
the range of 10-15~10-16 M. The dissociation constants are generally smaller than the 
reported values for Atx1s, HAH1, and MNK1 (Table V-4), which might reflect the strong 
stabilization effect of a linear S-Cu(I)-S coordination. One sees a ~3-fold decrease in Kd 
when the pH increases from 6.5 to 9.0. A similar pH-dependent affinity variation of Cu(I) 
to HAH1 and MNK1 has been reported previously.66 For HAH1 in particular, the 
affinities vary from 1019.3 at pH 10.8 to 1016.8 at pH 6.1. Fitting the change of affinities 
results in a pKa of 8.5, which corresponds to the deprotonation equilibrium of the cysteine 
thiol.66  
 
Table V-4. Cu(I) affinities  
Protein/peptide Kd/M (pH) 
TRIW-C 
a4.80(280) × 10-15  (6.5), 1.31(50) × 10-15 
(7.5), 4.50(12) × 10-17 (9.0) 
Atx1 (Saccharomyces cerevisiae) 4.2–7.1 × 10-19 (8.0)67, 10-16 (6.0)68 
HAH1 (homo sapiens) 1.8 × 10-18 (7.0)66 
MNK1b (homo sapiens) 2.8 × 10-18 (7.0)66 
Wilson protein MBDs 1–6c (homo 
sapiens) 
1.6–4.5 × 10-11 (7.5)69; 2.1 × 10-7–4.8 × 10-6 
(6.5)70 
Ccc2ac (Saccharomyces cerevisiae) 1.4–1.6 × 10-19 (8.0)67 
aThe dissociation constants at pH 6.5 and 7.5 were determined by Catherine S. Mocny.  
bMNK: Menkes protein ATP7A that has six MBDs; MNK1 refers to the first MBD. 
cWilson protein: ATP7B. CCcc2a: the first MBD of Ccc2, a yeast Golgi pump.  
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Figure V-6. BCS2– competitive chelation of Cu(I)(TRIW-C)32– at pH 9.0 (50 mM TAPS 
buffer). (A) titration spectra; [Cu(I)] = 40 μM, [3SCC] = 80 μM, [BCS2–] = 5.00 mM (B) 
maximum absorbance corresponding to Cu(I)(BCS)23– with respect to the total 
concentration of BCS2–. Experimental data are shown in black dots and fitting is shown in 
red line.   
  This study might potentially provide insight into the mechanism for Cu(I) transfer 
from copper chaperones to the corresponding cuproproteins. However, before the 
collection of another set of XAS data, the copper coordination environment cannot be 
described convincingly. The inability to distinguish possible impurities substantiates the 
importance of having a pure species for XAS samples for correct data interpretation.    
XAS to probe the Zn(II) coordination environment in a de novo designed construct 
 The Pecoraro lab has been interested in the hydrolytic chemistry conferred by a de 
novo designed zinc peptide.72,73 This construct represents one of the most advanced CA 
models, with catalytic efficiency only ~100-fold lower than that of CAII. Crystallography 
reveals a four-coordinate zinc center at pH 8.5, with Zn(II) coordinated to three His and 
an oxygen atom from either water or hydroxide.72 The hydroxide species has been 
demonstrated to be the active species in hydrolysis. One would expect a decrease in Zn-O 
distance (≤0.1 Å) when the Zn(II)-bound water is deprotonated into a Zn(II)-bound 
hydroxide, however, the resolution of protein crystallography cannot usually discern such 
a small change in bond distance. The goal of this study was to evaluate whether the use of 
XAS techniques to distinguish zinc-bound water versus zinc-bound hydroxide species at 
different pH would allow such differentiation.  
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 Samples were prepared according to the previously described procedures. The 
XANES of Zn(II)(TRI-H)32+ are shown in Figure V-7. Minimal perturbation is observed 
for the edge structure, indicating the coordination number or geometry of the zinc center 
does not change under these conditions. Based on the kinetic studies, the chemical model 
going from pH 7.5 to 9.5 is that [Zn(II)(His)3(OH2)]2+ deprotonates into 
[Zn(II)(His)3(OH)]+, with no change in coordination number, consistent with the XANES 
data. 
 
Figure V-7. XANES of Zn(II)(TRI-H)3 at pH 7.5, black solid line; pH 8.5, red solid line; 
pH 9.5, blue dashed line.  
 Theoretically, EXAFS would be able to distinguish the change in bond distances 
upon deprotonation as long as the data are collected to a high energy with good quality. 
Unfortunately, there are glitches in the higher energy region. The k region needs to be 
truncated to (1.5, 12.5) Å to yield a decent signal to noise ratio.  Multiple scattering 
fitting was carried out to distinguish the imidazole ring versus oxygen atom scattering 
(Table V-5). At pH 7.5, the best fit yields a 3N1O coordination with bond distances 
slightly shorter than the four-coordinate small molecule zinc complexes (Table V-5, 
Table V-6). At pH 8.5, two fits have the same level of goodness, one with 3N1O 
coordination and the other 2N2O. Since Dr. Melissa Zastrow has obtained a crystal 
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structure at pH 8.5, showing that Zn(II) is coordinated to three His and one oxygen (from 
water or hydroxide) or chloride, the coordination environment corresponding to fit1 
(Table V-5) is more reasonable. At pH 9.5, both 3N1O and 1N3O have a similar level of 
goodness (Table V-5). Again, the 3N1O coordination makes more sense chemically.  
 
Figure V-8. EXAFS (A) and Fourier transform of the EXAFS (B) of Zn(II)(TRI-H)32+ at 
pH 7.5. 
  
Figure V-9. EXAFS (A) and Fourier transform of the EXAFS (B) of Zn(II)(TRI-H)32+ at 
pH 8.5 corresponding to fit1.  
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Figure V-10. EXAFS (A) and Fourier transform of the EXAFS (B) of Zn(II)(TRI-H)32+ at 
pH 9.5 corresponding to fit1. EXAFS (C) and Fourier transform of the EXAFS (D) of 
Zn(II)(TRI-H)32+ at pH 9.5 corresponding to fit2. 
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Table V-6. Bond distances of relevant zinc complexes 
Compounds R(Zn-N)/Å R(Zn-O)/Å Ref 
{[PimPri ,But ]ZnOH}(ClO4)a 2.072, 2.086, 2.087 1.860 (OH) 74 
[L1Zn(OH2)](BNPP)2!6H2Ob 2.035, 2.015, 2.034 1.984 (OH2) 75 
[L1hZn(OH)]ClO4!1.5H2Oc 2.015, 2.016, 2.014 2.046 (OH) 
[(TriMIm)Zn(OH2)](BF4)2d 1.997, 2.000, 2.012 2.129 (OH2) 76 
The Chemdraw schemes of compound a, b, c, d are shown in Scheme V-3 
 
 
Scheme V-3 
 The bond distances based on EXAFS fits do not increase or decrease significantly 
to indicate a deprotonation process; however, this does not exclude the possibility of 
deprotonation. XANES data suggest that there is a change in the zinc coordination upon 
pH change. If R  stays the same, as in our case, the EXAFS resolution needs to be good 
enough so that the fitting should still be able to distinguish the change in bond distances. 
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As shown in Table V-6, the bond distances of Zn-O (water or hydroxide) span a range of 
1.86~2.05 Å, the assignment of water or hydroxide coordination simply based on bond 
distances is difficult. The challenge in interpreting the present data might derive from the 
fact that the pKa value of this water deprotonation is 9.2(1).73 The highest pH in this study 
is 9.5, which, based on the Henderson-Hasselbalch equation, would have ~67% 
hydroxide and ~33% water. Not having enough hydroxide species would lessen the 
change in bond lengths to an extent that might not be observable in this system. This 
could lead to unvaried bond lengths seen in this study. In addition, the pKa of both the 
buffer and peptide might change upon freezing. We used 50 mM CHES buffer for pH 8.5 
and 9.5 samples. At room temperature (25 oC), the pKa of CHES is 9.50. Based on the 
temperature dependence of CHES d(pKa)/dT = –0.011 oC-1,77 the pKa of CHES at 0 oC is 
estimated to be ~9.2. In the frozen state, the conjugate base of CHES is more than 50%, 
which might have an impact on the protonation state of the Zn(II)-bound water. On the 
other hand, how temperature influences the pKa of Zn(II)-bound water is still unknown. 
The uncertainty in the conditions of the solution adds on to the difficulty of data 
interpretation. It is worth noticing that the variation of conditions such as the change in 
buffer pKa upon freezing exists in all the XAS studies, but this is only critical in this case 
as the goal is to investigate the protonation equilibrium.   
 Based on the present data, it is difficult to judge which specific scenario described 
above is more plausible. Future studies involve obtaining a crystal structure at pH 9.5 to 
investigate the active form of this catalyst.  
Conclusion 
 In this chapter, I present the detailed EXAFS data fitting procedure for future 
reference. Using XAS techniques to probe the coordination environment of 
spectroscopically inert metals is prevalent in the study of metalloproteins. I have used 
XAS to investigate the coordination environment of a NiR model in the previous 
chapters. I describe a thiol-rich environment for Cu(I) binding in this chapter, using XAS 
aided by binding studies to understand the coordination preference of Cu(I) at different 
pH conditions. Unfortunately, the EXAFS data cannot be fitted to a reasonable model, 
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suggesting that the sample might contain mixed species. The XAS data need to be 
reproduced before further analysis. 
 XAS has been used to study the coordination environment of a hydrolytic zinc 
center in Zn(II)(TRI-H)32+. This study aims to distinguish the Zn(II)-bound water from 
Zn(II)-bound hydroxide by the bond distances from EXAFS fitting. The Zn(II)-N and 
Zn(II)-O distances remain the same going from pH 7.5 to 9.5, which spans over the pKa 
of 9.0~9.5 obtained by kinetic studies of p-NPA hydrolysis and CO2 hydration.73,78 The 
invariant bond lengths could mean that the hydroxide ratio is not high enough to cause a 
difference or that the conditions (variation of pKa values) may not allow for the effects to 
be observed via XAS techniques.  
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Chapter VI . Conclusions
 De novo protein design is an advanced strategy to create functional protein 
constructs.1–8 Taking a minimalist approach, de novo designed constructs maintain 
sufficient level of complexity while focusing on the core coordination environment of a 
metal center. Significant progress is seen in the past few decades in incorporating a stable 
metal site into a designed construct. The next challenge is to build a functional metal-
binding protein from scratch with minimal coordination factors to convey optimal 
activity. The Pecoraro group has used a highly modular peptide TRI to understand heavy 
metal sequestration and toxicity by binding metal ions to thiol-rich coordination 
environment. Based on a solid understanding of how metal ions interact with these de 
novo designed peptides, we started to focus on transition metal ions and their 
physiological roles.  
 In the context of model chemistry, the 13 well-characterized copper-peptide 
complexes presented in Chapter II, III, and IV of this thesis represent an advanced stage 
of designing structural and functional models of a native metal center. The amphipathic 
nature of helices allows for the co-existence of a hydrophobic core for metal binding and 
a hydrophilic exterior for solvation. The reaction is carried out in homogeneous aqueous 
solutions in a neutral pH region, more physiologically relevant than most of the synthetic 
small molecule models. Taking advantage of a highly modular scaffold, I have utilized 
two novel strategies to develop two more generations of models, which have advanced 
the understanding of the structure-function relationship of a Cu(His)3 center and has 
produced catalysts with higher rates.  
 While the copper center is embedded in an α-helical coiled coil, a scaffold 
completely different from that in native CuNiR, a certain level of structural integrity and 
reactivity is still retained for the Cu(His)3 centers described in this thesis. The 
coordination environment for Cu(I) is the same as that for the reduced form of the T2Cu 
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in native CuNiR,9 whereas Cu(II) in the current scaffold likely has a higher coordination 
number than the native center. Both oxidation levels have relatively high affinities to the 
peptide, which suggests that the α-helical coiled coil environment can accommodate a 
redox-active metal center with appropriate choice of coordinating ligands. The active site 
of CuNiR lies in the interface between two domains,9,10 whereas the copper center 
described in this thesis is situated inside the helical coiled coil. The dissimilarity of 
reactivity between this family of constructs and the T2Cu in CuNiR could be partially 
due to the level of substrate access and the hydrophobicity around the copper center, 
which is an inherent difference between the two protein scaffolds. The first generation 
construct can be viewed as a “reference point” of how much reactivity a Cu(His)3 center 
can confer. As described in Chapter II, although this peptide is capable of multiple 
turnovers, the rate is very limited.  
 Changing the second coordination sphere interactions leads to variation of copper 
binding properties, reduction potentials, deprotonation equilibria, and NiR rates. 
Comparison between the peptides described in Chapter III (second generation) and 
Chapter IV (third generation) suggests that interior modifications are way more effective 
in modulating the catalysis than the modifications of the charged residues at the helical 
interface, although both types of modifications show a similar level of impact on the 
reduction potentials. Specifically, the third generation peptides have a significant increase 
in NiR rates as compared to the previous two generations, reflecting the efficacy of 
interior modifications in tuning the rates. The NiR rates for the second generation models 
with Δcharge from 0 to –12 only vary by 4-fold at pH 5.8, whereas the third generation has 
a rate enhancement of up to 1300-fold. On the other hand, the series of peptides described 
in Chapter III have reduction potentials that span ~200 mV at different pH conditions 
with +400 mV being the lowest reduction potential [Cu(II)/(I)(TRIW-EHK24E)32+/+ at pH 
7.4] and +597(13) the highest [Cu(II)/(I)(TRIW-EHE27K)32+/+ at pH 5.8]; the peptides 
with interior modifications (Chapter IV) have reduction potentials of ~550 mV, which, 
compared to TRIW-H, is ~100–150 mV higher. This indicates that the ~200 mV range 
variation of reduction potentials is probably as much as one can achieve with these two 
types of modifications in the TRI family. All peptides considered, the reduction potentials 
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of Cu(II)/(I)-3SCC do not directly correlate to the NiR rates, so efforts to decrease the 
reduction potential would not necessarily increase the catalytic activity.  
 To enhance the NiR rates, a few factors need to be considered based on the results 
presented in this thesis. Since the major portion of the substrate reduction starts with 
Cu(I)-3SCC, one should focus on altering the cuprous state. When Cu(I) coordination 
number decreases from three (TRIW-H) to two (TRIW-HL19A), a 150-fold increase in 
rate is observed, which seems to suggest that this could be a strategy to create a better 
catalyst; however, TRIW-MH has a 500-fold rate enhancement as compared to TRIW-H, 
but both peptides bind Cu(I) in a (distorted) trigonal geometry. This analysis indicates 
that the Cu(I) coordination number is not the dominant factor for rate enhancement. A 
possible explanation for rate enhancement is the different binding modes of nitrite to 
Cu(I), which might lead to different intermediates. Some of these intermediates might be 
better than others for proton and electron transfer. The current data do not pertain 
information of these intermediates, but it is necessary to investigate these species and 
their relative energies. A two-dimensional potential energy surface based on a synthetic 
small molecule model shows that the electron transfer from Cu(I) to NO2– is energetically 
unfavorable.11 The protonation of the intermediate is a key step to shift the reduction 
potential. The incorporation of a general acid catalyst, for example, the imdiazolium in 
the case of TRIW-HL19A, can enhance the NiR rates by facilitating proton transfer.  
 In addition, the methylation of the imidazole probably plays a role in changing the 
electron density on the copper center, as seen in the modulated reduction potentials of 
TRIW-MH as compared to that of TRIW-H. It is worth mentioning that the methylation of 
the MHis in this work all occurs on the δN of the imidazole. This design is based on the 
crystal structure of Hg(II)SZn(II)N(CSL9PenL23H)3+, which reveals that Zn(II) is 
coordinated to three εN.12 This does not necessarily mean that copper would all bind to 
three εN, although Cu(εNimid)3 might be a preferred scenario. In a case where all the εNs 
are methylated, leaving only δN for copper binding, it would require a significant change 
in the orientation of the His side chains to form an appropriate binding pocket and the 
resulting triangle from the coordinating δNs is going to be larger than that formed by εNs 
(Figure VI-1). Since copper and zinc are similar in size, a larger binding pocket from δNs 
might not be optimal for copper binding.   
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Figure VI-1. Possible Chemdraw schemes of εN coordination (A) versus δN coordination 
(B). 
  Modifications of charged residues at the helical interface do not have a great 
impact on rates, but certain functionalities are still worth considering. For example, as 
compared to peptides with K22X or E27X mutations (X = Q or E), a more evident 
increase in NiR rate is observed for peptides with the K24X mutation (X = Q or E), 
although the side chain of Glu22 is closer to the copper center than that of the residue on 
the 24th position based on the PyMol models. The enhancement in rate is probably due to 
the appropriate distance of the carboxylate (Glu) or the amide group (Gln) on the 24th 
position residue in assisting either the proton transfer to the substrate-enzyme complex or 
the proper positioning of the substrate (a similar effect as the Asp98 in CuNiR13).  
 As introduced in Chapter II, a Cu(His)3 center is highly versatile in native 
metalloproteins, with functions ranging from electron transfer, catalysis, to oxygen 
activation (with the assist of other cofactors).14–31 It is the local environment that fine-
tunes the reduction potentials of these sites to afford their proper functions. The 
understanding of how different factors (electrostatics, H-bonding, salt bridges, etc.) in the 
protein matrix influence the behavior of the metal center is of great importance and is the 
foundation of designing redox-active models. In general, within the TRI family peptide 
models, most of the Cu(I) centers are three-coordinate, except for two scenarios: 1) 
peptides with L19A mutations; 2) when K22E and MH are simultaneous present in one 
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peptide. This might reflect the inherent preference of Cu(I) for a linear coordination. 
When the environment allows, be it extra room above the copper center or the putative H-
bond between Glu22 and MH (Chapter IV), Cu(I) readily adopts a linear Cu(I)(Nimid)2 
coordination. Cu(II)-3SCC is photo-reduced upon exposure to X-ray within 20 min: the 
corresponding reduced state is usually observed at the second scan. As a result, compared 
to Cu(I), the Cu(II) forms are not as well-defined due to the unavailability of XAS 
techniques. Spectroscopic studies indicate that the cupric forms of this family of peptides 
have higher coordination numbers with different geometries depending on the peripheral 
residues. Changing the residues on the second coordination sphere possibly leads to 
variations of geometry or the coordination number for Cu(II) so that the modifications 
have a significant impact on Cu(II) affinities and the reduction potentials calculated based 
on the affinities. So if one wants to create an electron transfer center based on this 
scaffold, changing the coordination environment of Cu(II) is the key to modulate the 
reduction potentials.  
  From the perspective of protein design, the strategies of tuning the coordination 
and the properties of the metal center can potentially inspire a plethora of functional 
protein-based catalysts. The models discussed in this thesis not only address the question 
of how much activity a primary coordination sphere can convey, but also push forward 
the design of extended outer coordination sphere, with the ultimate goal of constructing 
the most critical interactions to achieve the catalytic efficiency of the native T2Cu center.  
 The success of designing generations of structural and functional NiR models 
leads to numerous possibilities for future designs. I can envision two broad directions for 
future projects based on the major portion of this thesis. The first direction aims to 
understand the other possible factors that might influence the affinities, redox properties, 
and reactivity of the copper center, with the ultimate goal of improving the NiR activity. 
For example, since the L19A mutation confers higher rates, one can ask the question of 
whether a L26A mutation (the Leu layer below the copper binding His) would also lead 
to altered copper coordination and higher rates. In Chapter III, I described that the 
mutations toward the C-terminus of the copper-binding site lead to varied properties, 
more so than those toward the N-terminus. For example, if one compares TRIW-H, 
TRIW-HK22Q and TRIW-EH, one realizes that the reduction potentials and NiR rates 
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are similar; on the other hand, the TRIW-EH family peptides with different mutations 
toward the C-terminus exhibit distinct properties. This observation alludes to the 
possibility of water/substrate access from the C-terminus because of fraying. One can 
expect the L26A mutation to accommodate the imidazolium and to alter the 
solvent/substrate access to a higher degree than L19A. In extension, TRIW-MHL26A can 
be prepared, which may lead to a catalytically more favorable η2–N, O or η2–O, O Cu(I)-
NO2– intermediate. At the same time, the general acid catalysis is expected to be retained, 
which assists in proton transfer.  
 The next step is to incorporate some other important residues into this construct. 
For example, an Asp close to the T2Cu center is important in the positioning of nitrite by 
forming an H-bond.32 In addition, an Ile residue creates the steric bulk to alter the 
inhibition profile by small anionic ligands in the native enzyme.32 The limit of the current 
scaffold is that these residues would have to be introduced in copies of three due to the 
self-assembly nature of the 3SCC. Recently, the Pecoraro group has demonstrated the 
design of heterotrimeric peptides.33 With this strategy, one can use one strand containing 
the Asp or Ile functionality, together with the copper-coordinating His, and two strands 
without the extra functional residues but His, to assemble a heterotrimeric coiled coil. For 
example, peptide (GRW-CHL26D)(GRW-ACH)2 can be prepared (sequence of GRW-
CHL26D: Ac-G WKALEEK LKALEEK LKACEEK LKADEEK HKALEEK G-NH2, 
sequence of GRW-ACH: Ac-G WKALEEK LKALEEK AKACEEK LKALEEK 
HKALEEK G-NH2,) to create an Asp(His)3 pocket (Figure VI-2A), where the Asp is 
expect to H-bond to nitrite in the Cu(I)-NO2– adduct, playing a similar role as Asp98 in 
native CuNiR. Obviously, if the above-described L26A mutation results in higher 
enhancement in rates, one can consider placing the Asp below the His. An Ile residue can 
be placed analogously as the Asp, assisting in the positioning of the substrate (Figure 
VI-2B). In addition, the “L19A” mutation can be incorporated in this design to include 
general acid catalysis, creating a heterotrimer that contains one Ile and two Ala on the 
same layer (Figure VI-2C).     
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Figure VI-2. Schemes of heterotrimeric coiled coils. (A) Asp(His)3; (B) Ile(His)3; (C) 
Ile(Ala)2(His)3.   
 Another piece of insight gained from the constructs in this thesis is the possibility 
of a different reaction route. As discussed extensively in Chapter II, III, and IV, the 
sequence of substrate binding and Cu(II) reduction via electron transfer is essential to 
determine the reaction intermediates thus the reaction rates. Up to this point, all the 
reactions have been run in such a way that the majority of the copper-peptide reacts from 
the cuprous form, i.e. Cu(II) reduction happens before substrate binding. On one hand, 
this allows one to evaluate experimentally the reactivity of an alternative route from the 
proposed catalytic cycle in native NiR; on the other, it would be ideal if this system can 
also carry out reactions following the same route of native NiR for comparison. Tethering 
a [Ru(bpy)3]2+ complex onto a strand of TRI peptide as a photosensitizer is currently 
being pursued in the Pecoraro group with promising preliminary results. One can imagine 
attaching a photosensitizing complex onto one of the three strands in a heterotrimeric 
coiled coil with a Cu(His)3 site to carry out NiR reaction (Figure VI-3). A sacrificial 
reductant with a reduction potential higher than that of Cu(II)/(I)-peptide couple (e.g. 
[Co(NH3)5Cl]2+)34 should be selected to reduced Ru(III). Scheme VI-1 shows a possible 
reaction scheme to carry out the light-driven NiR reaction.  
! 286 
 
Figure VI-3. A PyMol model of the proposed catalyst. Different colors of the peptides 
represent different sequences. The green helix has a Cys at the C-terminus for the 
attachment of the Ru complex.  
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 The second direction for future projects should focus on expanding the realm of 
reactions that this T2Cu center can catalyze. As is discussed earlier (Chapter II), 
depending on the protein environment and other cofactors, a Cu(His)3 center can carry 
out electron transfer, oxygen activation, and other types of oxidoreductase reactions. The 
electron transfer capability can be examined by photophysical studies. Inter- and intra-
molecular electron transfer in these constructs will provide insight into the nature of 
electron transfer pathways and the influence of protein secondary structures on electron 
transfer rates.   
 Regarding the oxygen activation capability of these constructs, I have obtained 
preliminary data on O2 and H2O2 oxidation of Cu(I)(TRIW-H)3+ and a few of its 
derivatives. The oxidation of Cu(I)(TRIW-H)3+ by H2O2 leads to an increased absorbance 
at ~640–660 nm, indicating the production of Cu(II)(TRIW-H)32+ (Figure VI-4). Both the 
oxidation rate and the yield are low (initial rate ~4 × 10-6 M!s-1, ~25%). To model an 
oxygen activation center for the purpose of substrate oxidation, the reduction potential of 
the metal center needs to be low enough to reduce oxygen, and the metal-oxygen active 
species has to be a relatively long-lived intermediate or the production of this 
intermediate has to be fast so that the system can accumulate a certain amount of the 
active species.  
 
Figure VI-4. The oxidation of 0.23 mM Cu(I)(TRIW-H)3+ at pH 6.0 (50 mM MES) by 5 
eq. H2O2. Spectra were collected every 2 min.  
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 The study of copper coordination complexes has demonstrated that the diverse 
nature of copper-oxygen reactivity derives from the ligand donor type, chelate ring size, 
denticity, and aromatic substitutions (if applicable).35–38 As shown in the previous 
chapters, the reduction potentials of the T2Cu centers in the present constructs are 
generally above +400 mV. Lowering the reduction potential should be one of the most 
important considerations to create a functional oxygen activation center. One approach is 
to use unnatural amino acids with imidazole-like side chains as copper-binding residues. 
For example, imidazoles can be substituted with a pyrazole, pyrrole, pyrazine, or 
pyridine. These modifications would have different electronic effects on the copper 
center, possibly lowering the reduction potential through the stabilization of the cupric 
form or the destabilization of the cuprous form. Since these aromatic groups might adopt 
different orientations inside the helical coiled coils, the influence on either oxidation state 
might also be different. Substitutions on the aromatics can further fine-tune the reduction 
potentials.  
 Overall, the work presented in this dissertation is the first example of a functional 
copper nitrite reductase model constructed within a three-stranded coiled coil. With the 
ultimate goal of achieving native-like reactivity within a minimal construct, this project 
progresses from designing the first coordination sphere to the systematic modifications of 
the second coordination sphere. Modulated binding properties, reduction potentials, 
protonation equilibria have been achieved; more importantly, some of these constructs 
exhibit the best catalytic efficiency among the NiR models under homogeneous aqueous 
conditions in the literature. The design strategies have advanced the understanding of the 
structure-function relationship of a redox-active metal center. Providing the importance 
of the nitrite reduction process in the terrestrial nitrogen cycle and the critical role that 
nitric oxide plays in human health and diseases,19,39–41 my doctoral work lays a solid 
foundation for potential biotechnological and pharmaceutical applications. It is a 
benchmark against which all the future work on de novo designed redox-active catalytic 
centers will be evaluated.  
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